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ABSTRACT 
The Fusarium-produced mycotoxin, Fusaric acid (FA), is a frequent contaminant of agricultural 
foods that exhibits toxicity in plants and animals with little information on its molecular and 
epigenetic mechanisms. Epigenetic modifications including DNA methylation, histone 
methylation, N-6-methyladenosine (m6A) RNA methylation, and microRNAs are central 
mediators of cellular function and may constitute novel mechanisms of FA toxicity. This study 
aimed to determine epigenetic mechanisms of FA-induced hepatotoxicity in vitro and in vivo by 
specifically investigating DNA methylation, histone 3 lysine (K) 9 trimethylation (H3K9me3), 
and m6A-mediated regulation of p53 expression in human liver (HepG2) cells and C57BL/6 
mice livers. 
FA induced global DNA hypomethylation in HepG2 cells; decreased the expression of DNA 
methyltransferases (DNMT1, DNMT3A, and DNMT3B) by inducing promoter hypermethylation 
and upregulated expression of miR-29b. Further, FA decreased the ubiquitination of DNMT1, 
DNMT3A, and DNMT3B by decreasing the expression of the ubiquitination regulators, UHRF1 
and USP7. FA induced promoter hypomethylation of the demethylase, MBD2 and increased 
MBD2 expression contributing to global DNA hypomethylation in HepG2 cells. 
DNA methylation and H3K9me3 function in concert to regulate genome integrity and gene 
transcription. Sirtuin (Sirt) 1 is a histone deacetylase and direct target of miR-200a that 
regulates the repressive H3K9me3 mark by post-translationally modifying both H3K9Ac and 
the histone methyltransferase, SUV39H1. FA upregulated miR-200a and decreased Sirt1 
expression in HepG2 cells and C57BL/6 mice livers. FA decreased the expression of SUV39H1 
and histone demethylase, KDM4B which led to a decrease in H3K9me3 and an increase in 
H3K9me1. FA also decreased cell viability via apoptosis as evidenced by the significant 
increase in the activity of the executioner caspase-3/7. 
The tumor suppressor protein, p53 regulates cell cycle arrest and apoptosis in response to 
cellular stress. The expression of p53 is regulated at the transcriptional and post-transcriptional 
level by promoter methylation and m6A RNA methylation. In HepG2 cells, FA induced p53 
promoter hypermethylation and decreased p53 expression. FA also decreased m6A-p53 levels 
by decreasing the expression of the methyltransferases, METTL3 and METTL14, and the m6A 
readers, YTHDF1, YTHDF3, and YTHDC2, thereby, decreasing p53 translation. In C57BL/6 
mice livers FA, however, induced p53 promoter hypomethylation and increased p53 expression. 
FA increased m6A-p53 levels by increasing the expression of METTL3 and METTL14; and 
increased expression of YTHDF1, YTHDF3, and YTHDC2 increased p53 translation. 
xx 
 
In conclusion, this study provides evidence for alternative mechanisms of FA-induced 
hepatotoxicity (in vitro and in vivo) by modulating DNA methylation, H3K9me3, m6A RNA 
methylation, and epigenetically regulating p53 expression ultimately leading to genome 
instability and apoptotic cell death. These results provide insight into a better understanding of 
FA induced hepatic toxicity at the epigenetic and cellular level and may assist in the 
development of preventative and therapeutic measures against FA toxicity. It also suggests that 
exposure to FA may lead to the onset of human diseases via epigenetic changes/modifications. 
This is particularly relevant in under privileged communities where the food supply and storage 
conditions are inadequate. 
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CHAPTER 1 
INTRODUCTION 
The contamination of foods and feeds with pathogenic fungi and mycotoxins is a global 
problem that threatens food security. Every year, approximately 25% of the global food and 
feed output is contaminated by mycotoxins (Smith et al., 2016); and the exposure to mycotoxin-
contaminated commodities has been linked with adverse effects in humans and animals (Zain, 
2011). 
Fusaric acid (FA; 5-butyl picolinic acid) is a secondary metabolite and mycotoxin produced by 
several Fusarium species that parasitize agricultural foods consumed by humans and animals 
(Bacon et al., 1996). Previously, approximately 643µg/kg (Streit et al., 2013) and 18µg/kg 
(Chen et al., 2017b) FA were found to contaminate animal feeds and commercial foods, 
respectively. Many of these foods are a staple in human and animal diets and the regular 
consumption of FA-contaminated commodities may have serious health implications. Currently, 
a maximum dietary safety limit for FA has not been established; and humans and animals are 
continuously exposed to both low and extremely high concentrations of FA. 
FA was initially patented for its use in treating drug addiction and alleviating the cravings for 
and withdrawal from narcotics and amphetamines in humans (Pozuelo, 1978). It was also 
patented for its antiviral and anti-proliferative effects and used in creams for the treatment of 
warts, psoriasis, and skin cancer (Fernandez-Pol, 1998). Later it was determined that FA was in 
fact toxic; however, the molecular mechanisms underlying its toxicity were unknown. 
FA is a lipophilic toxin that traverses cellular membranes and affects multiple biochemical 
pathways exerting low to moderate toxicity in both plants (Singh et al., 2017, D'Alton and 
Etherton, 1984, Diniz and Oliveira, 2009, Pavlovkin et al., 2004) and animals (Diringer et al., 
1982, Hidaka et al., 1969, Reddy et al., 1996, Yin et al., 2015). In plants, FA-induced 
phytotoxicity has been attributed to alterations in plant physiology and cellular function, 
ultimately leading to wilt disease symptoms and death of the plant (Singh et al., 2017, D'Alton 
and Etherton, 1984, Pavlovkin et al., 2004). 
FA is a divalent metal chelator that has been implicated as a possible etiological agent in 
hypotension (Hidaka et al., 1969, Toshiharu et al., 1970, Terasawa and Kameyama, 1971), 
notochord malformation (Yin et al., 2015), and delayed growth in animals (Reddy et al., 1996). 
It also acts synergistically with other food-borne mycotoxins such as fumonisin B1 (FB1) (Bacon 
2 
 
et al., 1995), deoxynivalenol (DON) (Smith et al., 1997) and 4,15-diacetoxyscirpenol (DAS) 
(Fairchild et al., 2005), thereby, mediating toxicity in various animal models. 
Studies evaluating the toxicity of FA in humans are limited. Recently, in vitro studies on several 
human cell lines indicated that FA is toxic by inducing oxidative stress (Abdul et al., 2016, 
Devnarain et al., 2017, Dhani et al., 2017), mitochondrial dysfunction (Abdul et al., 2016), 
DNA damage (Ghazi et al., 2017, Mamur et al., 2018), and apoptosis (Abdul et al., 2016, 
Devnarain et al., 2017, Dhani et al., 2017, Ghazi et al., 2017, Ogata et al., 2001).  
Despite studies evaluating the toxic effects of FA, there are currently no studies on the effects of 
FA-induced epigenetic changes both in vitro and in vivo. Our preliminary work on FA in human 
liver (HepG2) cells indicated that FA induced genotoxic effects (Addendum A) (Ghazi et al., 
2017); and it was this study that prompted further investigation of FA-induced epigenetic 
changes in the liver. The elucidation of cellular epigenetic mechanisms can lead to a better 
understanding of FA toxicity as well as assist in the development of preventative and 
therapeutic measures against FA exposure and toxicity. This will be beneficial in 
underprivileged communities where the food supply and storage methods are inadequate.  
Epigenetic mechanisms influence gene expression in response to environmental stimuli and are 
essential in regulating various cell signaling pathways. DNA methylation, promoter 
methylation, histone modifications, N-6-methyladenosine (m6A) RNA methylation, and 
variations in microRNA (miRNA) expression are common epigenetic modifications that may 
provide alternative mechanisms of FA-induced toxicity (Handy et al., 2011, Moore et al., 2009, 
Moarii et al., 2015). 
Promoter methylation, methylation of CpG islands within the promoter region of genes, 
regulates gene transcription by controlling the accessibility of transcription factors to the gene 
promoter region. Promoter hypermethylation masks gene promoter regions, prevents binding of 
transcription factors, and inhibits gene transcription whereas promoter hypomethylation 
activates gene transcription (Moarii et al., 2015).  
DNA methylation occurs on the 5
th
 position of cytosine in CpG islands and is regulated by DNA 
methyltransferases (DNMTs; DNMT1, DNMT3A, and DNMT3B) and demethylases (MBD2) 
(Lin and Wang, 2014). The expression of DNMTs and MBD2 is regulated at the transcriptional 
level by promoter methylation (Novakovic et al., 2010, Naghitorabi et al., 2013) and at the post-
transcriptional level by miRNAs such as miR-29b (Garzon et al., 2009, Fabbri et al., 2007). 
MiR-29b negatively regulates DNA methylation by targeting DNMT1, DNMT3A, and DNMT3B 
(Garzon et al., 2009, Fabbri et al., 2007). The activity and stability of DNMTs are also regulated 
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by post-translational modifications. Post-translational modifications such as ubiquitination are 
mediated by the E3 ligase, ubiquitin-like and ring finger domain 1 (UHRF1) and the 
deubiquitylating enzyme, ubiquitin specific peptidase 7 (USP7), and mark DNMTs for 
proteasomal degradation (Lin and Wang, 2014, Scott et al., 2014, Denis et al., 2011).  
A complex relationship exists between DNA methylation and histone modifications. DNA 
methylation is a pre-requisite for histone methylation and changes in global DNA methylation 
regulate histone modifications by recruiting histone modifying enzymes. Histone methylation 
can also control DNA methylation by recruiting DNMTs (Rose and Klose, 2014, Jin et al., 
2011). The dynamic relationship between DNA methylation and histone methylation plays a 
crucial role in maintaining genome integrity, gene transcription, and cell death (Rose and Klose, 
2014, Espada et al., 2004, Estève et al., 2006). 
Histone 3 lysine (K) 9 trimethylation (H3K9me3) is mediated by the histone methyltransferase, 
suppressor of variegation 3-9 homolog 1 (SUV39H1) and is associated with a closed tightly 
compacted and repressed chromatin structure (Bosch-Presegué et al., 2011). SUV39H1-
mediated H3K9me3 is crucial for regulating genome integrity (Peters et al., 2001), cell division 
(Melcher et al., 2000), cell viability (Reimann et al., 2010), and apoptosis (Watson et al., 2014). 
Post-translational modifications such as acetylation and ubiquitination regulate SUV39H1 and 
H3K9me3 (Bosch-Presegué et al., 2011). The acetylation of SUV39H1 decreases SUV39H1 
activity and mediates proteasomal degradation by promoting SUV39H1 polyubiquitination 
(Bosch-Presegué et al., 2011). The histone deacetylase, Sirtuin (Sirt) 1 is a direct target of miR-
200a that maintains H3K9me3 by deacetylating SUV39H1 thus increasing its catalytic activity 
and preventing its proteasomal degradation (Eades et al., 2011, Bosch-Presegué et al., 2011, 
Vaquero et al., 2007). 
Histone methylation can regulate m6A RNA methylation by recruiting m6A methyltransferases; 
and a decrease in H3K9me3 was associated with a decrease in m6A levels (Wang et al., 2018). 
Additionally, m6A RNA methylation can influence histone methylation by destabilizing 
transcripts that encode histone modifying enzymes (Wang et al., 2018, Li et al., 2018, Chen et 
al., 2019, Lai et al., 2018).  
M6A RNA methylation is an epi-transcriptomic mark and one of the most prevalent post-
transcriptional modifications of messenger RNA (mRNA) (Fu et al., 2014, Geula et al., 2015). 
M6A methylation is regulated by the methyltransferases, METTL3, METTL14, and WTAP, and 
the demethylases, FTO and ALKBH5; and recruits the m6A-dependent readers, YTHDF1, 
YTHDF2, YTHDF3, YTHDC1, and YTHDC2 to regulate RNA transcripts, splicing, and 
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protein translation (Geula et al., 2015, Fu et al., 2014, Jia et al., 2011, Xiao et al., 2016). To 
date, several RNA transcripts have been found to be regulated by m6A methylation (Li et al., 
2019, Li et al., 2017a). Additionally, m6A patterns were shown to be dysregulated during 
cellular stress (Engel et al., 2018), and may play a crucial role in regulating the expression of the 
tumor suppressor and stress response protein, p53. Studies on m6A and p53 indicate that m6A 
located within the coding region of p53 leads to the translation of mutant p53 that alters the p53 
signaling pathway and contributes to tumor formation and progression (Uddin et al., 2019, 
Kwok et al., 2017).  
The role of epigenetics in mycotoxicology is limited. The liver, due to its detoxification and 
metabolizing functions as well as its close relationship with the gastrointestinal tract, is highly 
susceptible to damage by chemical substances and mycotoxins. The HepG2 cell line is a 
common in vitro liver model for evaluating drug/mycotoxin metabolism and hepatotoxicity as it 
displays similar physiological functions to primary human hepatocytes (Ruoß et al., 2019). It is 
enriched with cytochrome P450 enzymes that enable toxins to undergo first pass metabolism 
and are thus susceptible to damage. In addition to its increased metabolic capacity, the HepG2 
cell line displays an epigenetic profile that is similar to primary human hepatocytes; and the 
regulation of epigenetic enzymes such as SUV39H1 in HepG2 cells is most comparable to the 
expression in primary human hepatocytes (Ruoß et al., 2019). This indicates that HepG2 cells 
may also be used as a reliable model for determining mycotoxin-induced epigenetic changes. In 
vivo animal models, due to its functional organ systems and absence of diseases, are analogous 
to humans and are also able to provide a reliable link between epigenetic changes and cellular 
outcomes (Rosenfeld, 2010). In particular, the inbred C57BL/6 mice model lacks genetic 
variation and, in response to dietary factors, is capable of exhibiting changes in DNA and 
histone methylation patterns that can be linked with developmental and cellular abnormalities in 
the various organs (Rosenfeld, 2010). Previous studies have highlighted key roles for epigenetic 
mechanisms in mycotoxin-induced adverse health effects in the liver; FB1 was shown to have 
carcinogenic potential by altering global DNA methylation (Chuturgoon et al., 2014a), promoter 
methylation (Demirel et al., 2015), histone methylation (Chuturgoon et al., 2014a, Sancak and 
Ozden, 2015), and miRNA expression (Chuturgoon et al., 2014b). Similarly, other Fusarium 
mycotoxins such as zearalenone, DON, and T2-toxin were shown to exert its toxic effects by 
altering DNA methylation (So et al., 2014, Han et al., 2016) and histone methylation (Han et al., 
2016, Zhu et al., 2016, Zhu et al., 2014). This suggests a possible role for epigenetics in FA-
mediated hepatotoxicity. 
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In this study, we hypothesized that FA induced genotoxic and cytotoxic effects in vitro and in 
vivo via alterations in epigenetic mechanisms. This hypothesis was tested by measuring changes 
in global DNA methylation, promoter DNA methylation, H3K9me3, miRNAs (miR-29b and 
miR-200a), and m6A-mediated regulation of p53 expression; and relating these changes in 
epigenetic modifications with the genotoxic and cytotoxic effects of FA. 
The aim of this study was to determine epigenetic changes of FA-induced hepatotoxicity in 
vitro (HepG2 cells) and in vivo (C57BL/6 mice). The specific objectives of the study were to 
determine the effect of FA on: 
1. Global DNA methylation as well as FA-induced changes in DNA methylation by 
transcriptional (promoter methylation), post-transcriptional (miR-29), and post-translational 
(ubiquitination) regulation of DNMTs and MBD2 in HepG2 cells. 
2. miR-200a, SUV39H1-mediated H3K9me3, genome integrity, and apoptosis in HepG2 cells 
and C57BL/6 mice livers. 
3. p53 expression and its epigenetic regulation at the transcriptional and post-transcriptional 
level by promoter methylation and m6A RNA methylation in HepG2 cells and C57BL/6 
mice livers. 
Ethical approval for this study was obtained from the University of Kwazulu-Natal Biomedical 
Research Ethics Committee (Ethical approval number: BE316/19; Addendum B) for procedures 
involving the HepG2 cells and from the University of KwaZulu-Natal Animal Research Ethics 
Committee (Ethical approval number: AREC/079/016; Addendum C) for all procedures 
involving mice. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1. Mycotoxins 
Mycotoxins are low molecular weight natural compounds produced as secondary metabolites of 
fungi and toxigenic molds (Bennett and Klich, 2003, Zain, 2011). These toxins are produced in 
cereal grains and animal feeds before, during, and after harvests, in various environmental 
conditions (Yiannikouris and Jouany, 2002); and are capable of exerting harmful effects in 
humans and animals. 
There are currently over 300 compounds that have been identified as mycotoxins since 1960 
following the outbreak of Turkey X Disease in which 100,000 turkey poults died as a result of 
consuming aflatoxin B1 (AFB1; a mycotoxin produced by Aspergillus flavus) contaminated 
peanut meal (Bennett and Klich, 2003, Zain, 2011); the most common mycotoxins of human 
and agro-economic importance include AFB1, FB1, ochratoxin A (OTA), DON, T2-toxin, 
patulin (PAT), and zearalenone (Zain, 2011). These mycotoxins frequently contaminate a wide 
variety of food sources and have been classified by the Food and Agriculture Organization 
(FAO) and World Health Organization (WHO) as potent neurotoxins, nephrotoxins, 
hepatotoxins, immuno-toxins, and carcinogens (Bennett and Klich, 2003, Yiannikouris and 
Jouany, 2002, Zain, 2011, Omotayo et al., 2019). 
The worldwide contamination of foods and feeds with mycotoxins is a significant problem 
(Zain, 2011). The global prevalence of mycotoxins in foods and feeds has dramatically 
increased over the past five years due to global warming, pest infestation, and poor harvest and 
storage practices (Meyer et al., 2019, Omotayo et al., 2019);  and each year, an estimated 25% 
of the world’s agricultural food and feed output is contaminated by mycotoxins (Omotayo et al., 
2019). This threatens food security and puts humans at a high risk of exposure to mycotoxin-
contaminated commodities. Human exposure to mycotoxins can occur via the consumption of 
contaminated plant-derived foods, from the carry-over of mycotoxins and toxic metabolites in 
animal products such as milk, meat and eggs, skin-contact with mold-infested substrates, and 
inhalation of spore-borne toxins (Bennett and Klich, 2003, Yiannikouris and Jouany, 2002, 
Zain, 2011, Omotayo et al., 2019).  
Exposure to mycotoxins can lead to several, often unrecognized, diseases known as 
mycotoxicoses (Bennett and Klich, 2003). Mycotoxicoses are common in developing countries 
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and poverty stricken areas where malnutrition is a major concern and where contaminated maize 
and cereal grains form a staple diet for many people (Omotayo et al., 2019). It also commonly 
occurs in areas where there are poor methods of food handling and improper storage of foods 
(Bennett and Klich, 2003, Yiannikouris and Jouany, 2002, Zain, 2011, Omotayo et al., 2019). 
The severity of mycotoxicoses varies among individuals and is dependent on the type of 
mycotoxin, dose and length of exposure, routes of exposure as well as the health and sex of the 
affected individual (Bennett and Klich, 2003, Zain, 2011). Synergistic interactions between the 
mycotoxin and other mycotoxins or chemicals to which the individual may have been exposed 
is also a major determinant of toxicity (Yiannikouris and Jouany, 2002). While it often occurs 
that mycotoxicoses can be treated, chronic toxicity can have irreversible and life-changing 
effects (Zain, 2011). 
Fungi are natural contaminants of food and therefore, the presence of mycotoxins is often 
unavoidable. Several efforts to minimize mycotoxin contamination and exposure include the 
application of modern agricultural practices to prevent fungal growth and mycotoxin 
production, establishing maximum food safety limits for mycotoxins, and removing unsafe 
contaminated commodities from the food supply by regular government screening (Bennett and 
Klich, 2003, Yiannikouris and Jouany, 2002, Zain, 2011). Despite this, extensive mycotoxin 
contamination still continues to occur in foods and feeds around the world.  
2.2. Fusaric Acid 
Fusaric acid (FA) is a mycotoxin produced by fungi of the genus Fusarium that contaminates 
agricultural foods and feeds (Bacon et al., 1996). These foods are an integral part of the human 
and animal diet and regular consumption of FA-contaminated commodities may have adverse 
effects on human and animal health.  
To date, only a few studies have measured FA concentration in foods and feeds, although its 
presence has been detected in various corn and wheat-based foods and feeds worldwide 
(Placinta et al., 1999). A study conducted on mycotoxins in corn and wheat silages reported that 
FA had the highest prevalence and concentration (765µg/kg FA) compared to 22 other common 
mycotoxins (Shimshoni et al., 2013); feed samples were reported to contain an average of 
643µg/kg FA (Streit et al., 2013) and approximately 2.5-18µg/kg FA were reported to 
contaminate commercial foods and feeds (Chen et al., 2017b). It was also found that corn and 
swine feeds were contaminated with up to 36µg/kg FA (Smith and Sousadias, 1993) and 
approximately 12.4µg/kg FA was found in livestock and poultry feeds (Voss et al., 1999).  
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FA is a neglected mycotoxin that is usually not monitored and to date a maximum dietary safety 
limit has not been determined, this puts humans and animals at a high risk of exposure to FA at 
both low and extremely high concentrations. 
2.2.1. Structure of FA 
FA is an aromatic carboxylic acid and picolinic acid derivative that consists of the chemical 
formula, C10H13NO2 (ŠroBároVá et al., 2009). The structure of FA is based on the structure of 
picolinic acid (2-pyridine carboxylic acid) which is an isomer of nicotinic acid that consists of a 
six membered pyridine ring structure (Figure 2.1A and B) (Grant et al., 2009). The structure of 
FA resembles picolinic acid in that it contains the pyridine ring structure of picolinic acid as 
well as an additional fused aromatic ring or 5-butyl side chain (Figure 2.1C). The butyl side 
chain is responsible for increasing the lipophilicity of FA and enables it to penetrate cell 
membranes that are mostly composed of lipids (Bochner et al., 1980). The structure of FA also 
consists of a hydroxyl (OH-) group that acts as a proton donor and is responsible for the acidic 
properties of FA. 
FA is a chelator of divalent cations, and similar to picolinic acid which is a bidentate metal 
chelating agent (Grant et al., 2009); it is capable of forming conjugates with essential ions such 
as zinc, iron, copper, and manganese (Li et al., 2013). Mechanistically, this occurs via the N-
atom of the pyridine ring of FA which binds with the carboxyl group of the metal to form 
chelates that prevent these ions from functioning in biological processes (Li et al., 2013). 
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Figure 2.1 Chemical structure of nicotinic acid (A), picolinic acid (B), and Fusaric acid (C) 
(May et al., 2000) 
2.2.2. Effects of FA 
FA is a non-specific mycotoxin known to have diverse toxicological effects in plants and 
animals (Singh et al., 2017, D'Alton and Etherton, 1984, Diniz and Oliveira, 2009, Pavlovkin et 
al., 2004, Diringer et al., 1982, Hidaka et al., 1969, Reddy et al., 1996, Yin et al., 2015); 
however, studies evaluating the effects of FA on humans and its mechanisms of toxicity are 
limited. In plants, FA is phytotoxic and has been implicated in the pathogenesis of wilt diseases  
(Singh et al., 2017, Diniz and Oliveira, 2009, D'Alton and Etherton, 1984, Pavlovkin et al., 
2004). Other effects of FA on plants include alterations in membrane permeability (D'Alton and 
Etherton, 1984, Pavlovkin et al., 2004), increased electrolyte leakage (Pavlovkin et al., 2004, 
D'Alton and Etherton, 1984, Singh et al., 2017), damage to plant photosynthetic machinery 
(Singh et al., 2017), and inhibition of respiration (Singh et al., 2017, D'Alton and Etherton, 
1984). It also reduces leaf protein content by increasing the activity of proteolytic enzymes and 
inhibits root and leaf cell function leading to necrotic cell death (Singh et al., 2017). 
FA is a cell membrane permeating weak acid (pKa = 5.04) and is therefore, potentially toxic as 
a proton conductor (Bochner et al., 1980). It alters the mitochondrial membrane potential of 
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cells and decreases ATP production by inhibiting cytochrome c oxidase and the ATPase/ATP 
synthase pump (Köhler and Bentrup, 1983, D'Alton and Etherton, 1984, Telles-Pupulin et al., 
1996). FA impairs mitochondrial function and biogenesis in HepG2 liver cells; and induces 
apoptosis by increasing the activity of caspases -8, -9, and -3/7 (Abdul et al., 2016, Devnarain et 
al., 2017, Ogata et al., 2001, Ghazi et al., 2017). FA also elevates oxidative stress, induces lipid 
peroxidation, and increases the activity of anti-oxidant enzymes: superoxide dismutase (SOD), 
catalase (CAT), and ascorbate peroxidase (Abdul et al., 2016, Devnarain et al., 2017, Sapko et 
al., 2011, Kuźniak, 2001).  
FA is immuno-toxic to peripheral blood mononuclear cells (PBMCs) and human monocytic 
(THP-1) cells by altering the MAPK signaling pathway (Dhani et al., 2017); it increases 
cytokine production in human cervical carcinoma (Hep-2) cells and docetaxel-resistant Hep-2 
cells (Ye et al., 2013). FA also has immuno-suppressive activity in HepG2 cells by inhibiting 
the activation of the NRLP3 inflammasome, and disrupting the synthesis and maturation of 
interleukin-1-beta (IL-1β) (Abdul et al., 2019); however, no effect was observed between FA 
and the production of interleukin-2 (IL-2) and interleukin-5 (IL-5) in murine thymoma (EL-4) 
cells (Marin et al., 1996). 
FA is a potent chelator of divalent cations and the removal of essential metal ions may serve as 
a mechanism by which this mycotoxin exerts its effects. FA has anti-proliferative and anti-
tumor effects in several human cancer cell lines (Fernandez-Pol et al., 1993); it has anti-tumor 
activity against head and neck squamous cell carcinoma (HNSCC) by chelating divalent cations 
from catalytic DNA-associated metalloproteins, thereby, increasing DNA damage and 
preventing its synthesis and repair (Stack Jr et al., 2004). FA has anti-proliferative effects in 
WI-38 fibroblasts, and is a potent inhibitor of DNA synthesis in breast cancer (MDA-MB-468) 
cells and WI-38 fibroblasts (Fernandez-Pol et al., 1993). Additionally, FA was shown to induce 
DNA damage and decrease HepG2 cell viability by post-translationally modifying the tumor 
suppressor protein, p53 (Mamur et al., 2018, Ghazi et al., 2017).  
FA is toxic to mice (intra-peritoneal LD50 = 80mg/kg and intravenous LD50 = 100mg/kg) and 
death caused by the lethal dose has been attributed to its hypotensive effect (Hidaka et al., 1969, 
Toshiharu et al., 1970, Terasawa and Kameyama, 1971). FA has hypotensive activity in cats, 
dogs, rabbits, and rats by inhibiting the copper-dependent enzyme, dopamine-beta-hydroxylase, 
a key enzyme in the synthesis of the neurotransmitter noradrenaline (Hidaka et al., 1969, 
Terasawa and Kameyama, 1971, Toshiharu et al., 1970). The FA-induced decrease in 
noradrenaline was also shown to prevent the formation of gastric ulcers in rats (Osumi et al., 
1973).  
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FA has neurochemical effects in mice (Diringer et al., 1982), rats (Porter et al., 1995), and pigs 
(Smith and MacDonald, 1991), and reduced aggressive behavior and motor activity (Diringer et 
al., 1982). FA attenuates isoproterenol-induced heart failure in mice by inactivating the 
PI3K/AKT and TGF-beta/SMAD signaling pathways, thereby, preventing the development of 
cardiac hypertrophy and fibrosis (Li et al., 2017b).  
FA is toxic to zebrafish by chelating copper and inhibiting the enzyme lysyl oxidase resulting in 
notochord malformation (Yin et al., 2015) whereas calcium chelation was shown to cause 
toxicity in mice by affecting blood coagulation (Devaraja et al., 2013), delaying the bone 
ossification process, and affecting the growth of fetuses (Reddy et al., 1996). 
Synergistic interactions between FA and other co-produced Fusarium mycotoxins have also 
been demonstrated. Studies conducted in pigs indicate that FA enhances the toxicity of DON by 
decreasing feed intake and reducing body weight (Smith et al., 1997); it increases tryptophan 
uptake and serotonin synthesis by competing with tryptophan for binding to blood albumin and 
increases the concentration of free tryptophan in the blood (Smith et al., 1997). Exposure to FA 
also increases vomiting, feed refusal, and brain metabolism in pigs given trichothecenes (Smith 
and MacDonald, 1991); although no toxic synergistic effects were observed in broiler chicks 
and young turkey poults fed a combination of FA and T2-toxin (Ogunbo et al., 2007). 
Synergism between FA and DAS has been demonstrated in insects; FA enhances the toxicity of 
DAS in insects by increasing mortality from 5% with DAS alone to over 20% with DAS and FA 
combined (Dowd, 1988). Contrastingly, a recovery in body weight and body weight gains were 
observed in turkey poults fed a combination of FA and DAS as opposed to a diet with FA and 
DAS alone (Fairchild et al., 2005). FA also has a toxic synergistic interaction with FB1 in 
chicken embryos (Bacon et al., 1995); although no synergistic toxic effects were observed 
between FA and FB1 in rats (Voss et al., 1999). 
2.3. Epigenetics 
The term “epigenetics” was coined in 1942 by Conrad H. Waddington to describe the 
relationship between genes and the cellular phenotype. Epigenetics refers to inherited 
modifications that influence gene expression by regulating the structure and function of the 
genome (Handy et al., 2011). These modifications occur independently of the DNA sequence 
and play a crucial role in regulating cell signaling pathways that are essential for the normal 
growth and development of higher organisms (Handy et al., 2011, Moore et al., 2013).  
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Epigenetic phenomena are mediated by a variety of molecular mechanisms including DNA 
methylation, promoter DNA methylation, histone modifications, RNA methylation, and 
microRNAs (miRNAs). Among those, DNA methylation, promoter methylation, and histone 
modifications are the most studied epigenetic mediators that regulate gene transcription by 
altering chromatin structure and DNA accessibility (Handy et al., 2011, Moore et al., 2013) 
whereas RNA methylation and miRNAs function post transcription and directly target RNA 
transcripts to regulate protein expression (Shi et al., 2019, Winter et al., 2009). 
Epigenetic mechanisms can be modified by exogenous influences and as a result can contribute 
to or be a consequence of environmental alterations of the cells phenotype or patho-phenotype 
(Handy et al., 2011). The role of epigenetics in various human diseases such as cancer 
(Gopalakrishnan et al., 2008), cardiovascular disease (Handy et al., 2011), and 
neurodegenerative disorders (Iraola‐Guzmán et al., 2011) are well established; however, studies 
concerning the association between epigenetics and mycotoxicology are still limited (see section 
2.11: The Role of Epigenetics in Mycotoxicology; Page 36-37). 
2.4. Structure of Chromatin 
Chromatin is a complex of DNA and histone proteins that form the scaffold for the packaging of 
the entire genome. The nucleus, approximately 6µm in diameter, consists of nearly 2 meters of 
DNA packaged into chromatin (Handy et al., 2011, Moore et al., 2013). Nucleosomes are the 
basic functional units of chromatin and consist of approximately 147 base pairs of negatively 
charged DNA wrapped around an octamer of positively charged histone proteins, two copies 
each of H2A, H2B, H3, and H4 (Figure 2.2) (Handy et al., 2011, Moore et al., 2013). Linker 
histones such as H1 interact with linker DNA situated between nucleosomes and organize 
nucleosomes and intervening linker DNA into higher order chromatin structures (Handy et al., 
2011, Moore et al., 2013).   
The structure of chromatin is important in regulating gene expression and can be divided into 
either a closed tightly compacted and transcriptionally silent, heterochromatin or a relatively 
open loosely packed and transcriptionally active, euchromatin (Figure 2.2) (Handy et al., 2011, 
Moore et al., 2013, Pieterman et al., 2014). The structure of chromatin is regulated by post-
translational modifications to both DNA and histone tails (Handy et al., 2011).  
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Figure 2.2 Structure of chromatin (Pieterman et al., 2014) 
2.5. DNA Methylation 
DNA methylation is an important biochemical process that maintains genomic stability and is 
often associated with a repressed chromatin structure and gene silencing (Handy et al., 2011). 
DNA methylation plays a major role in the regulation of pluripotency genes, transposon 
silencing, genomic imprinting, and X-chromosome inactivation (Handy et al., 2011). It controls 
transcriptional gene silencing during development and differentiation and is involved in creating 
distinct cell lineages in adult organisms (Handy et al., 2011, Moore et al., 2013). 
DNA methylation occurs almost exclusively at CpG dinucleotides where a cytosine nucleotide 
occurs next to a guanine nucleotide (Hervouet et al., 2018), and nearly 70-80% of CpG 
dinucleotides are methylated in mammalian DNA (Hervouet et al., 2018). DNA methylation is 
catalyzed by DNA methyltransferases (DNMTs) that transfer a methyl (CH3) group from the 
methyl donor, s-adenosyl methionine (SAM) to the fifth carbon of cytosine residues (Figure 2.3) 
(Moore et al., 2013, Thankam et al., 2019). This process yields 5-methylcytosine which can 
undergo spontaneous deamination to produce thymine.  
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Figure 2.3 Process of DNA methylation (Miranda-Gonçalves et al., 2018)  
The most common DNMTs include DNMT1, DNMT3A, DNMT3B, and DNMT3L. DNMT1 is 
a maintenance DNMT that functions during DNA replication where it recognizes and binds 
specifically to hemi-methylated (CpG dinucleotides on only one of the two DNA strands are 
methylated) DNA and is responsible for conserving the methylation pattern from one generation 
to the next (Lin and Wang, 2014). Additionally, DNMT1 has the ability to repair DNA 
methylation patterns (Moore et al., 2013); and knockout of DNMT1 in mice embryos exhibited a 
two-thirds loss of DNA methylation, increased apoptosis, and embryonic lethality (Moore et al., 
2013).  
DNMT3A and DNMT3B are de novo DNMTs that establish DNA methylation patterns by 
targeting unmethylated (CpG dinucleotides on both DNA strands are unmethylated) cytosine 
bases to initiate methylation (Lin and Wang, 2014). DNMT3A and DNMT3B are functionally 
active during embryogenesis; and knockout studies in mice indicate that de novo DNA 
methylation is essential for early development and differentiation since DNMT3A-null mice die 
shortly after birth and DNMT3B-null mice die in utero with multiple developmental defects 
(Okano et al., 1999). Additionally, DNMT3A and DNMT3B double knockout mice embryos 
arrest shortly after gastrulation (Okano et al., 1999), and mouse embryonic fibroblasts deleted of 
both DNMT3A and DNMT3B are susceptible to genomic instability and spontaneous 
immortalization (Dodge et al., 2005). 
DNMT3L is a DNMT3-related protein homologous to DNMT3A and DNMT3B that lacks 
catalytic activity and functions to stimulate the methyltransferase activity of DNMT3A and 
DNMT3B by increasing their ability to bind to SAM (Moore et al., 2013). DNMT3L is 
expressed mainly during development and in germ cells where it is required for establishing 
maternal and paternal genomic imprinting, methylates retrotransposons, and compaction of the 
X-chromosome (Zamudio et al., 2011). Male DNMT3L knockout mice display defects in 
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spermatogenesis and are unable to produce mature sperm cells (Webster et al., 2005) whereas 
female DNMT3L knockout mice produce methylation-deficient oocytes that result in embryos 
that die during gestation (Kobayashi et al., 2012). 
2.5.1. Structure of DNMTs 
The DNMT1 gene is located on human chromosome 19 (19p13.2) and encodes a 183 kDa 
protein upon translation. This protein comprises of 1616 amino acids and is made up of three 
main regions – an N-terminal regulatory region, a series of lysine-glycine (KG)-repeats, and a 
C-terminal catalytic region (Figure 2.4) (Hervouet et al., 2018). The N-terminal region includes 
a DNMT-associated protein 1 (DMAP1) interaction domain, a proliferating cell nuclear antigen 
(PCNA) binding domain (PBD), a nuclear localization signal (NLS), a replication foci targeting 
domain (RFTD), a cysteine-rich zinc (CXXC) binding domain, and two bromo-adjacent 
homology (BAH1 and BAH2) domains (Cheng and Blumenthal, 2008, Hervouet et al., 2018). 
The DMAP1 domain interacts with the transcriptional repressor, DMAP1 and targets it to 
replication foci where it maintains DNA methylation patterns during early development (Jeltsch 
and Jurkowska, 2016). The PBD domain contains the DNA-binding motif and is involved in 
recruiting DNMT1 to the replication fork during DNA replication (Jeltsch and Jurkowska, 
2016). The NLS is responsible for importing DNMT1 into the nucleus (Hervouet et al., 2018), 
and the RFTD domain targets DNMT1 to replication foci and centromeric chromatin (Jeltsch 
and Jurkowska, 2016). The CXXC domain follows the RFTD domain and functions by binding 
to unmethylated CpG dinucleotides (Cheng and Blumenthal, 2008). The BAH1 and BAH2 
domains are required for the folding of the DNMT1 protein (Jeltsch and Jurkowska, 2016). The 
N- and C-terminal regions are linked via a series of KG-repeats that can undergo post-
translational modifications to regulate the stability and activity of the DNMT1 protein 
(Yarychkivska et al., 2018). The C-terminal region consists of the catalytic domain and is 
essential in mediating the interaction between SAM and DNMT1. It favours the binding of 
DNMT1 for hemi-methylated CpG dinucleotides and is responsible for the DNMT activity of 
DNMT1 (Hervouet et al., 2018, Jeltsch and Jurkowska, 2016). DNMT1 also contains an 
allosteric site that is independent of the catalytic domain and binds to 5-methylcytosine to 
increase the affinity of DNMT1 for both SAM and DNA (Hervouet et al., 2018). 
The DNMT3A and DNMT3B gene, located on human chromosome 2 (2p23.3) and human 
chromosome 20 (20q11.2), encodes a 101 and 130 kDa protein upon translation. These proteins 
comprising of 912 and 853 amino acids for DNMT3A and DNMT3B, respectively, are 
structurally similar and vary only in the length of their variable regions (Cheng and Blumenthal, 
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2008). The structure of DNMT3A and DNMT3B is made up of two main regions – an N-
terminal region and a C-terminal region (Figure 2.4) (Hervouet et al., 2018). The N-terminal 
region is further subdivided into a variable region, a proline-tryptophan-tryptophan-proline 
(PWWP) domain, and a DNMT3L-type zinc finger (ADD) domain (Hervouet et al., 2018, 
Cheng and Blumenthal, 2008). The PWWP domain non-specifically binds to DNA and is 
responsible for targeting DNMT3A and DNMT3B to pericentric heterochromatin (Cheng and 
Blumenthal, 2008). The ADD domain contains six CXXC motifs (Cheng and Blumenthal, 
2008) and a DNMT3L-type zinc finger that binds to the regulatory DNMT3L and mediates 
protein-protein interactions (Hervouet et al., 2018). The C-terminal region contains the catalytic 
domain which is responsible for the DNMT activity of DNMT3A and DNMT3B (Hervouet et 
al., 2018). 
The structure of DNMT3L (DNMT3L gene is located on human chromosome 21 (21q22.3) and 
encodes a 44 kDa protein) is similar to DNMT3A and DNMT3B; however, it lacks the PWWP 
domain and the C-terminal catalytic region found in both DNMT3A and DNMT3B (Figure 2.4) 
(Hervouet et al., 2018, Jeltsch and Jurkowska, 2016).  
 
Figure 2.4 Structure of DNMT proteins (Jeltsch and Jurkowska, 2016) 
2.5.2. Regulation of DNMTs  
DNMTs are the major regulators of DNA methylation and alterations in their expression and 
activity affects DNA methylation patterns and many cellular functions (Lin and Wang, 2014). 
Previously, aberrant DNA methylation patterns owing to dysregulated and dysfunctional 
DNMTs have been implicated in the pathogenesis of several human diseases especially, cancer 
(Gopalakrishnan et al., 2008). The expression of DNMT1, DNMT3A, and DNMT3B were 
reportedly elevated in various malignancies including hepatomas, prostrate, colorectal, and 
breast tumors (Girault et al., 2003, Saito et al., 2003, Eads et al., 1999, Patra et al., 2002); and 
DNMT1 and DNMT3B were elevated in lung cancer (Kim et al., 2006). These changes in DNMT 
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expression as well as the methylation pattern were correlated with a poor prognosis in the 
affected patients (Kim et al., 2006). 
Numerous studies have aimed to elucidate the mechanisms of DNMT regulation in vitro and in 
vivo, and it was determined that the DNMTs are regulated at the transcriptional level by 
promoter methylation and at the protein level by post-translational modifications (Scott et al., 
2014, Lin and Wang, 2014, Denis et al., 2011, Peng et al., 2011). 
2.5.2.1. Regulation of DNMTs via Promoter Methylation 
Promoter methylation refers to the methylation of CpG dinucleotides within the promoter region 
of target genes (Moore et al., 2013, Moarii et al., 2015). Promoter methylation plays a crucial 
role in regulating gene transcription by either promoting or preventing the binding of 
transcription factors to gene promoter regions (Moarii et al., 2015). Promoter hypermethylation 
prevents transcription factors from binding to gene promoters and as a result inhibits gene 
transcription (Moarii et al., 2015) whereas promoter hypomethylation enables transcription 
factors to bind to gene promoters and activate its transcription (Figure 2.5) (Moore et al., 2013).  
 
Figure 2.5 Regulation of gene expression via promoter methylation (Dabrowski and Wojtas, 
2019) 
Studies conducted on the regulation of DNMTs at the transcriptional level indicate that 
promoter methylation plays an important role in controlling DNMT transcript levels 
(Naghitorabi et al., 2013, Novakovic et al., 2010). Promoter hypermethylation of DNMT1 was 
associated with a decrease in DNMT1 expression in both cancerous (Rajendran et al., 2011) and 
non-cancerous (Novakovic et al., 2010) cells. Similarly, promoter hypomethylation of DNMT3A 
and DNMT3B was accompanied with an increased expression of DNMT3A and DNMT3B in 
embryonic tissues (Novakovic et al., 2010), glioma tumors (Rajendran et al., 2011), and breast 
cancer cells (Naghitorabi et al., 2013). The silencing of genes by aberrant promoter methylation 
is a major initiating event in various human diseases, especially cancer where the silencing of 
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tumor suppressor genes by changes in promoter methylation is required for both the onset and 
progression of cancer (Gopalakrishnan et al., 2008, Naghitorabi et al., 2013, Rajendran et al., 
2011). 
2.5.2.2. Regulation of DNMTs via Post-Translational Modifications: Acetylation and 
Ubiquitination 
DNMTs are synthesized in the cytoplasm and imported into the nucleus where they perform 
their enzymatic functions; thereafter, they are exported out of the nucleus to the cytoplasm 
where they are degraded by the proteasome (Scott et al., 2014). The DNMTs are subject to a 
variety of post-translational modifications that regulate its cellular localization, catalytic 
activity, stability, and protein-protein interactions (Lin and Wang, 2014). These modifications 
occur in the N- and C-terminal regions of the protein and include acetylation and ubiquitination, 
(Lin and Wang, 2014). 
The acetylation-mediated ubiquitination of DNMTs plays a major role in inhibiting DNMT 
activity and stability as well as promoting its proteasomal degradation (Jeltsch and Jurkowska, 
2016, Lin and Wang, 2014, Scott et al., 2014, Denis et al., 2011). The acetyltransferase, Tip60 
promotes the acetylation of DNMTs which triggers ubiquitination by the E3 ligase, ubiquitin-
like and ring finger domain 1 (UHRF1); thereby, targeting the DNMTs for proteasomal 
degradation (Jeltsch and Jurkowska, 2016, Lin and Wang, 2014, Scott et al., 2014, Denis et al., 
2011). Conversely, the deacetylases, HDAC1 and HDAC2, and the deubiquitylating enzyme, 
ubiquitin specific peptidase 7 (USP7) protect the DNMTs from degradation via deacetylation 
and deubiquitination, respectively (Lin and Wang, 2014).  
The role of acetylation and ubiquitination on the regulation of DNMT1 is well understood. 
Previously, the acetylation of DNMT1 on lysine (K) residues (K1111, K1113, K1115, and 
K1117) in the KG-repeat was shown to increase the transcriptional repressor activity of 
DNMT1 (Lin and Wang, 2014, Jeltsch and Jurkowska, 2016, Peng et al., 2011) and promote the 
ubiquitination and degradation of DNMT1 by increasing the DNMT1-UHRF1 interaction and 
impairing the DNMT1-USP7 interaction (Figure 2.6) (Cheng et al., 2015). Additionally, 
HDAC1-mediated deacetylation of DNMT1 in the KG-repeat restores the DNMT1-USP7 
interaction and increases the stability of DNMT1 by preventing its ubiquitination and 
proteosomal degradation (Cheng et al., 2015, Jeltsch and Jurkowska, 2016). Deacetylation of 
DNMT1 at K1111, K1113, K1115, and K1117 in the KG-repeat also reduces its transcriptional 
repressor activity; however, no effect was observed on the methyltransferase activity of 
DNMT1 (Peng et al., 2011).  
19 
 
The acetylation of DNMT1 on K1349 and K1415 in the catalytic domain decreases DNMT1 
activity and the deacetylase, Sirtuin (Sirt) 1 was shown to physically interact with DNMT1 both 
in vitro and in vivo (Peng et al., 2011). Deacetylation of DNMT1 at K1349 and K1415 by Sirt1 
increases the methyltransferase activity of DNMT1 (Figure 2.6) (Peng et al., 2011).  
DNMT1 is also acetylated in the N-terminal region containing the NLS and RFTD domain on 
K160, K188, K259, and K266 and in the BAH1 and BAH2 domains on K749, K861, K957, 
K961, and K975 affecting DNMT1 localization and protein-protein interactions (Peng et al., 
2011). 
 
Figure 2.6 Regulation of DNMT1 by acetylation and ubiquitination. (A) Tip60 acetylates 
DNMT1 promoting UHRF1-mediated ubiquitination and proteasomal degradation. (B) Sirt1 
deacetylates DNMT1 preventing its proteasomal degradation and increasing its DNMT activity 
(Lin and Wang, 2014) 
Studies determining the role of acetylation and ubiquitination on the regulation of DNMT3A 
and DNMT3B are limited. Previously, UHRF1 was shown to physically interact with both 
DNMT3A and DNMT3B leading to a reduction in its catalytic activity as well as its 
ubiquitination and proteasomal degradation (Jia et al., 2016). Additionally, UHRF2 was also 
shown to inhibit DNA methylation in a DNNMT3A and/or DNMT3B-dependent manner by 
negatively regulating the protein expression of DNMT3A and DNMT3B (Jia et al., 2016). 
UHRF2 enhances the ubiquitination and proteasomal degradation of both DNMT3A and 
DNMT3B as determined via knockout studies in various cancer cell lines (Jia et al., 2016).   
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2.6. Methyl-CpG Binding Proteins 
DNA methylation forms a platform for several methyl binding proteins (Du et al., 2015). 
Methyl-CpG binding domain (MBD) proteins are a family of nuclear proteins that have a high 
affinity for 5-methylcytosine and regulate DNA methylation and gene transcription by 
recruiting chromatin remodelling complexes to regions of methylated DNA (Du et al., 2015, 
Jeltsch and Jurkowska, 2016).  
MBD proteins, comprising of MBD1 to MBD6, play a crucial role in mammalian development 
where they regulate cell proliferation, genome integrity, embryonic stem cell pluripotency, cell 
differentiation, and neurogenesis (Du et al., 2015, Detich et al., 2002, Liu et al., 2010). The 
structure of all MBD proteins consist of the highly conserved MBD that binds single 
symmetrically methylated CpG dinucleotides as well as additional domains such as the CXXC 
domain of MBD1 that enables MBD1 to maintain heterochromatin structure/transcriptional 
repression by binding to both methylated and unmethylated DNA (Figure 2.7) (Du et al., 2015). 
The transcriptional repression domain (TRD) found in MBD1 and MBD2 as well as the coiled 
coil (CC) domain found in MBD2 and MBD3 mediate protein-protein interactions and are 
responsible for recruiting chromatin repressor proteins (Figure 2.7) (Du et al., 2015). MBD2 
also contains an N-terminal glycine-arginine (GR) rich domain that undergoes post-translational 
modifications (Figure 2.7); and although MBD2 shares the highest amino acid sequence 
similarity with MBD3, MBD3 lacks the GR-rich domain and is unable to bind to methylated 
DNA due to a tyrosine to phenylalanine substitution in the MBD domain (Figure 2.7) (Hendrich 
et al., 2001, Du et al., 2015). MBD4, due to the presence of a C-terminal glycosylase domain 
(Figure 2.7), plays an important role in repairing mismatched DNA (Hendrich et al., 1999). 
MBD5 and MBD6 consist of a proline-rich domain and PWWP domain that binds methylated 
histones and regulates heterochromatin (Figure 2.7) (Du et al., 2015).  
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Figure 2.7 Structure of MBD1 to MBD6 (Du et al., 2015) 
2.6.1. MBD2 
MBD2 is the major MBD protein that binds to methylated DNA and functions as both a 
methylation-dependent transcriptional repressor and DNA demethylase (Detich et al., 2002). 
Studies conducted on MBD2 knockout mice indicate that MBD2 is dispensible for embryonic 
development but is required for maternal behaviour and neurogenesis (Hendrich et al., 2001). 
Deletion of MBD2 inhibits cell proliferation in vitro (Cheng et al., 2018); however, 
overexpression of MBD2 contributes to tumourigenesis by causing DNA hypomethylation and 
genome instability, and silencing methylated tumour suppressor genes such as p16 and p14 
(Magdinier and Wolffe, 2001). MBD2 is also involved in the activation of pro-metastatic genes 
(Cheishvili et al., 2014). 
2.6.2. Regulation of MBD2 via Promoter Methylation 
Similar to the DNMTs, MBD2 is regulated at the transcriptional level by promoter methylation. 
Hypomethylation of the MBD2 gene promoter activates MBD2 transcription leading to 
increased MBD2 expression and DNA hypomethylation (a hallmark of cancer) in cancerous 
liver tissue (Liu et al., 2016). Additionally, hypermethylation of the MBD2 promoter was 
associated with an inhibition in MBD2 expression (Cheishvili et al., 2014). Dysregulations in 
MBD2 promoter methylation has been observed in neurological disorders (Liu et al., 2010), 
cancer (Liu et al., 2016), defective embryonic development and differentiation (Du et al., 2015, 
Detich et al., 2002). 
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2.7. Histone Modifications 
A loss in DNA methylation is associated with a loss in genome integrity which leads to 
irreparable DNA damage and mutations (Hervouet et al., 2018, Moore et al., 2013). In 
eukaryotes, DNA interacts with histone proteins that help package it into higher order chromatin 
structures and thus the orientation and structure of histone proteins and chromatin are important 
in regulating genome integrity. Post-translational modifications that occur on the N- and C-
terminal histone tails alter chromatin structure and influence the orientation in which DNA is 
packaged as well as its transcriptional activity (Moore et al., 2013). 
The most common post-translational modifications of histones include acetylation and 
methylation. Acetylation occurs on the K residues of histone tails and facilitates decondensation 
of chromatin by neutralizing the positive charge of histones and loosening the interaction 
between DNA and histone proteins (Moore et al., 2013, Thankam et al., 2019). This 
modification exposes genes making them accessible to transcription factors and enhances gene 
transcription (Moore et al., 2013, Thankam et al., 2019). Conversely, histone deacetylation 
reinforces the positive charge of histones and tightens the interaction between DNA and histone 
proteins producing a condensed chromatin structure that represses gene transcription (Moore et 
al., 2013, Thankam et al., 2019). 
Histone methylation occurs on both arginine (R) and K residues and can have different effects 
on gene expression depending on the R or K residue being methylated as well as the degree of 
methylation (Moore et al., 2013, Thankam et al., 2019). The methylation of K residues are best 
characterized; K residues can be mono-, di-, or tri- methylated providing functional diversity to 
each site of methylation (Moore et al., 2013, Thankam et al., 2019). Several methylation sites 
have been identified for H3 (K4, K9, K27, K36, and K79) and H4 (K20). Methylation of H3K4, 
H3K36, and H3K79 is often associated with active genes whereas methylation of H3K9, 
H3K27, and H4K20 is associated with inactive genes (Morales et al., 2017). 
In this study, the interest is focused on histone 3 lysine 9 trimethylation (H3K9me3) due to its 
distinct role in maintaining heterochromatin structure and genome stability as well as its 
possible susceptibility to alteration by genotoxic agents. 
2.7.1 H3K9me3 
H3K9me3 is regulated by the histone methyltransferase, suppressor of variegation 3-9 homolog 
1 (SUV39H1) and the lysine demethylase 4B (KDM4B). KDM4B specifically demethylates 
H3K9me3 by catalyzing the removal of H3K9 di- and tri- methyl marks and converts H3K9me3 
23 
 
to its mono-methylated state (H3K9me1), which then forms a substrate for trimethylation by 
SUV39H1 (Zheng et al., 2014). H3K9 is mono-methylated by the histone methyltransferase, 
G9a (also known as EHMT2, euchromatic histone-lysine N-methyltransferase 2). 
H3K9me3 is a functionally important histone mark associated with transcriptional inactivation 
and gene silencing (Bosch-Presegué et al., 2011, Vaquero et al., 2007). Previously SUV39H1-
mediated H3K9me3 was shown to play a crucial role in maintaining genome stability (Peters et 
al., 2001), heterochromatin organization (Vaquero et al., 2007), chromosome segregation (Park 
et al., 2011), and mitosis (Melcher et al., 2000). H3K9me3 is essential in determining cell fates 
during development and differentiation (Nicetto et al., 2019); and it is involved in telomere 
maintenance and aging (García-Cao et al., 2004). 
The inactivation of SUV39H1 and H3K9me3 causes ectopic expression of cell-inappropriate 
genes leading to various human pathologies (Nicetto et al., 2019). Dysregulation of H3K9me3 
has been associated with diseases marked by oxidative stress and inflammation (Chen et al., 
2017a), and H3K9me3-mediated loss in heterochromatin and genome instability has been 
shown to be a hallmark in the onset of cancer (Dong et al., 2013). 
Defects in heterochromatin are most evident in SUV39H1 and SUV39H2 double knockout mice 
which lose H3K9me3 and display a significant reduction in embryonic viability, small stature, 
chromosome instability, and increased susceptibility to tumors (Peters et al., 2001). Evidence 
from transgenic mice also reveals that a loss or overexpression of SUV39H1 and SUV39H2 is 
associated with severe defects in growth and development due to alterations in cell cycle (Chiba 
et al., 2015), and apoptosis (Watson et al., 2014). 
2.7.2 Structure of SUV39H1 
The SUV39H1 gene is located on human chromosome X (Xp11.23) and encodes a 48 kDa 
protein that comprises of an N-terminal chromo-domain and a C-terminal SET domain (Figure 
2.8) (Wang et al., 2012, Firestein et al., 2000). The chromo-domain consists of a highly 
conserved motif that functions to target SUV39H1 to chromosomal loci and is involved in 
DNA, RNA, and histone binding (Wang et al., 2012). The SET domain together with the 
adjacent cysteine-rich domain is responsible for the catalytic histone methyltransferase activity 
of SUV39H1 (Wang et al., 2012). 
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Figure 2.8 Structure of SUV39H1 (Firestein et al., 2000) 
2.7.3 Post-Translational Regulation of SUV39H1: Acetylation and Ubiquitination 
The regulation of SUV39H1 expression and activity is critical for maintaining heterochromatin 
and genome stability (Bosch-Presegué et al., 2011). The acetylation-mediated ubiquitination of 
SUV39H1 controls the activity, stability, and cellular localization of SUV39H1 (Bosch-
Presegué et al., 2011, Vaquero et al., 2007). The acetylation of SUV39H1 on K266 in the 
catalytic SET domain is mediated by the acetyltransferase, CREB-binding protein (CBP)/p300, 
and decreases SUV39H1 activity (Bosch-Presegué et al., 2011). The acetylation of SUV39H1 
on K266 also enables the E3 ubiquitin ligase, murine double minute 2 (MDM2) to 
polyubiquitinate SUV39H1 on K87, thereby, targeting it for proteasomal degradation (Bosch-
Presegué et al., 2011). 
Sirt1 is a class III NAD
+
-dependent lysine deacetylase closely related to the yeast counterpart, 
Sir2 (silencing information regulator 2). Sirt1 is one of four chromatin-associated sirtuins (Sirt1, 
Sirt2, Sirt3, and Sirt6) that is predominantly localized in the nucleus where it regulates 
chromatin structure by catalyzing the deacetylation of acetyl-lysine residues of histones (H3K9, 
H3K4, and H4K16) and non-histone proteins in a reaction that cleaves NAD
+
 and generates O-
acetyl ADP-ribose (Vaquero et al., 2007). RNA-mediated silencing of Sirt1 expression in 
human liver cells led to hyper-acetylation of H3K9 and H4K16, and a reduction in H3K9me3 
(Zhang et al., 2014).      
Previously, co-immunoprecipitation studies have shown that Sirt1 interacts with SUV39H1 in 
vitro and this interaction between Sirt1 and SUV39H1 is essential in regulating SUV39H1 
activity and expression as well as maintaining H3K9me3 (Vaquero et al., 2007, Bosch-Presegué 
et al., 2011). Sirt1 interacts with the chromo-domain of SUV39H1 and deacetylates SUV39H1 
on K266, thereby, enhancing the catalytic activity of SUV39H1 and facilitating heterochromatin 
formation (Vaquero et al., 2007, Bosch-Presegué et al., 2011). Interestingly, other chromatin-
associated Sirtuins such as Sirt2, Sirt3, and Sirt6 failed to co-localize with SUV39H1 and 
suggested that SUV39H1-mediated deacetylation is Sirt1-dependent (Bosch-Presegué et al., 
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2011). No interaction was observed between Sirt1 and the H3K9 mono-methyltransferase, G9a 
in vitro and in vivo (Bosch-Presegué et al., 2011). 
Sirt1 also regulates SUV39H1 protein expression by inhibiting polyubiquitination of K87 in the 
SUV39H1 chromo-domain, preventing its proteasomal degradation and increasing its half-life 
by nearly four times (Bosch-Presegué et al., 2011). This was also observed in cervical cancer 
(HELA) cells where an increase in Sirt1 expression was positively correlated with an increase in 
SUV39H1 protein levels (Bosch-Presegué et al., 2011). Sirt1 also deacetylates H3K9Ac and 
recruits SUV39H1 promoting H3K9me3 and heterochromatin formation (Bosch-Presegué et al., 
2011). 
2.7.4 The Relationship between DNA Methylation and H3K9me3 
A complex interplay exists between DNA methylation and H3K9me3 (Fuks et al., 2003). DNA 
methylation forms a scaffold for MBD proteins to recruit SUV39H1 and maintain H3K9me3 in 
vivo (Fuks et al., 2003). DNMTs directly interact with enzymes that regulate H3K9me3, and 
both DNMT1 and DNMT3A are known to bind to SUV39H1 and mediate H3K9me3 (Fuks et 
al., 2003). DNMT1 and DNMT3B can also bind to histone deacetylases that remove acetyl 
residues from H3K9Ac enabling SUV39H1 to mediate H3K9me3 (Fuks et al., 2003). 
Furthermore, H3K9me3 can recruit DNMT3A and DNMT3B to unmethylated CpG 
dinucleotides in order to initiate methylation (Cedar and Bergman, 2009). This occurs via 
DNMT3L which binds to H3K9me3 and recruits DNMT3A and DNMT3B to methylate DNA 
(Ooi et al., 2007). A loss in DNA methylation and H3K9me3 is associated with a loss in 
heterochromatin and genome stability (Rose and Klose, 2014, Espada et al., 2004, Estève et al., 
2006). 
2.7.5 H2Ax 
Histone modifications are also central regulators of the DNA damage response. The 
phosphorylation of histone H2Ax on serine 139 (p-S139-H2Ax) is an early response to DNA 
double-strand breaks that is essential in mediating cell cycle arrest and initiating DNA repair 
pathways (Podhorecka et al., 2010). During DNA damage several protein kinases such as ataxia 
telangiectasia mutated (ATM), DNA-dependent protein kinase (DNA-PK), and ATM and 
RAD3-related protein (ATR) are triggered (Podhorecka et al., 2010). These protein kinases 
rapidly phosphorylate H2Ax on serine 139 causing a conformational change in the DNA-H2Ax 
complex that enables DNA repair proteins such as poly (ADP-ribose) polymerase 1 (PARP1) to 
be recruited to sites of DNA double-strand breaks and initiate DNA repair (Podhorecka et al., 
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2010). Previously, mouse embryonic stem cells deficient in H2Ax showed an increase in 
chromosomal aberrations and an inefficiency of DNA repair (Celeste et al., 2003, Bassing et al., 
2002). It was also found that H2Ax knockout cells have impaired recruitment of DNA repair 
proteins that are consistent with genome instability (Bassing et al., 2002). 
2.8. Apoptosis  
Irreparable DNA damage is a major initiating event of apoptosis. Apoptosis, also referred to as 
programmed cell death, is a physiological process that is responsible for the removal of cells in 
normal tissues as well as in some pathological states (Kerr et al., 1972). It is a sequential 
process involving cell shrinkage, chromatin condensation, DNA fragmentation, membrane 
blebbing, and the formation of apoptotic bodies (Hengartner, 2000, Kerr et al., 1994). The 
apoptotic bodies are phagocytosed and digested by nearby resident cells such as phagocytes and 
macrophages, preventing the spillage of intracellular contents and avoiding an inflammatory 
response (Kerr et al., 1994). Apoptotic bodies not subjected to phagocytosis are released into the 
adjacent lumen where they exhibit progressive dilation and degradation of cytoplasmic 
organelles in a process known as necrosis. Necrosis differs from apoptosis in which the cell 
swells and the plasma membrane ruptures releasing cytosolic contents into the extracellular 
space where they produce an inflammatory response (Kerr et al., 1994). 
Apoptosis has an indispensable role in both physiological and pathological conditions and 
anomalies in the apoptotic pathway are associated with various pathological conditions such as 
developmental defects, autoimmune diseases, and cancer with some diseases pertaining to 
excessive apoptosis or its absence thereof (Kerr et al., 1994). 
2.8.1. Caspases 
Caspases, also referred to as death proteases, are a family of cysteine aspartate proteases 
responsible for the initiation and execution of apoptosis (Hengartner, 2000). Caspases consist of 
an active site cysteine and are able to cleave proteins at aspartic acid residues (Hengartner, 
2000). To control the apoptotic process, caspases are initially synthesized as inactive zymogens 
that consist of three domains, an N-terminal pro-domain, a p20 domain, and a p10 domain. 
Proteolytic cleavage of these zymogens between the pro-domain and p20 domain as well as 
between the p20 domain and p10 domain leads to the activation of caspases (Hengartner, 2000). 
Caspases act by activating or inactivating apoptotic regulatory proteins and are responsible for 
majority of the morphological changes observed during apoptosis (Hengartner, 2000). 
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Initiator caspases such as caspase -2, -8, and -9 are the apical caspases in apoptosis and their 
cleavage and activation is required for the cleavage and activation of the downstream 
executioner caspases -3, -6, and -7. The activation of the executioner caspases is usually 
irreversible and ensures that apoptosis occurs (Hengartner, 2000). 
2.8.2. Pathways of Apoptosis 
Apoptosis is initiated by a variety of physiological death signals as well as pathological cellular 
insults (Hengartner, 2000). It is an energy-dependent process that occurs via several pathways 
of which the two main pathways involve caspase activation and are referred to as the intrinsic 
and extrinsic apoptotic pathways.  
2.8.2.1. The Intrinsic Apoptotic Pathway 
In the intrinsic apoptotic pathway, a death signal such as irreparable DNA damage or oxidative 
stress causes the pro-apoptotic molecule, BAX to translocate from the cytosol to the 
mitochondria where it undergoes a conformational change allowing it to act as an integral 
membrane protein (Elmore, 2007). BAX then interacts with members of the mitochondrial 
permeability transition pore (MPTP; adenine nucleotide translocator (ANT), voltage-dependent 
anion channel (VDAC), and peripheral benzodiazepine receptor (PBR)) resulting in the opening 
of the MPTP and release of cytochrome c and apoptosis inducing factor (AIF) from the 
mitochondria (Elmore, 2007). The cytochrome c binds with the apoptotic protease activating 
factor-1 (Apaf-1), pro-caspase-9, and ATP to form an apoptosome which cleaves and activates 
caspase-9, consequently activating caspases-3/7 resulting in apoptotic cell death (Figure 2.9) 
(Elmore, 2007).  
The anti-apoptotic molecule, BCL-2 maintains the integrity of the mitochondrial membrane by 
inhibiting cellular free radical formation, cytochrome c release, and caspase activation; thereby, 
preventing apoptosis (Elmore, 2007). Following apoptotic stimuli, the BH3-domain-only 
molecule, BIM translocates to the mitochondria where it interacts with BCL-2 to antagonize its 
anti-apoptotic activity and promote apoptosis (Elmore, 2007).  
2.8.2.2. The Extrinsic Apoptotic Pathway 
In the extrinsic apoptotic pathway, death ligands such as tumor necrosis factor alpha (TNF-α), 
tumor necrosis factor related apoptosis inducing ligand (TRAIL) and Fas ligand (FasL) bind to 
death receptors on the cell’s surface, type 1 TNF receptor (TNFR1), death receptor 4/5 (DR4/5), 
and Fas receptor (FasR), respectively (Elmore, 2007). These death receptors have an 
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intracellular death domain that recruits adaptor proteins such as TNFR-associated death domain 
(TRADD) and Fas-associated death domain (FADD) resulting in the formation of a death 
inducing signaling complex (DISC). DISC is responsible for the assembly and auto-catalytic 
activation of pro-caspase-8 to caspase-8 (Elmore, 2007). Caspase-8 activates caspases-3/7 
leading to apoptotic cell death (Figure 2.9). 
The activation of the extrinsic apoptotic pathway can initiate activation of the intrinsic apoptotic 
pathway via the BH3-domain-only molecule, Bid (Elmore, 2007). The activation of caspase-8, 
via the extrinsic apoptotic pathway, cleaves cytosolic p22 Bid at the amino-terminus leading to 
the formation of a p15 carboxy-terminal fragment of Bid known as truncated p15 Bid (tBid). 
tBid translocates to the mitochondria and directly activates pro-apoptotic proteins to induce 
mitochondrial membrane permeabilization causing the release of cytochrome c and activation of 
the intrinsic apoptotic cascade (Figure 2.9) (Elmore, 2007).  
 
Figure 2.9 Intrinsic and extrinsic pathways of apoptosis (Favaloro et al., 2012) 
2.9. The p53 Tumor Suppressor Protein 
The tumor suppressor protein, p53 often referred to as the guardian of the genome is a 
transcription factor involved in regulating the expression of genes critical for cell cycle arrest 
and apoptosis (Laptenko and Prives, 2006, Prives and Hall, 1999). It is encoded by one of the 
most frequently mutated genes in human cancers and over 50% of cancers have been reported to 
contain mutated or inactive p53 (Liu et al., 2013). 
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p53 is the central regulator of several cell signaling pathways and its major activators include 
DNA damage, excessive oncogene activation, hypoxia and oxidative stress (Figure 2.10) (Liu et 
al., 2013). Once activated, p53 acts as a critical regulator of cell proliferation by functioning as a 
checkpoint protein to monitor DNA damage, arrest the cell cycle, and initiate DNA repair 
(Figure 2.10) (Kruiswijk et al., 2015, Vousden and Prives, 2009). In the event of irreparable 
DNA damage, p53 induces apoptosis preventing the propagation of cells with damaged DNA 
and tumor formation (Liu et al., 2013). p53 also functions to recruit core transcriptional 
machinery to its target promoters enabling the transcription of genes such as MDM2, p21, and 
BAX which are involved in regulating cell proliferation and apoptosis (Kruiswijk et al., 2015, 
Vousden and Prives, 2009). p53 also has a major role in metabolic pathways by regulating 
glycolysis (Budanov, 2014, Liu et al., 2018), fatty acid oxidation (Liu et al., 2018), and 
autophagy (Jin, 2005). It enhances the antioxidant response and prevents oxidative damage to 
cellular macromolecules (Budanov, 2014). 
Dysregulation in the expression of p53 has been linked with several cellular abnormalities and 
diseases such as neurodegenerative disorders (Chang et al., 2012, Szybińska and Leśniak, 2017) 
and cancer (Spafford et al., 1996). It has been shown to affect metabolic pathways contributing 
to the metabolic changes characteristic of the cancer phenotype (Liu et al., 2018). Previously, 
p53 knockout mice displayed excessive DNA damage and inhibition of apoptosis and are 
extremely susceptible to early tumor development (Donehower et al., 1992).  
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Figure 2.10 Activation and functions of p53 (Bieging et al., 2014) 
2.9.1. Regulation of p53 
The tight regulation of p53 function is essential for maintaining normal cell growth and 
preventing tumourigenesis (Brooks and Gu, 2003). p53 is subjected to a variety of post-
translational modifications that regulate its function as a tumor suppressor protein (Brooks and 
Gu, 2003). The role of post-translational modifications such as phosphorylation, acetylation, 
and ubiquitination in regulating the stability and activity of p53 has been extensively studied 
(Barlev et al., 2001, Shieh et al., 1997, Tang et al., 2008); and our previous work showed that 
FA has the ability to induce genotoxic and cytotoxic effects in human liver (HepG2) cells by 
post-translationally increasing the stability and activity of p53 (Ghazi et al., 2017) (Addendum 
A). However, p53 is also regulated at the transcriptional and post-transcriptional level by 
promoter methylation and N6-methyladenosine (m6A) RNA methylation (Chmelarova et al., 
2013, Kang et al., 2001, Uddin et al., 2019). 
2.9.1.1. Promoter Methylation of p53 
The methylation of CpG dinucleotides within the p53 gene promoter is essential in regulating 
p53 transcription. The p53 gene contains a basal promoter region of approximately 85 base pairs 
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that is essential for its full promoter activity and the p53 promoter has putative binding sites for 
transcription factors (Tuck and Crawford, 1989).  
Alterations in p53 promoter methylation have been linked with an array of p53 mutations, loss 
in tumor suppressor function, and cancer progression (Mitsudomi et al., 1992). Previously, it 
was determined that promoter hypermethylation of p53 inhibits the binding of transcription 
factors and reduces p53 transcription whereas promoter hypomethylation enables access to 
transcription factors and increases p53 expression (Chmelarova et al., 2013, Kang et al., 2001).  
The epigenetic silencing of tumor suppressor genes is a frequent phenomenon of cancer cells, 
and studies conducted on glioma cell lines indicate that p53 promoter methylation significantly 
affects p53 expression contributing to tumourigenesis (Soto-Reyes and Recillas-Targa, 2010, 
Amatya et al., 2005). Similarly, single-site methylation of the p53 gene promoter was associated 
with a significant reduction in wild-type p53 and tumourigenesis in vivo (Pogribny et al., 2000).  
2.9.1.2. M6A RNA Methylation 
Chemical modifications of RNA transcripts are involved in regulating RNA-protein and RNA-
RNA interactions, thereby, regulating gene expression by modulating RNA processing, 
localization, translation, and decay (Meyer et al., 2015, Wang et al., 2014b, Xiao et al., 2016, 
Zheng et al., 2013). M6A RNA methylation is a predominant post-transcriptional modification 
of mammalian messenger RNA (mRNA) that occurs in an estimated 0.2-0.5% of adenines (Fu 
et al., 2014, Geula et al., 2015). It is found in the coding region, 3’ untranslated region (UTR), 
and 5’UTR of mRNA where it plays an important role in gene expression regulation (Meyer et 
al., 2015, Wang et al., 2015, Wang et al., 2014b), animal development (Frye et al., 2018), and 
disease (Hsu et al., 2017).  
M6A is deposited on mRNA co-transcriptionally by a methyltransferase complex which 
consists of methyltransferase-like 3 (METTL3), methyltransferase-like 14 (METTL14), and 
Wilm’s tumor 1-associated protein (WTAP) (Figure 2.11) (Wang and He, 2014, Liu et al., 
2014). METTL3 is catalytically active and regulates m6A levels by transferring a methyl group 
from SAM to the N-6 position of specific adenines on the target mRNA, METTL14 facilitates 
RNA binding and stabilizes METTL3, whereas WTAP binds to the METTL3-METTL14 
complex and is required for substrate recruitment and nuclear localization (Liu et al., 2014, Shi 
et al., 2019). Adaptor proteins such as Vir-like m6A methyltransferase-associated (VIRMA), 
zinc finger CCCH-type-containing 13 (ZC3H13), and RNA binding motif protein 15 (RBM15) 
also form part of the methyltransferase complex where they act as cofactors to facilitate RNA 
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binding, nuclear localization, and m6A deposition (Shi et al., 2019). The demethylases, fat mass 
and obesity-associated protein (FTO) and ALKB homolog 5 (ALKBH5), are Fe
2+
 and alpha-
ketoglutarate-dependent and function by oxidizing N-methyl groups of m6A to a 
hydroxymethyl group (Figure 2.11) (Woo and Chambers, 2019, Jia et al., 2011). Previously, 
knockdown of FTO increased m6A levels on myc mRNA leading to mRNA decay and myc 
downregulation (Su et al., 2018). Knockdown of FTO also increased m6A levels on USP7 
mRNA leading to USP7 degradation and decreased USP7 expression in human lung cancer cell 
lines (Li et al., 2019). Additionally, knockdown of METTL3 and METTL14 reduced m6A-p21 
levels and decreased p21 mRNA and protein expression in HELA cells (Li et al., 2017a). 
M6A is enriched on several RNA transcripts where it affects RNA processing by recruiting 
specific reader proteins: YT521-B homology domain containing proteins 1 and 2 (YTHDC1 and 
YTHDC2) and the YT521-B homology domain family proteins 1, 2, and 3 (YTHDF1, 
YTHDF2, and YTHDF3) (Meyer et al., 2015, Wang et al., 2015, Wang et al., 2014b, Xiao et al., 
2016, Zheng et al., 2013). YTHDF1, YTHDF3, and YTHDC2 regulate mRNA translation by 
interacting with translation machinery and enhancing translation efficiency (Meyer et al., 2015, 
Wang et al., 2015), YTHDF1 induces mRNA degradation by recruiting the CCR4-NOT 
deadenylation complex (Wang et al., 2014b), and YTHDC1 regulates cellular localization and 
mRNA splicing by recruiting the pre-mRNA splicing factor, SRSF3 (Figure 2.11) (Xiao et al., 
2016, Zheng et al., 2013). 
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Figure 2.11 Regulation and function of m6A RNA methylation (Liao et al., 2018) 
M6A-containing genes are enriched in important cellular processes, and a subset of m6A sites 
appear in response to stimuli and stress (Dominissini et al., 2015, Meyer et al., 2015). 
Previously, dietary factors have also been found to affect m6A levels on RNA transcripts (Li et 
al., 2016, Lu et al., 2018) suggesting a possible effect of FA on the m6A levels and regulation of 
the stress response protein, p53. Studies on m6A and p53 have indicated that m6A at the point 
mutated codon 273 of p53 pre-mRNA promotes the expression of p53 R273H mutant protein 
and drug resistance of cancer cells (Uddin et al., 2019). Similarly, alterations in m6A have been 
strongly associated with a reduction in wild type p53 and the presence of p53 mutations in 
patients with acute myeloid leukemia (Kwok et al., 2017). 
2.10. MicroRNAs 
MicroRNAs (miRNAs) are endogenously expressed small (20-23 nucleotides) non-coding RNA 
molecules that control both physiological and pathological processes by post-transcriptionally 
regulating gene expression (Winter et al., 2009). This process occurs in a sequence specific 
manner and involves binding of the miRNA to the 3’UTR of mRNA and negatively regulating 
the processing, stability, and translation of the mRNA (Winter et al., 2009).  
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MiRNAs are critical for normal development and are involved in various biological processes 
such as cell cycle and apoptosis (Winter et al., 2009, O'Brien et al., 2018). While a single 
miRNA can regulate several target mRNAs, several miRNAs can also target a single mRNA; 
and dysregulation in the expression and regulatory functions of miRNAs have been implicated 
in the pathogenesis of several human diseases (Winter et al., 2009, O'Brien et al., 2018). 
MiRNAs are known to be aberrantly expressed in cancer where they are capable of acting as 
either tumor suppressors or oncogenes depending on their expression and cellular targets 
(Winter et al., 2009, O'Brien et al., 2018). MiRNAs also serve as cell signaling molecules to 
mediate cell-cell communication and aberrant levels of extracellular miRNAs have been 
identified as potential biomarkers for cancer and other human diseases (Weiland et al., 2012, 
Chen et al., 2008, Kim, 2015, Wang et al., 2014a, Ha, 2011). 
2.10.1. Biogenesis of MiRNAs 
The biogenesis of miRNAs occurs via two pathways: a canonical pathway and a non-canonical 
pathway (O'Brien et al., 2018). The canonical pathway is mediated by RNA polymerase II and 
III and is the dominant pathway by which mammalian miRNAs are generated (Winter et al., 
2009, O'Brien et al., 2018). In this pathway, miRNA biogenesis begins in the nucleus where the 
RNA polymerase II and RNA polymerase III dependent transcription of miRNA genes 
generates a long primary miRNA (pri-miRNA) transcript that can fold into a hairpin structure 
(Winter et al., 2009, O'Brien et al., 2018). These pri-miRNAs are cleaved into short 70 
nucleotide precursor miRNAs (pre-miRNAs) by the micro-processor complex which is 
comprised of the RNase III enzyme, Drosha and its cofactor, DGCR8 (DiGeorge Syndrome 
Critical Region 8) (O'Brien et al., 2018). DGCR8 binds to double-stranded RNA and positions 
Drosha approximately 11 base pairs away from the base of the hairpin stem where its two 
RNase domains cleaves the 5’ and 3’ arms of the pri-miRNA hairpin (Winter et al., 2009). The 
resultant pre-miRNAs are then exported out of the nucleus to the cytoplasm by the Ran-GTP-
dependent transporter, exportin-5 where it is cleaved by the RNase III enzyme, Dicer and its 
double-stranded RNA binding cofactor, trans-activation response (TAR) RNA-binding protein 
(TRBP) to yield mature double-stranded miRNA duplexes that are approximately 20-23 
nucleotides in length (Winter et al., 2009). These mature miRNAs are then loaded together with 
Argonaute (Ago2) proteins into the RNA-induced silencing complex (RISC) leading to 
unwinding of the miRNA duplex and the generation of mature single-stranded miRNAs (Winter 
et al., 2009). The passenger strand is degraded and the mature miRNA binds, via 
complementary base pairing, to target mRNAs leading to the degradation, inhibition of 
translation, and deadenylation of the mRNA (Figure 2.12) (Winter et al., 2009).  
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Figure 2.12 The canonical pathway of microRNA biogenesis (Winter et al., 2009) 
The non-canonical pathway of miRNA biogenesis is also referred to as the Drosha-DGCR8-
independent and Dicer-TRBP-independent pathways (O'Brien et al., 2018). In this pathway, 
mirtrons (pre-miRNAs produced from the introns of mRNAs during splicing) and 7-
methylguanosine-capped pre-miRNAs are produced independent of Drosha and directly 
exported into the cytoplasm where, independent of Dicer-TRBP cleavage, it is loaded onto 
Ago2 proteins and further processed by RISC into mature miRNAs (O'Brien et al., 2018). 
2.10.2. MiRNAs and DNA Methylation 
DNA methylation in miRNA gene promoters has been reported as a mechanism that may cause 
dysregulation of mature miRNAs and consequently impact gene expression (Moore et al., 
2013). Previously, the loss of DNMT1 and DNMT3B revealed that approximately 10% of 
miRNAs are regulated by DNA methylation (Han et al., 2007); and the hypo- and hyper- 
methylation of miRNA gene promoters causes an increase and decrease in miRNA expression, 
respectively (Ortiz et al., 2018). Additionally, miRNAs can regulate DNA methylation patterns 
by altering the expression of DNMTs (Fabbri et al., 2007, Garzon et al., 2009). 
MiR-29b, a member of the miR-29 family that consists of miR-29a, miR-29b, and miR-29c, 
displays sequence complementarity to the 3’UTRs of DNMT3A and DNMT3B (Garzon et al., 
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2009, Fabbri et al., 2007). The expression of miR-29b is inversely correlated with the 
expression of DNMT3A and DNMT3B in lung cancer tissues and miR-29b was shown to 
directly target both DNMT3A and DNMT3B (Fabbri et al., 2007). MiR-29b was also found to 
regulate the expression of DNMT1 in an indirect mechanism that involves the direct targeting 
and repression of the transcriptional activator, Sp1 (Fabbri et al., 2007, Garzon et al., 2009). 
Additionally, the expression of miR-29b is itself regulated by DNA methylation and enforced 
expression of miR-29b was shown to decrease the expression of DNMT1, DNMT3A, and 
DNMT3B leading to DNA hypomethylation in acute myeloid leukemia cells (Garzon et al., 
2009).  
2.10.3. MiRNAs and Histone Methylation 
MiRNAs have been reported to control chromatin structure and histone methylation by post-
transcriptionally regulating the expression of chromatin-modifying enzymes such as histone 
methyltransferases and demethylases (Moore et al., 2013).  
MiR-200a is a member of the miR-200 family (miR-200a, miR-200b, miR-200c, miR-429, and 
miR-141) that has been shown to play a significant role in regulating histone methylation 
(Eades et al., 2011). MiR-200a modulates H3K9me3 by directly targeting Sirt1 and decreasing 
the activity and expression of the histone methyltransferase, SUV39H1 (Eades et al., 2011, 
Bosch-Presegué et al., 2011, Vaquero et al., 2007). MiR-200a was also found to directly target 
SUV39H2 and reduce H3K9me3 in CD4+ T cells (Quiroz et al., 2019). Additionally, histone 
methylation on miRNA gene promoters can influence the expression of miRNAs. H3K9me3 on 
the promoter of miR-200a decreased miR-200a expression and led to epithelial to mesenchymal 
transition in glioma cells (Bian et al., 2019). 
2.11. The Role of Epigenetics in Mycotoxicology  
The chronic consumption of mycotoxin-contaminated commodities is long known to cause 
harmful effects in humans and animals. In the body, mycotoxins are bio-transformed into highly 
toxic metabolites that interact with various biomolecules such as DNA and RNA affecting their 
normal functions with adverse cellular outcomes (Dai et al., 2017). To date, the majority of the 
information available on mycotoxins indicate that they are unlikely to act via a single well-
defined mechanism; and recently, epigenetic studies on mycotoxins have provided insights into 
their mechanisms of toxicity (Bbosa et al., 2013, Marin-Kuan et al., 2008, Chuturgoon et al., 
2014a, Chuturgoon et al., 2014b, Dai et al., 2017, Demirel et al., 2015, Zhu et al., 2016, Zhu et 
al., 2014, Sancak and Ozden, 2015, Han et al., 2016). 
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AFB1 is a mycotoxin produced by fungi of the genus Aspergillus that was shown to induce 
hepatocellular carcinoma by altering global DNA methylation (Hernandez-Vargas et al., 2015) 
and inducing promoter hypermethylation of genes (MGMT, RASSF1A, and p16) involved in 
DNA repair and cell cycle control (Zhang et al., 2003, Zhang et al., 2002).  
OTA, a mycotoxin produced by some Aspergillus and Penicillium species, induced cytotoxicity 
by decreasing global DNA methylation in vitro (Li et al., 2015), and OTA-induced 
nephrotoxicity occurred via modulation of DNMT1 and alterations in global DNA methylation 
in vivo (Li et al., 2015). OTA-induced promoter hypermethylation of cell adhesion-related 
genes, E-cadherin and N-cadherin activated the Wnt and PI3K/AKT signaling pathways leading 
to nephrotoxicity (Li et al., 2015).  
The Fusarium mycotoxins, FB1, zearalenone, T2-toxin, and DON were also shown to have 
epigenetic effects in vitro and in vivo. FB1 induced chromatin instability and liver 
tumourigenesis by inducing global DNA hypomethylation and histone methylation in human 
liver cells (Chuturgoon et al., 2014a). FB1 inhibited miR-27b, increased cytochrome P450 1B1, 
and altered promoter methylation of tumor suppressor genes (c-myc, p15, p16, and e-cadherin) 
leading to hepatic neoplastic transformation (Chuturgoon et al., 2014b, Demirel et al., 2015). 
FB1-induced increase in H3K9me2/3 and decrease in H3K9Ac and H4K20me3 also provided a 
mechanism for carcinogenesis in rat kidney cells (Sancak and Ozden, 2015).  
Zearalenone induced global DNA hypomethylation (So et al., 2014), and decreased H3K9me3, 
H3K4me2, and H4K20me1/2/3 leading to a reduction in cell viability (Zhu et al., 2014). In 
contrast, other Fusarium mycotoxins such as DON and T2-toxin induced autophagy and 
apoptosis by increasing both global DNA methylation and histone methylation (Han et al., 
2016, Zhu et al., 2016).  
These studies provide evidence for the role of epigenetic mechanisms in regulating mycotoxin-
induced toxicities, and suggest that alterations in epigenetic modifications may be a crucial 
underlying mechanism of their toxicities. 
 
 
 
 
38 
 
2.12. References 
Abdul NS, Nagiah S, Chuturgoon AA. (2016). Fusaric acid induces mitochondrial stress in 
human hepatocellular carcinoma (HepG2) cells. Toxicon, 119, 336-344. 
Abdul NS, Nagiah S, Chuturgoon AA. (2019). Fusaric acid induces NRF2 as a cytoprotective 
response to prevent NLRP3 activation in the liver derived HepG2 cell line. Toxicology In Vitro, 
55, 151-159. 
Amatya VJ, Naumann U, Weller M, Ohgaki H. (2005). TP53 promoter methylation in human 
gliomas. Acta Neuropathologica, 110, 178-184. 
Bacon C, Porter J, Norred W, Leslie J. (1996). Production of fusaric acid by Fusarium species. 
Applied and Environmental Microbiology, 62, 4039-4043. 
Bacon CW, Porter JK, Norred WP. (1995). Toxic interaction of fumonisin B1 and fusaric acid 
measured by injection into fertile chicken egg. Mycopathologia, 129, 29-35. 
Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, Berger SL. (2001). 
Acetylation of p53 activates transcription through recruitment of coactivators/histone 
acetyltransferases. Molecular Cell, 8, 1243-1254. 
Bassing CH, Chua KF, Sekiguchi J, Suh H, Whitlow SR, Fleming JC, Monroe BC, Ciccone 
DN, Yan C, Vlasakova K. (2002). Increased ionizing radiation sensitivity and genomic 
instability in the absence of histone H2AX. Proceedings of the National Academy of Sciences, 
99, 8173-8178. 
Bbosa GS, Kitya D, Odda J, Ogwal-okeng J. (2013). Aflatoxins metabolism, effects on 
epigenetic mechanisms and their role in carcinogenesis. Health, 5, 720-726. 
Bennett J, Klich M. (2003). Mycotoxins. Clinical Microbiological Reviews, 16, 497-516. 
Bian E, Chen X, Xu Y, Ji X, Cheng M, Wang H, Fang Z, Zhao B. (2019). A central role for 
MeCP2 in the epigenetic repression of miR-200c during epithelial-to-mesenchymal transition of 
glioma. Journal of Experimental and Clinical Cancer Research, 38, 1-15. 
Bieging KT, Mello SS, Attardi LD. (2014). IUnravelling mechanisms of p53-mediated tumour 
suppression. Nature Reviews Cancer, 14, 359-370. 
Bochner BR, Huang HC, Schieven GL, Ames BN. (1980). Positive selection for loss of 
tetracycline resistance. Journal of Bacteriology, 143, 926-933. 
39 
 
Bosch-Presegué L, Raurell-Vila H, Marazuela-Duque A, Kane-Goldsmith N, Valle A, Oliver J, 
Serrano L, Vaquero A. (2011). Stabilization of Suv39H1 by SirT1 is part of oxidative stress 
response and ensures genome protection. Molecular Cell, 42, 210-223. 
Brooks CL, Gu W. (2003). Ubiquitination, phosphorylation and acetylation: the molecular basis 
for p53 regulation. Current Opinion in Cell Biology, 15, 164-171. 
Budanov AV. (2014). The role of tumor suppressor p53 in the antioxidant defense and 
metabolism. Subcellular Biochemistry, 85, 337-358.  
Cedar H, Bergman Y. (2009). Linking DNA methylation and histone modification: patterns and 
paradigms. Nature Reviews Genetics, 10, 295-304. 
Celeste A, Difilippantonio S, Difilippantonio MJ, Fernandez-Capetillo O, Pilch DR, 
Sedelnikova OA, Eckhaus M, Ried T, Bonner WM, Nussenzweig A. (2003). H2AX 
haploinsufficiency modifies genomic stability and tumor susceptibility. Cell, 114, 371-383. 
Chang JR, Ghafouri M, Mukerjee R, Bagashev A, Chabrashvili T, Sawaya BE. (2012). Role of 
p53 in neurodegenerative diseases. Neurodegenerative Diseases, 9, 68-80. 
Cheishvili D, Chik F, Li CC, Bhattacharya B, Suderman M, Arakelian A, Hallett M, Rabbani 
SA, Szyf M. (2014). Synergistic effects of combined DNA methyltransferase inhibition and 
MBD2 depletion on breast cancer cells; MBD2 depletion blocks 5-aza-2ʹ-deoxycytidine-
triggered invasiveness. Carcinogenesis, 35, 2436-2446. 
Chen J, Zhang YC, Huang C, Shen H, Sun B, Cheng X, Zhang YJ, Yang YG, Shu Q, Yang Y. 
(2019). m6A Regulates Neurogenesis and Neuronal Development by Modulating Histone 
Methyltransferase Ezh2. Genomics, Proteomics and Bioinformatics, 17, 154-168. 
Chen TT, Wu SM, Ho SC, Chuang HC, Liu CY, Chan YF, Kuo LW, Feng PH, Li WT, Chen 
KY. (2017a). SUV39H1 reduction is implicated in abnormal inflammation in COPD. Scientific 
Reports, 7, 46667-46924. 
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo L, Zhang Y, Chen L, Guo X. (2008). 
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer 
and other diseases. Cell Research, 18, 997-1006. 
Chen Z, Luo Q, Wang M, Chen B. (2017b). A rapid method with UPLC for the determination 
of fusaric acid in fusarium strains and commercial food and feed products. Indian Journal of 
Microbiology, 57, 68-74. 
40 
 
Cheng J, Yang H, Fang J, Ma L, Gong R, Wang P, Li Z, Xu Y. (2015).  Molecular mechanism 
for USP7-mediated DNMT1 stabilization by acetylation. Nature Communications, 6, 7023-
7033. 
Cheng L, Tang Y, Chen X, Zhao L, Liu S, Ma Y, Wang N, Zhou K, Zhou J, Zhou M. (2018). 
Deletion of MBD2 inhibits proliferation of chronic myeloid leukaemia blast phase cells. Cancer 
Biology and Therapy, 19, 676-686. 
Cheng X, Blumenthal RM. (2008). Mammalian DNA methyltransferases: a structural 
perspective. Structure, 16, 341-350. 
Chiba T, Saito T, Yuki K, Zen Y, Koide S, Kanogawa N, Motoyama T, Ogasawara S, Suzuki E, 
Ooka Y. (2015). Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic 
therapy of hepatocellular carcinoma. International Journal of Cancer, 136, 289-298. 
Chmelarova M, Krepinska E, Spacek J, Laco J, Beranek M, Palicka V. (2013). Methylation in 
the p53 promoter in epithelial ovarian cancer. Clinical and Translational Oncology, 15, 160-
163. 
Chuturgoon A, Phulukdaree A, Moodley D. (2014a). Fumonisin B1 induces global DNA 
hypomethylation in HepG2 cells–An alternative mechanism of action. Toxicology, 315, 65-69. 
Chuturgoon AA, phulukdaree A, Moodley D. (2014b). Fumonisin B1 modulates expression of 
human cytochrome P450 1b1 in human hepatoma (Hepg2) cells by repressing Mir-27b. 
Toxicology Letters, 227, 50-55. 
Dabrowski MJ, Wojtas B. (2019). Global DNA methylation patterns in human gliomas and their 
interplay with other epigenetic modifications. International Journal of Molecular Sciences, 20, 
3478-3494. 
Dai Y, Huang K, Zhang B, Zhu L, Xu W. (2017). Aflatoxin B1-induced epigenetic alterations: 
an overview. Food and Chemical Toxicology, 109, 683-689. 
D'alton A, Etherton B. (1984). Effects of fusaric acid on tomato root hair membrane potentials 
and ATP levels. Plant Physiology, 74, 39-42. 
Demirel G, Alpertunga B, Ozden S. (2015). Role of fumonisin B1 on DNA methylation changes 
in rat kidney and liver cells. Pharmaceutical Biology, 53, 1302-1310. 
41 
 
Denis H, Ndlovu MN, Fuks F. (2011). Regulation of mammalian DNA methyltransferases: a 
route to new mechanisms. EMBO Reports, 12, 647-656. 
Detich N, Theberge J, Szyf M. (2002). Promoter-specific activation and demethylation by 
MBD2/demethylase. Journal of Biological Chemistry, 277, 35791-35794. 
Devaraja S, Girish KS, Santhosh MS, Hemshekhar M, Nayaka SC, Kemparaju K. (2013). 
Fusaric acid, a mycotoxin, and its influence on blood coagulation and platelet function. Blood 
Coagulation and Fibrinolysis, 24, 419-423. 
Devnarain N, Tiloke C, Nagiah S, Chuturgoon AA. (2017). Fusaric acid induces oxidative stress 
and apoptosis in human cancerous oesophageal SNO cells. Toxicon, 126, 4-11. 
Dhani S, Nagiah S, Naidoo DB, Chuturgoon AA. (2017). Fusaric Acid immunotoxicity and 
MAPK activation in normal peripheral blood mononuclear cells and Thp-1 cells. Scientific 
Reports, 7, 3051-3060. 
Diniz S, Oliveira R. (2009). Effects of fusaric acid on Zea mays L. seedlings. Phyton (Buenos 
Aires), 78, 155-160. 
Diringer MN, Kramarcy NR, Brown JW, Thurmond JB. (1982). Effect of fusaric acid on 
aggression, motor activity, and brain monoamines in mice. Pharmacology Biochemistry and 
Behavior, 16, 73-79. 
Dodge JE, Okano M, Dick F, Tsujimoto N, Chen T, Wang S, Ueda Y, Dyson N, Li E. (2005). 
Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, 
chromosomal instability, and spontaneous immortalization. Journal of Biological Chemistry, 
280, 17986-17991. 
Dominissini D, Moshitch-Moshkovitz S, Amariglio N, Rechavi G. (2015). Transcriptome-wide 
mapping of N6-methyladenosine by m6A-Seq. Methods in Enzymology, 560, 131-147.  
Donehower LA, Harvey M, Slagle BL, Mcarthur MJ, Montgomery Jr CA, Butel JS, Bradley A. 
(1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous 
tumours. Nature, 356, 215-221. 
Dong C, Wu Y, Wang Y, Wang C, Kang T, Rychahou PG, Chi YI, Evers BM, Zhou BP. 
(2013). Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast 
cancer. Oncogene, 32, 1351-1362. 
42 
 
Dowd PF. (1988). Toxicological and biochemical interactions of the fungal metabolites fusaric 
acid and kojic acid with xenobiotics in Heliothis zea (F.) and Spodoptera frugiperda. Pesticide 
Biochemistry and Physiology, 32, 123-134. 
Du Q, Luu PL, Stirzaker C, Clark SJ. (2015). Methyl-CpG-binding domain proteins: readers of 
the epigenome. Epigenomics, 7, 1051-1073. 
Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. (2011). MiR-200a regulates SIRT1 
expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary 
epithelial cells. Journal of Biological Chemistry, 286, 25992-26002. 
Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird PW. (1999). CpG 
island hypermethylation in human colorectal tumors is not associated with DNA 
methyltransferase overexpression. Cancer Research, 59, 2302-2306. 
Elmore S. (2007). Apoptosis: a review of programmed cell death. Toxicologic Pathology, 35, 
495-516. 
Engel M, Eggert C, Kaplick PM, Eder M, Röh S, Tietze L, Namendorf C, Arloth J, Weber P, 
Rex-Haffner M. (2018). The role of m6A/m-RNA methylation in stress response regulation. 
Neuron, 99, 389-403.  
Espada J, Ballestar E, Fraga MF, Villar-Garea A, Juarranz A, Stockert JC, Robertson KD, Fuks 
F, Esteller M. (2004). Human DNA methyltransferase 1 is required for maintenance of the 
histone H3 modification pattern. Journal of Biological Chemistry, 279, 37175-37184. 
Estève PO, Chin HG, Smallwood A, Feehery GR, Gangisetty O, Karpf AR, Carey MF, Pradhan 
S. (2006). Direct interaction between DNMT1 and G9a coordinates DNA and histone 
methylation during replication. Genes and Development, 20, 3089-3103. 
Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, 
Fernandez-Cymering C. (2007). MicroRNA-29 family reverts aberrant methylation in lung 
cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy 
of Sciences, 104, 15805-15810. 
Fairchild A, Grimes J, Porter J, Croom Jr W, Daniel L, Hagler Jr W. (2005). Effects of 
diacetoxyscirpenol and fusaric acid on poults: Individual and combined effects of dietary 
diacetoxyscirpenol and fusaric acid on turkey poult performance. International Journal of 
Poultry Science, 4, 350-355. 
43 
 
Favaloro B, Allocati N, Graziano V, Di Ilio C, De Laurenzi V. (2012). Role of apoptosis in 
disease. Aging (Albany NY), 4, 330-349. 
Fernandez-Pol J, Klos D, Hamilton P. (1993). Cytotoxic activity of fusaric acid on human 
adenocarcinoma cells in tissue culture. Anticancer Research, 13, 57-64. 
Fernandez-Pol JA. (1998). Antiviral agent. Google patents number: EP0869789A4. 
Firestein R, Cui X, Huie P, Cleary ML. (2000). SET domain-dependent regulation of 
transcriptional silencing and growth control by SUV39H1, a mammalian ortholog of Drosophila 
Su (var) 3-9. Molecular and Cellular Biology, 20, 4900-4909. 
Frye M, Harada BT, Behm M, He C. (2018). RNA modifications modulate gene expression 
during development. Science, 361, 1346-1349. 
Fu Y, Dominissini D, Rechavi G, He C. (2014). Gene expression regulation mediated through 
reversible m 6 A RNA methylation. Nature Reviews Genetics, 15, 293-306. 
Fukz F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. (2003). The methyl-CpG-binding 
protein MeCP2 links DNA methylation to histone methylation. Journal of Biological Chemistry, 
278, 4035-4040. 
García-Cao M, O’sullivan R, Peters AH, Jenuwein T, Blasco MA. (2004). Epigenetic regulation 
of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. 
Nature Genetics, 36, 94-99. 
Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, 
Muthusamy N. (2009). MicroRNA-29b induces global DNA hypomethylation and tumor 
suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B 
and indirectly DNMT1. Blood, 113, 6411-6418. 
Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AA, Kol N, Salmon-Divon M, 
Hershkovitz V, Peer E, Mor N, Manor YS. (2015). M6A mRNA methylation facilitates 
resolution of naïve pluripotency toward differentiation. Science, 347, 1002-1006. 
Ghazi T, Nagiah S, Tiloke C, Abdul NS, Chuturgoon AA. (2017). Fusaric acid induces DNA 
damage and post‐translational modifications of p53 in human hepatocellular carcinoma 
(HepG2) cells. Journal of Cellular Biochemistry, 118, 3866-3874. 
44 
 
Girault I, Tozlu S, Lidereau R, Bièche I. (2003). Expression analysis of DNA 
methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clinical Cancer Research, 9, 
4415-4422. 
Gopalakrishnan S, Van Emburgh BO, Robertson KD. (2008). DNA methylation in development 
and human disease. Mutation Research, 647, 30-38. 
Grant R, Coggan S, Smythe G. (2009). The physiological action of picolinic acid in the human 
brain. International Journal of Tryptophan Research, 2, 71-79.  
Ha TY. (2011). MicroRNAs in human diseases: from cancer to cardiovascular disease. Immune 
Network, 11, 135-154. 
Han J, Wang QC, Zhu CC, Liu J, Zhang Y, Cui XS, Kim NH, Sun SC. (2016). Deoxynivalenol 
exposure induces autophagy/apoptosis and epigenetic modification changes during porcine 
oocyte maturation. Toxicology and Applied Pharmacology, 300, 70-76. 
Han L, Witmer PDW, Casey E, Valle D, Sukumar S. (2007). DNA methylation regulates 
microRNA expression. Cancer Biology and Therapy, 6, 1290-1294. 
Handy DE, Castro R, Loscalzo J. (2011). Epigenetic modifications: basic mechanisms and role 
in cardiovascular disease. Circulation, 123, 2145-2156. 
Hendrich B, Guy J, Ramsahoye B, Wilson VA, Bird A. (2001). Closely related proteins MBD2 
and MBD3 play distinctive but interacting roles in mouse development. Genes and 
Development, 15, 710-723. 
Hendrich B, Hardeland U, Ng HH, Jiricny J, Bird A. (1999). The thymine glycosylase MBD4 
can bind to the product of deamination at methylated CpG sites. Nature, 401, 301-304. 
Hengartner MO. (2000). The biochemistry of apoptosis. Nature, 407, 685-700. 
Hernandez-Vargas H, Castelino J, Silver MJ, Dominguez-Salas P, Cros MP, Durand G, Calvez-
Kelm FL, Prentice AM, Wild CP, Moore SE. (2015). Exposure to aflatoxin B1 in utero is 
associated with DNA methylation in white blood cells of infants in Gambia. International 
Journal of Epidemiology, 44, 1238-1248. 
Hervouet E, Peixoto P, Delage-Mourroux R, Boyer-Guittaut M, Cartron PF. (2018). Specific or 
not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma. Clinical 
Epigenetics, 10, 17-34. 
45 
 
Hidaka H, Nagatsu T, Takeya K, Takeuchi T, Suda H, Kojiri K, Matsuzaki M, Umezawa H. 
(1969). Fusaric acid, a hypotensive agent produced by fungi. The Journal of Antibiotics, 22, 
228-230. 
Hsu PJ, Shi H, He C. (2017). Epitranscriptomic influences on development and disease. 
Genome Biology, 18, 197-205. 
Iraola-Guzán S, Estivill X, Rabionet R. (2011). DNA methylation in neurodegenerative 
disorders: a missing link between genome and environment? Clinical Genetics, 80, 1-14. 
Jeltsch A, Jurkowska RZ. (2016). Allosteric control of mammalian DNA methyltransferases–a 
new regulatory paradigm. Nucleic Acids Research, 44, 8556-8575. 
Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, Yi C, Lindahl T, Pan T, Yang YG. (2011). N6-
methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nature 
Chemical Biology, 7, 885-887. 
Jia Y, Li P, Fang L, Zhu H, Xu L, Cheng H, Zhang J, Li F, Feng Y, Li Y. (2016). Negative 
regulation of DNMT3A de novo DNA methylation by frequently overexpressed UHRF family 
proteins as a mechanism for widespread DNA hypomethylation in cancer. Cell Discovery, 2, 
16007-16026. 
Jin B, Li Y, Robertson KD. (2011). DNA methylation: superior or subordinate in the epigenetic 
hierarchy? Genes and Cancer, 2, 607-617. 
Jin S. (2005). p53, autophagy and tumor suppression. Autophagy, 1, 171-173. 
Kang JH, Kim SJ, Noh DY, Park IA, Choe KJ, Yoo OJ, Kang HS. (2001). Methylation in the 
p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG 
methylation in the p53 promoter and the mutation of the p53 gene in the progression from 
ductal carcinoma in situ to invasive ductal carcinoma. Laboratory Investigation, 81, 573-579. 
Kerr JF, Winterford CM, Harmon BV. (1994). Apoptosis its significance in cancer and cancer 
therapy. Cancer, 73, 2013-2026. 
Kerr JF, Wyllie AH, Currie AR. (1972). Apoptosis: a basic biological phenomenon with 
wideranging implications in tissue kinetics. British Journal of Cancer, 26, 239-257. 
Kim H, Kwon YM, Kin JS, Han J, Shim YM, Park J, Kim DH. (2006). Elevated mRNA levels 
of DNA methyltransferase‐1 as an independent prognostic factor in primary nonsmall cell lung 
46 
 
cancer. Cancer: Interdisciplinary International Journal of the American Cancer Society, 107, 
1042-1049. 
Kim YK. (2015). Extracellular microRNAs as biomarkers in human disease. Chonnam Medical 
Journal, 51, 51-57. 
Kobayashi H, Sakurai T, Imai M, Takahashi N, Fukuda A, Yayoi O, Sato S, Nakabayashi K, 
Hata K, Sotomaru Y. (2012). Contribution of intragenic DNA methylation in mouse gametic 
DNA methylomes to establish oocyte-specific heritable marks. PLoS Genetics, 8, 1002440-
1002454. 
Köhler K, Bentrup FW. (1983). The effect of fusaric acid upon electrical membrane properties 
and ATP level in photoautotrophic cell suspension cultures of Chenopodium rubrum L. 
Zeitschrift für Pflanzenphysiologie, 109, 355-361. 
Kruiswijk F, Labuschagne CF, Vousden KH. (2015). p53 in survival, death and metabolic 
health: a lifeguard with a licence to kill. Nature Reviews Molecular Cell Biology, 16, 393-405. 
Kuźniak E. (2001). Effects of fusaric acid on reactive oxygen species and antioxidants in tomato 
cell cultures. Journal of Phytopathology, 149, 575-582. 
Kwok CT, Marshall AD, Rasko JE, Wong JJ. (2017). Genetic alterations of m6A regulators 
predict poorer survival in acute myeloid leukemia. Journal of Hematology and Oncology, 10, 
39-44. 
Lai W, Jia J, Yan B, Jiang Y, Shi Y, Chen L, Mao C, Liu X, Tang H, Gao M. (2018). Baicalin 
hydrate inhibits cancer progression in nasopharyngeal carcinoma by affecting genome 
instability and splicing. Oncotarget, 9, 901-914. 
Laptenko O, Prives C. (2006). Transcriptional regulation by p53: one protein, many 
possibilities. Cell Death and Differentiation, 13, 951-961. 
Li C, Zuo C, Deng G, Kuang R, Yang Q, Hu C, Sheng O, Zhang S, Ma L, Wei Y. (2013). 
Contamination of bananas with beauvericin and fusaric acid produced by Fusarium oxysporum 
f. sp. cubense. PLoS One, 8, 70226-70236. 
Li J, Han Y, Zhang H, Qian Z, Jia W, Gao Y, Zheng H, Li B. (2019). The m6A demethylase 
FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA. 
Biochemical and Biophysical Research Communications, 512, 479-485. 
47 
 
Li M, Zhao X, Wang W, Shi H, Pan Q, Lu Z, Perez SP, Suganthan R, He C, Bjørås M. (2018). 
Ythdf2-mediated m6A mRNA clearance modulates neural development in mice. Genome 
Biology, 19, 69-84. 
Li Q, Li X, Tang H, Jiang B, Dou Y, Gorospe M, Wang W. (2017a). NSUN2‐mediated m5C 
methylation and METTL3/METTL14‐mediated m6A methylation cooperatively enhance p21 
translation. Journal of Cellular Biochemistry, 118, 2587-2598. 
Li X, Gao J, Huang K, Qi X, Dai Q, Mei X, Xu W. (2015). Dynamic changes of global DNA 
methylation and hypermethylation of cell adhesion-related genes in rat kidneys in response to 
ochratoxin A. World Mycotoxin Journal, 8, 465-476. 
Li X, Yang J, Zhu Y, Liu Y, Shi XE, Yang G. (2016). Mouse maternal high-fat intake 
dynamically programmed mRNA m6A modifications in adipose and skeletal muscle tissues in 
offspring. International Journal of Molecular Sciences, 17, 1336-1344. 
Li X, Zhang ZL, Wang HF. (2017b). Fusaric acid (FA) protects heart failure induced by 
isoproterenol (ISP) in mice through fibrosis prevention via TGF-β1/SMADs and PI3K/AKT 
signaling pathways. Biomedicine and Pharmacotherapy, 93, 130-145. 
Liao S, Sun H, Xu C. (2018). YTH domain: a family of N6-methyladenosine (m6A) readers. 
Genomics, Proteomics and Bioinformatics, 16, 99-107. 
Lin RK, Wang YC. (2014). Dysregulated transcriptional and post-translational control of DNA 
methyltransferases in cancer. Cell and Bioscience, 4, 1-11. 
Liu C, Teng ZQ, Santistevan NJ, Szulwach KE, Guo W, Jin P, Zhao X. (2010). Epigenetic 
regulation of miR-184 by MBD1 governs neural stem cell proliferation and differentiation. Cell 
Stem Cell, 6, 433-444. 
Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, Jia G, Yu M, Lu Z, Deng X. (2014). A 
METTL3–METTL14 complex mediates mammalian nuclear RNA N 6-adenosine methylation. 
Nature Chemical Biology, 10, 93-95. 
Liu J, Zhang C, Feng Z. (2013). Tumor suppressor p53 and its gain-of-function mutants in 
cancer. Acta Biochimica et Biophysica Sinica, 46, 170-179. 
Liu J, Zhang C, Hu W, Feng Z. (2018). Tumor suppressor p53 and metabolism. Journal of 
Molecular Cell Biology, 11, 284-292. 
48 
 
Liu W, Wang N, Lu M, Du XJ, Xing BC. (2016). MBD2 as a novel marker associated with poor 
survival of patients with hepatocellular carcinoma after hepatic resection. Molecular Medicine 
Reports, 14, 1617-1623. 
Lu N, Li X, Yu J, Li Y, Wang C, Zhang L, Wang T, Zhong X. (2018). Curcumin attenuates 
lipopolysaccharide‐induced hepatic lipid metabolism disorder by modification of m6A RNA 
methylation in piglets. Lipids, 53, 53-63. 
Magdinier F, Wolffe AP. (2001). Selective association of the methyl-CpG binding protein 
MBD2 with the silent p14/p16 locus in human neoplasia. Proceedings of the National Academy 
of Sciences, 98, 4990-4995. 
Mamur S, Ünal F, Yilmaz S, Erikel E, Yüzbaşıoğlu D. (2018). Evaluation of the cytotoxic and 
genotoxic effects of mycotoxin fusaric acid. Drug and Chemical Toxicology, 1-9. 
Marin-Kuan M, Cavin C, Delatour T, Schilter B. (2008). Ochratoxin A carcinogenicity involves 
a complex network of epigenetic mechanisms. Toxicon, 52, 195-202. 
Marin ML, Murtha J, Dong W, Pestka JJ. (1996). Effects of mycotoxins on cytokine production 
and proliferation in EL-4 thymoma cells. Journal of Toxicology and Environmental Health, 48, 
379-396. 
May HD, Wu Q, Blake CK. (2000). Effects of the Fusarium spp. mycotoxins fusaric acid and 
deoxynivalenol on the growth of Ruminococcus albus and Methanobrevibacter ruminantium. 
Canadian Journal of Microbiology, 46, 692-699. 
Melcher M, Schmid M, Aagaard L, Selenko P, Laible G, Jenuwein T. (2000). Structure-function 
analysis of SUV39H1 reveals a dominant role in heterochromatin organization, chromosome 
segregation, and mitotic progression. Molecular and Cellular Biology, 20, 3728-3741. 
Meyer H, Skhosana ZD, Motlanthe M, Louw W, Rohwer E. (2019). Long term monitoring 
(2014–2018) of multi-mycotoxins in South African commercial maize and wheat with a locally 
developed and validated LC-MS/MS method. Toxins, 11, 271-291. 
Meyer KD, Patil DP, Zhou J, Zinoviev A, Skabkin MA, Elemento O, Pestova TV, Qian SB, 
Jaffrey SR. (2015). 5′ UTR m6A promotes cap-independent translation. Cell, 163, 999-1010. 
Miranda-Gonçalves V, Lameirinhas A, Henrique R, Jeronimo C. (2018). Metabolism and 
epigenetic interplay in cancer: Regulation and putative therapeutic targets. Frontiers in 
Genetics, 9, 1-21. 
49 
 
Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D’amico D, Bodner S, Oie HK, Linnoila RI, 
Mulshine JL, Minna JD. (1992). p53 gene mutations in non-small-cell lung cancer cell lines and 
their correlation with the presence of ras mutations and clinical features. Oncogene, 7, 171-180. 
Moarii M, Boeva V, Vert JP, Reyal F. (2015). Changes in correlation between promoter 
methylation and gene expression in cancer. BMC Genomics, 16, 873-886. 
Moore LD, Le T, Fan G. (2013). DNA methylation and its basic function. 
Neuropsychopharmacology, 38, 23-38. 
Morales S, Monzo M, Navarro A. (2017). Epigenetic regulation mechanisms of microRNA 
expression. Biomolecular Concepts, 8, 203-212. 
Naghitorabi M, Asl JM, Sadeghi HMM, Rabbani M, Jafarian-Dehkordi A, Javanmard HS. 
(2013). Quantitative evaluation of DNMT3B promoter methylation in breast cancer patients 
using differential high resolution melting analysis. Research in Pharmaceutical Sciences, 8, 
167-175. 
Nicetto D, Donahue G, Jain T, Peng T, Sidoli S, Sheng L, Montavon T, Becker JS, Grindheim 
JM, Blahnik K. (2019). H3K9me3-heterochromatin loss at protein-coding genes enables 
developmental lineage specification. Science, 363, 294-297. 
Novakovic B, Wong NC, Sibson M, Ng HK, Morley R, Manuelpillai U, Down T, Rakyan VK, 
Beck S, Hiendleder S. (2010). DNA methylation-mediated down-regulation of DNA 
methyltransferase-1 (DNMT1) is coincident with, but not essential for, global hypomethylation 
in human placenta. Journal of Biological Chemistry, 285, 9583-9593. 
O'brien J, Hayder H, Zayed Y, Peng C. (2018). Overview of microRNA biogenesis, 
mechanisms of actions, and circulation. Frontiers in Endocrinology, 9, 1-12. 
Ogata S, Inoue K, Iwata K, Okumura K, Taguchi H. (2001). Apoptosis induced by picolinic 
acid-related compounds in HL-60 cells. Bioscience, Biotechnology, and Biochemistry, 65, 2337-
2339. 
Ogunbo S, Broomhead J, Ledoux D, Bermudez A, Rottinghaus G. (2007). The individual and 
combined effects of fusaric acid and T-2 toxin in broilers and turkeys. International Journal of 
Poultry Science, 6, 484-488. 
Okano M, Bell DW, Haber DA, Li E. (1999). DNA methyltransferases Dnmt3a and Dnmt3b are 
essential for de novo methylation and mammalian development. Cell, 99, 247-257. 
50 
 
Omotayo OP, Omotayo AO, Mwanza M, Babalola OO. (2019). Prevalence of mycotoxins and 
their consequences on Human health. Toxicological Research, 35, 1-7. 
Ooi SK, Qiu C, Bernstein E, Li K, Jia D, Yang Z, Erdjument-Bromage H, Tempst P, Lin SP, 
Allis CD. (2007). DNMT3L connects unmethylated lysine 4 of histone H3 to de novo 
methylation of DNA. Nature, 448, 714-717. 
Ortiz IMDP, Barros-Filho MC, Dos Reis MB, Beltrami CM, Marchi FA, Kuasne H, Do Canto 
LM, De Mello JBH, Abildgaard C, Pinto CAL. (2018). Loss of DNA methylation is related to 
increased expression of miR-21 and miR-146b in papillary thyroid carcinoma. Clinical 
Epigenetics, 10, 144-156. 
Osumi Y, Takaori S, Fujiwara M. (1973). Preventive effect of fusaric acid, a dopamine β-
hydroxylase inhibitor, on the gastric ulceration induced by water-immersion stress in rats. 
Japanese Journal of Pharmacology, 23, 904-906. 
Park JA, Kim AJ, Kang Y, Jung YJ, Kim HK, Kim KC. (2011). Deacetylation and methylation 
at histone H3 lysine 9 (H3K9) coordinate chromosome condensation during cell cycle 
progression. Molecules and Cells, 31, 343-349. 
Patra SK, Patra A, Zhao H, Dahiya R. (2002). DNA methyltransferase and demethylase in 
human prostate cancer. Molecular Carcinogenesis, 33, 163-171. 
Pavlovkin J, Mistrik I, Prokop M. (2004). Some aspects of the phytotoxic action of fusaric acid 
on primary Ricinus roots. Plant Soil and Environment, 50, 397-401. 
Peng L, Yuan Z, Ling H, Fukasawa K, Robertson K, Olashaw N, Koomen J, Chen J, Lane WS, 
Seto E. (2011). SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters 
its activities. Molecular and Cellular Biology, 31, 4720-4734. 
Peters AH, O’carroll D, Scherthan H, Mechtler K, Sauer S, Schöfer C, Weipoltshammer K, 
Pagani M, Lachner M, Kohlmaier A. (2001). Loss of the Suv39h histone methyltransferases 
impairs mammalian heterochromatin and genome stability. Cell, 107, 323-337. 
Pieterman C, Conemans E, Dreijerink K, De Laat J, Timmers HTM, Vriens M, Valk G. (2014). 
Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: 
natural history and function of menin in tumorigenesis. Endocrine-Related Cancer, 21, 121-142. 
51 
 
Placinta C, D’mello J, Macdonald A. (1999). A review of worldwide contamination of cereal 
grains and animal feed with Fusarium mycotoxins. Animal Feed Science and Technology, 78, 
21-37. 
Podhorecka M, Skladanowski A, Bozko P. (2010). H2AX phosphorylation: its role in DNA 
damage response and cancer therapy. Journal of Nucleic Acids, 2010, 1-9. 
Pogribny IP, Pogribna M, Christman JK, James SJ. (2000). Single-site methylation within the 
p53 promoter region reduces gene expression in a reporter gene construct: possible in vivo 
relevance during tumorigenesis. Cancer Research, 60, 588-594. 
Porter JK, Bacon CW, Wray EM, Hagler Jr WM. (1995). Fusaric acid in fusarium moniliforme 
cultures, corn, and feeds toxic to livestock and the neurochemical effects in the brain and pineal 
gland of rats. Natural Toxins, 3, 91-100. 
Pozuelo J. (1978). Method of pharmacologically treating drug addiction with fusaric acid. 
Google patents number: US4124715A. 
Prives C, Hall PA. (1999). The p53 pathway. Journal of Pathology, 187, 112-126. 
Quiroz EN, Quiroz RN, Lugo LP, Martínez GA, Escorcia LG, Torres HG, Bonfanti AC, Del 
CMM, Sanchez E, Camacho JLV. (2019). Integrated analysis of microRNA regulation and its 
interaction with mechanisms of epigenetic regulation in the etiology of systemic lupus 
erythematosus. PloS One, 14, 1-13. 
Rajendran G, Shanmuganandam K, Bendre A, Mujumdar D, Goel A, Shiras A. (2011). 
Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas. Journal 
of Neuro-Oncology, 104, 483-494. 
Reddy R, Larson C, Brimer G, Frappier B, Reddy C. (1996). Developmental toxic effects of 
fusaric acid in CD1 mice. Bulletin of Environmental Contamination and Toxicology, 57, 354-
360. 
Reimann M, Lee S, Loddenkemper C, Dörr JR, Tabor V, Aichele P, Stein H, Dörken B, 
Jenuwein T, Schmitt CA. (2010). Tumor stroma-derived TGF-β limits myc-driven 
lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell, 17, 262-272. 
Rose NR, Klose RJ. (2014). Understanding the relationship between DNA methylation and 
histone lysine methylation. Biochimica et Biophysica Acta (BBA)-Gene Regulatory 
Mechanisms, 1839, 1362-1372. 
52 
 
Rosenfeld CS. (2010). Animal models to study environmental epigenetics. Biology of 
Reproduction, 82, 473-488. 
Ruoß M, Damm G, Vosough M, Ehret L, Grom-Baumgarten C, Petkov M, Naddalin S, 
Ladurner R, Seehofer D, Nussler A, Sajadian  S. (2019). Epigenetic modifications of the liver 
tumour cell line HepG2 increase their drug metabolic capacity. International Journal of 
Molecular Sciences, 20, 347-362. 
Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H, Hirohashi S. (2003). Increased 
protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the 
malignant potential and poor prognosis of human hepatocellular carcinomas. International 
Journal of Cancer, 105, 527-532. 
Sancak D, Ozden S. (2015). Global histone modifications in fumonisin B1 exposure in rat 
kidney epithelial cells. Toxicology In Vitro, 29, 1809-1815. 
Sapko O, Utarbaeva AS, Makulbek S. (2011). Effect of fusaric acid on prooxidant and 
antioxidant properties of the potato cell suspension culture. Russian Journal of Plant 
Physiology, 58, 828-835. 
Scott A, Song J, Ewing R, Wang Z. (2014). Regulation of protein stability of DNA 
methyltransferase 1 by post-translational modifications. Acta Biochimica et Biophysica Sinica, 
46, 199-203. 
Shi H, Wei J, He C. (2019). Where, when, and how: context-dependent functions of RNA 
methylation writers, readers, and erasers. Molecular Cell, 74, 640-650. 
Shieh SY, Ikeda M, Taya Y, Prives C. (1997). DNA damage-induced phosphorylation of p53 
alleviates inhibition by MDM2. Cell, 91, 325-334. 
Shimshoni J, Cuneah O, Sulyok M, Krska R, Galon N, Sharir B, Shlosberg A. (2013). 
Mycotoxins in corn and wheat silage in Israel. Food Additives and Contaminants: Part A, 30, 
1614-1625. 
Singh VK, Singh HB, Upadhyay RS. (2017). Role of fusaric acid in the development of 
fusarium wilt symptoms in tomato: Physiological, biochemical and proteomic perspectives. 
Plant Physiology and Biochemistry, 118, 320-332. 
Smith MC, Madec S, Coton E, Hymery N. (2016). Natural co-occurrence of mycotoxins in 
foods and feeds and their in vitro combined toxicological effects. Toxins, 8, 94-129. 
53 
 
Smith T, Macdonald E. (1991). Effect of fusaric acid on brain regional neurochemistry and 
vomiting behavior in swine. Journal of Animal Science, 69, 2044-2049. 
Smith TK, McMillan EG, Castillo JB. (1997). Effect of feeding blends of fusarium mycotoxin-
contaminated grains containing deoxynivalenol and fusaric acid on growth and feed 
consumption of immature swine. Journal of Animal Science, 75, 2184-2191. 
Smith TK, Sousadias MG. (1993). Fusaric acid content of swine feedstuffs. Journal of 
Agricultural and Food Chemistry, 41, 2296-2298. 
So MY, Tian Z, Phoon YS, Sha S, Antoniou MN, Zhang J, Wu RS, Tan-Un KC. (2014). Gene 
expression profile and toxic effects in human bronchial epithelial cells exposed to zearalenone. 
PLoS One, 9, 1-19. 
Soto-Reyes E, Recillas-Targa F. (2010). Epigenetic regulation of the human p53 gene promoter 
by the CTCF transcription factor in transformed cell lines. Oncogene, 29, 2217-2227. 
Spafford MF, Koeppe J, Pan Z, Archer PG, Meyers AD, Franklin WA. (1996). Correlation of 
tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in 
laryngeal squamous cell carcinoma. Archives of Otolaryngology–Head & Neck Surgery, 122, 
627-632. 
Šrobárová A, Eged Š, Da Silva JT, Ritieni A, Santini A. (2009). The use of Bacillus subtilis for 
screening fusaric acid production by Fusarium spp. Czech Journal of Food Sciences, 27, 203-
209. 
Stack Jr BC, Hansen JP, Ruda JM, Jaglowski J, Shvidler J, Hollenbeak CS. (2004). Fusaric 
acid: a novel agent and mechanism to treat HNSCC. Otolaryngology—Head and Neck Surgery, 
131, 54-60. 
Streit E, Schwab C, Sulyok M, Naehrer K, Krska R, Schatzmayr G. (2013). Multi-mycotoxin 
screening reveals the occurrence of 139 different secondary metabolites in feed and feed 
ingredients. Toxins, 5, 504-523. 
Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C. 
(2018). R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling. 
Cell, 172, 90-105.  
Szybińska A, Leśniak W. (2017). P53 dysfunction in neurodegenerative diseases-the cause or 
effect of pathological changes? Aging and disease, 8, 506-518. 
54 
 
Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. (2008). Acetylation is indispensable for p53 
activation. Cell, 133, 612-626. 
Telles-Pupulin AR, Diniz S, Bracht A, Ishii-Iwamoto E. (1996). Effects of fusaric acid on 
respiration in maize root mitochondria. Biologia Plantarum, 38, 421-429. 
Terasawa F, Kameyama M. (1971). The clinical trial of a new hypotensive agent, fusaric acid 
(5-butylpicolinic acid): the preliminary report. Japanese Circulation Journal, 35, 339-357. 
Thankam FG, Boosani CS, Dilisio MF, Agrawal DK. (2019). Epigenetic mechanisms and 
implications in tendon inflammation. International Journal of Molecular Medicine, 43, 3-14. 
Toshiharu N, Hiroyoshi H, Hiroshi K, Kazumi T, Hamao U, Tomio T, Hiroyuki S. (1970). 
Inhibition of dopamine β-hydroxylase by fusaric acid (5-butylpicolinic acid) in vitro and in 
vivo. Biochemical Pharmacology, 19, 35-44. 
Tuck SP, Crawford L. (1989). Characterization of the human p53 gene promoter. Molecular and 
Cellular Biology, 9, 2163-2172. 
Uddin MB, Roy KR, Hosain SB, Khiste SK, Hill RA, Jois SD, Zhao Y, Tackett AJ, Liu YY. 
(2019). An N6-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the 
expression of R273H mutant protein and drug resistance of cancer cells. Biochemical 
Pharmacology, 160, 134-145. 
Vaquero A, Scher M, Erdjument-Bromage H, Tempst P, Serrano L, Reinberg D. (2007). SIRT1 
regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. Nature, 
450, 440-444. 
Voss K, Porter J, Bacon C, Meredith F, Norred W. (1999). Fusaric acid and modification of the 
subchronic toxicity to rats of fumonisins in F. moniliforme culture material. Food and Chemical 
Toxicology, 37, 853-861. 
Vousden KH, Prives C. (2009). Blinded by the light: the growing complexity of p53. Cell, 137, 
413-431. 
Wang J, Zhang KY, Liu SM, Sen S. (2014a). Tumor-associated circulating microRNAs as 
biomarkers of cancer. Molecules, 19, 1912-1938. 
55 
 
Wang T, Xu C, Liu Y, Fan K, Li Z, Sun X, Ouyang H, Zhang X, Zhang J, Li Y. (2012). Crystal 
structure of the human SUV39H1 chromodomain and its recognition of histone H3K9me2/3. 
PloS One, 7, 1-7. 
Wang X, He C. (2014). Dynamic RNA modifications in post-transcriptional regulation. 
Molecular Cell, 56, 5-12. 
Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G. (2014b). N 
6-methyladenosine-dependent regulation of messenger RNA stability. Nature, 505, 117-120. 
Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, Weng X, Chen K, Shi H, He C. (2015). 
N6-methyladenosine modulates messenger RNA translation efficiency. Cell, 161, 1388-1399. 
Wang Y, Li Y, Yue M, Wang J, Kumar S, Wechsler-Reya RJ, Zhang Z, Ogawa Y, Kellis M, 
Duester G. (2018). N6-methyladenosine RNA modification regulates embryonic neural stem 
cell self-renewal through histone modifications. Nature Neuroscience, 21, 195-206. 
Watson G, Wickramasekara S, Palomera-Sanchez Z, Black C, Maier C, Williams D, Dashwood 
R, Ho E. (2014). SUV39H1/H3K9me3 attenuates sulforaphane-induced apoptotic signaling in 
PC3 prostate cancer cells. Oncogenesis, 3, 1-9. 
Webster KE, O’bryan MK, Fletcher S, Crewther PE, Aapola U, Craig J, Harrison DK, Aung H, 
Phutikanit N, Lyle R. (2005). Meiotic and epigenetic defects in Dnmt3L-knockout mouse 
spermatogenesis. Proceedings of the National Academy of Sciences, 102, 4068-4073. 
Weiland M, Gao XH, Zhou L, Mi QS. (2012). Small RNAs have a large impact: circulating 
microRNAs as biomarkers for human diseases. RNA Biology, 9, 850-859. 
Winter J, Jung S, Keller S, Gregory RI, Diederichs S. (2009). Many roads to maturity: 
microRNA biogenesis pathways and their regulation. Nature Cell Biology, 11, 228-234. 
Woo HH, Chambers SK. (2019). Human ALKBH3-induced m1A demethylation increases the 
CSF-1 mRNA stability in breast and ovarian cancer cells. Biochimica et Biophysica Acta 
(BBA)-Gene Regulatory Mechanisms, 1862, 35-46. 
Xiao W, Adhikari S, Dahal U, Chen YS, Hao YJ, Sun BF, Sun HY, Li A, Ping XL, Lai WY. 
(2016). Nuclear m6A reader YTHDC1 regulates mRNA splicing. Molecular Cell, 61, 507-519. 
56 
 
Yarychkivska O, Shahabuddin Z, Comfort N, Boulard M, Bestor TH. (2018). BAH domains and 
a histone-like motif in DNA methyltransferase 1 (DNMT1) regulate de novo and maintenance 
methylation in vivo. Journal of Biological Chemistry, 293, 19466-19475. 
Ye J, Montero M, Stack Jr BC. (2013). Effects of fusaric acid treatment on HEp2 and docetaxel-
resistant HEp2 laryngeal squamous cell carcinoma. Chemotherapy, 59, 121-128. 
Yiannikouris A, Jouany JP. (2002). Mycotoxins in feeds and their fate in animals: a review. 
Animal Research, 51, 81-99. 
Yin ES, Rakhmankulova M, Kucera K, De Sena Filho JG, Portero CE, Narváez-Trujillo A, 
Holley SA, Strobel SA. (2015). Fusaric acid induces a notochord malformation in zebrafish via 
copper chelation. BioMetals, 28, 783-789. 
Zain ME. (2011). Impact of mycotoxins on humans and animals. Journal of Saudi Chemical 
Society, 15, 129-144. 
Zamudio NM, Scott HS, Wolski K, Lo CY, Law C, Leong D, Kinkel SA, Chong S, Jolley D, 
Smyth GK. (2011). DNMT3L is a regulator of X chromosome compaction and post-meiotic 
gene transcription. PLoS One, 6, 1-12.  
Zhang B, Chen J, Cheng AS, Ko BC. (2014). Depletion of sirtuin 1 (SIRT1) leads to epigenetic 
modifications of telomerase (TERT) gene in hepatocellular carcinoma cells. PLoS One, 9, 
84931-84937. 
Zhang YJ, Ahsan H, Chen Y, Lunn RM, Wang LY, Chen SY, Lee PH, Chen CJ, Santella RM. 
(2002). High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship 
to aflatoxin B1–DNA adduct levels in human hepatocellular carcinoma. Molecular 
Carcinogenesis, 35, 85-92. 
Zhang YJ, Chen Y, Ahsan H, Lunn RM, Lee PH, Chen CJ, Santella RM. (2003). Inactivation of 
the DNA repair gene O6‐methylguanine‐DNA methyltransferase by promoter hypermethylation 
and its relationship to aflatoxin B1‐DNA adducts and p53 mutation in hepatocellular carcinoma. 
International Journal of Cancer, 103, 440-444. 
Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, Vågbø CB, Shi Y, Wang WL, Song 
SH. (2013). ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and 
mouse fertility. Molecular Cell, 49, 18-29. 
57 
 
Zheng H, Chen L, Pledger WJ, Fang J, Chen J. (2014). p53 promotes repair of heterochromatin 
DNA by regulating JMJD2b and SUV39H1 expression. Oncogene, 33, 734-744. 
Zhu CC, Hou YJ, Han J, Cui XS, Kim NH, Sun SC. (2014). Zearalenone exposure affects 
epigenetic modifications of mouse eggs. Mutagenesis, 29, 489-495. 
Zhu CC, Zhang Y, Duan X, Han J, Sun SC. (2016). Toxic effects of HT-2 toxin on mouse 
oocytes and its possible mechanisms. Archives of Toxicology, 90, 1495-1505. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
58 
 
CHAPTER 3 
Fusaric acid-induced promoter methylation of DNA methyltransferases triggers 
DNA hypomethylation in human hepatocellular carcinoma (HepG2) cells 
Terisha Ghazi, Savania Nagiah, Pragalathan Naidoo, and Anil A. Chuturgoon* 
Discipline of Medical Biochemistry and Chemical Pathology, School of Laboratory Medicine 
and Medical Science, College of Health Sciences, Howard College Campus, University of Kwa-
Zulu Natal, Durban 4041, South Africa 
*Corresponding author: Professor Anil A. Chuturgoon, Discipline of Medical Biochemistry and 
Chemical Pathology, School of Laboratory Medicine and Medical Science, College of Health 
Sciences, Howard College Campus, University of Kwa-Zulu Natal, Durban 4041, South Africa. 
Telephone: +27 31 260 4404; Fax: +27 31 260 4785; Email: CHUTUR@ukzn.ac.za 
Author Email Addresses: 
Terisha Ghazi: terishaghazi@gmail.com 
Savania Nagiah: nagiah.savania@gmail.com 
Pragalathan Naidoo: pragalathan.naidoo@gmail.com 
Anil A. Chuturgoon: CHUTUR@ukzn.ac.za 
 
 
 
Epigenetics 14 (8): 804-817 (2019) 
DOI: 10.1080/15592294.2019.1615358 
 
 
 
 
59 
 
ABSTRACT 
Fusaric acid (FA), a mycotoxin contaminant of maize, displays toxicity in plants and animals; 
however, its epigenetic mechanism is unknown. DNA methylation, an epigenetic modification 
that regulates gene expression, is mediated by DNA methyltransferases (DNMTs; DNMT1, 
DNMT3A, and DNMT3B) and demethylases (MBD2). The expression of DNMTs and 
demethylases are regulated by promoter methylation, microRNAs (miR-29b), and post-
translational modifications (ubiquitination). Alterations in these DNA methylation modifying 
enzymes affect DNA methylation patterns and offer novel mechanisms of FA toxicity. We 
determined the effect of FA on global DNA methylation as well as a mechanism of FA-induced 
changes in DNA methylation by transcriptional (promoter methylation), post-transcriptional 
(miR-29b), and post-translational (ubiquitination) regulation of DNMTs and MBD2 in the 
human hepatocellular carcinoma (HepG2) cell line. FA induced global DNA hypomethylation 
(p < 0.0001) in HepG2 cells. FA decreased the mRNA and protein expression of DNMT1 (p < 
0.0001), DNMT3A (p < 0.0001), and DNMT3B (p < 0.0001) by upregulating miR-29b (p < 
0.0001) and inducing promoter hypermethylation of DNMT1 (p < 0.0001) and DNMT3B (p < 
0.0001). FA decreased the ubiquitination of DNMT1 (p = 0.0753), DNMT3A (p = 0.0008), and 
DNMT3B (p < 0.0001) by decreasing UHRF1 (p < 0.0001) and USP7 (p < 0.0001). FA also 
induced MBD2 promoter hypomethylation (p < 0.0001) and increased MBD2 expression (p < 
0.0001). Together these results indicate that FA induces global DNA hypomethylation by 
altering DNMT promoter methylation, upregulating miR-29b, and increasing MBD2 in HepG2 
cells. 
KEYWORDS: Fusaric acid; global DNA hypomethylation; promoter methylation; DNA 
methyltransferases; miR-29b; DNMT ubiquitination; MBD2 
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Introduction 
Fusaric acid (FA; 5-butylpicolinic acid), a ubiquitous mycotoxin and secondary metabolite 
produced by pathogenic fungi of the genus Fusarium, contaminates agricultural foods and 
exhibits low to moderate toxicity [1]. Previously, feed samples were reported to contain an 
average of 643 µg/kg FA [2] and approximately 2.5 to 18 µg/kg FA were reported to 
contaminate commercial foods and feeds [3]. These foods, especially maize, form an essential 
part of the human and animal diet; and the consumption of FA-contaminated commodities may 
have serious health implications. Studies evaluating the effects of FA are limited and 
understanding the molecular and epigenetic effects of FA exposure is important in decreasing 
FA contamination and lowering the risk of FA-related adverse health outcomes. 
FA is phytotoxic to several plants by inhibiting root and leaf cell function [4] and has been 
implicated in the pathogenesis of wilt diseases [4, 5, 6, 7]; it is a highly lipophilic toxin that 
traverses cellular membranes and induces toxicity by altering various biochemical processes. 
Known mechanisms of FA toxicity include alterations in membrane permeability [5, 7], 
oxidative stress [8, 9], mitochondrial dysfunction [6, 10, 11], DNA damage [12, 13], and 
apoptosis [10, 12, 14, 15]. It is also immuno-toxic to peripheral blood mononuclear cells 
(PBMCs) and human monocytic (THP-1) cells [14]. FA has tumouristatic and tumouricidal 
effects in several mammalian tumor cell lines, thereby, displaying anti-cancer activity [13, 16]. 
It has neurochemical effects in mice brain and reduced aggressive behavior and motor activity 
[17]. FA also attenuates isoproterenol induced heart failure by preventing the development of 
cardiac hypertrophy and fibrosis [18].  
FA is a chelating agent and the removal of essential divalent cations such as calcium affects 
bone ossification [19] and blood coagulation [20]; it also chelates copper causing hypotension 
[21, 22] and notochord malformation [23]. The toxicity of FA may also be attributed to 
synergistic interactions with other co-occurring mycotoxins such as fumonisin B1 (FB1) [24], 
deoxynivalenol (DON) [25], and 4,15-diacetoxyscirpenol (DAS) [26]. 
DNA methylation is a common epigenetic modification that regulates gene expression and plays 
a major role in cell signaling pathways that are essential in the normal growth and development 
of higher organisms. Dysregulation in the DNA methylation pattern has been observed in 
several human diseases such as cancer [27] and neurodegeneration [28]. DNA methylation is 
catalyzed by DNA methyltransferases (DNMTs) such as DNMT1, DNMT3A, and DNMT3B. 
DNMT1 is a maintenance DNMT that binds specifically to hemi-methylated DNA and is 
responsible for conserving the methylation pattern from one generation to the next [29]. 
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DNMT3A and DNMT3B are de novo DNMTs that target unmethylated cytosine bases to 
initiate methylation [29]. DNMTs are the major regulators of DNA methylation and alterations 
in their expression and activity affects DNA methylation patterns and cellular function. The 
activity and stability of DNMTs are regulated by promoter methylation, microRNAs, and post-
translational modifications (PTMs). 
Promoter methylation, methylation of CpG islands within the promoter region of specific genes, 
is important in regulating gene transcription; promoter hypermethylation prevents binding of 
transcription factors and inhibits gene transcription, whereas promoter hypomethylation 
activates gene transcription. 
MicroRNAs are small non-coding RNA molecules that post-transcriptionally regulate gene 
expression by binding to the 3’ untranslated region (3’UTR) of the target messenger RNA 
(mRNA) and negatively regulating the processing, stability, and translation of the mRNA [30]. 
MiR-29 plays a major role in cell proliferation, differentiation, and apoptosis [31, 32]. The miR-
29 family consists of two clusters: cluster 1, located on chromosome 7q32.3, consists of miR-
29a and miR-29b-1; and cluster 2, located on chromosome 1q32.2, consists of miR-29b-2 and 
miR-29c. MiR-29b-1 and miR-29b-2 have identical mature sequences and are collectively 
referred to as miR-29b. Several effects of miR-29b have been identified such as activating the 
tumor suppressor protein, p53 and regulating cell proliferation, and apoptosis by targeting p85α 
and the cell division cycle 42 (CDC42) [31, 32]. It prevents liver fibrosis by targeting the 
PI3K/AKT signaling pathway [33], and targets AKT2 and AKT3 to regulate the Warburg effect 
in ovarian cancer cells [34]. MiR-29b can also regulate the DNA methylation status of the cell 
in a negative feedback loop by directly targeting DNMT3A and DNMT3B [35, 36]. Furthermore, 
the expression of miR-29b is itself epigenetically regulated and thus inversely correlated with 
the DNA methylation status of the cell. 
PTMs also regulate the expression and activity of DNMTs. These modifications occur in the N- 
and C-terminal regions of the protein and include acetylation and ubiquitination [29]. The 
acetylation of DNMTs is regulated by the acetyltransferase, Tip60 and the deacetylases, 
HDAC1 and HDAC2 [29, 37, 38]. The ubiquitination of DNMTs is triggered by DNMT 
acetylation and is regulated by the E3 ligase, ubiquitin-like and ring finger domain 1 (UHRF1), 
and the deubiquitylating enzyme, ubiquitin specific peptidase 7 (USP7) [29, 37, 38]. The 
ubiquitination of DNMTs play a major role in inhibiting DNMT stability and promoting 
proteasomal degradation. 
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DNA methylation forms a platform for several methyl binding proteins. Methyl-CpG binding 
domain proteins (MBDs) are a family of nuclear proteins that play an important role in 
regulating DNA methylation and gene transcription by recruiting chromatin remodeling 
complexes to regions of methylated DNA. Several MBDs have been identified (MBD1-6); 
however, MBD2 is the major MBD that binds specifically to methylated CpG islands and acts 
as a methylation-dependent transcriptional repressor and DNA demethylase [39]. 
Although several effects of FA have been described, the effect of FA on epigenetic regulation 
has not been determined. This study aimed to determine an epigenetic effect of FA in the human 
hepatocellular carcinoma (HepG2) cell line, as a mechanism of FA-induced toxicity. The effect 
of FA on global DNA methylation as well as the mechanism of FA-induced changes in DNA 
methylation by transcriptional (promoter methylation), post-transcriptional (miR-29b), and post-
translational (ubiquitination) regulation of DNMTs and MBD2 was determined.   
Results 
Fusaric acid induced global DNA hypomethylation in HepG2 cells 
We first determined the effect of FA on global DNA methylation in liver (HepG2) cells. 5-
methylcytosine, a common marker of global DNA methylation, was quantified using a 
commercialized kit (Abcam, ab117128) and 5-aza-2-DC was used as a negative control. The 
percentage of 5-methylcytosine in the 5-aza-2-DC and FA-treated HepG2 cells were decreased 
compared to the control (p < 0.0001; Figure 3.1). This suggested that FA induced a dose-
dependent decrease in global DNA methylation in HepG2 cells. 
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Figure 3.1 Fusaric acid induced global DNA hypomethylation in HepG2 cells. DNA 
isolated from control and FA-treated HepG2 cells were assayed for global DNA methylation by 
quantifying 5-methylcytosine using a Colorimetric Methylated DNA Quantification Kit. Fusaric 
acid decreased the percentage of 5-methylcytosine in HepG2 cells compared to the control. 
Results are represented as mean fold-change ± SD (n = 3). Statistical significance was 
determined by one-way ANOVA with the Bonferroni multiple comparisons test (**p < 0.005, 
***p < 0.0001). 
Fusaric acid decreased the expression of DNMT1, DNMT3A, and DNMT3B in 
HepG2 cells 
The DNMTs, DNMT1, DNMT3A, and DNMT3B, play a major role in initiating and 
maintaining DNA methylation patterns. Due to the FA-induced global DNA hypomethylation in 
the HepG2 cells, we evaluated the mRNA and protein expressions of DNMT1, DNMT3A, and 
DNMT3B. FA significantly decreased the mRNA expression of DNMT1 (p < 0.0001; Figure 
3.2A), DNMT3A (p < 0.0001; Figure 3.2A), and DNMT3B (p < 0.0001; Figure 3.2A) in HepG2 
cells compared to the control. The protein expression of DNMT1 (p < 0.0001; Figure 3.2B), 
DNMT3A (p < 0.0001; Figure 3.2B), and DNMT3B (p < 0.0001; Figure 3.2B) was also 
significantly decreased in the FA-treated HepG2 cells compared to the control.  
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Figure 3.2 The effect of FA on DNA methyltransferases in HepG2 cells. (A) RNA isolated 
from control and FA-treated HepG2 cells were reverse transcribed into cDNA and analyzed by 
qPCR. Fusaric acid significantly decreased the mRNA expression of DNMT1, DNMT3A, and 
DNMT3B in HepG2 cells. (B) Protein expression of DNMT1, DNMT3A, and DNMT3B were 
determined by western blot. Fusaric acid decreased the protein expression of DNMT1, 
DNMT3A, and DNMT3B in HepG2 cells. Results are represented as mean fold-change ± SD (n 
= 3). Statistical significance was determined by one-way ANOVA with the Bonferroni multiple 
comparisons test (*p < 0.05, **p < 0.005, ***p < 0.0001).  
Fusaric acid altered DNMT promoter methylation in HepG2 cells 
The methylation of gene promoters plays a major role in determining transcriptional activity and 
gene expression. We determined if the decrease in the mRNA expression of DNMT1, DNMT3A, 
and DNMT3B observed in the FA-treated HepG2 cells were a result of promoter methylation. 
FA significantly increased promoter methylation of DNMT1 (p < 0.0001; Figure 3.3) and 
DNMT3B (p < 0.0001; Figure 3.3) in HepG2 cells compared to the control; however, the 
promoter methylation of DNMT3A was decreased in the lower FA concentrations (25, 50, and 
104 µg/ml) and increased in the higher FA concentration (150 µg/ml) (p < 0.0001; Figure 3.3). 
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Figure 3.3 The effect of FA on the promoter methylation of DNMT1, DNMT3A, and 
DNMT3B in HepG2 cells. DNA isolated from control and FA-treated HepG2 cells were 
assayed for DNMT promoter methylation using the OneStep qMethyl Kit. Fusaric acid induced 
promoter hypermethylation of DNMT1 and DNMT3B, and altered promoter methylation of 
DNMT3A in HepG2 cells. Results are represented as mean fold-change ± SD (n = 3). Statistical 
significance was determined by one-way ANOVA with the Bonferroni multiple comparisons 
test (***p < 0.0001).  
Fusaric acid decreased miR-29b promoter methylation, upregulated miR-29b, and 
decreased the expression of Sp1 in HepG2 cells 
The expression of miR-29b is regulated by DNA methylation; miR-29b is silenced by DNA 
hypermethylation whereas DNA hypomethylation is known to upregulate miR-29b [36]. Since 
FA induced DNA hypomethylation in HepG2 cells, we determined the effect of FA on the 
promoter methylation and expression of miR-29b. FA significantly decreased the promoter 
methylation of miR-29b (p < 0.0001; Figure 3.4A) and increased the expression of miR-29b (p 
< 0.0001; Figure 3.4B) in HepG2 cells compared to the control. The expression of miR-29b was 
also significantly increased by 5-aza-2-DC (p < 0.0001; Figure 3.4B).  
MiR-29b is also a known regulator of DNMT expression. MiR-29b was previously shown to 
directly target DNMT3A and DNMT3B and indirectly target DNMT1 via repression of the 
transcriptional activator, Sp1 [35, 36, 40]. This was confirmed using the bioinformatics 
prediction algorithm software, TargetScan version 7.1. MiR-29b was found to have 
complementary base pairs with DNMT3A at positions 862 – 868, 1305 – 1311 and 5559 – 5565; 
DNMT3B at position 1202 – 1209; and Sp1 at position 3584 – 3591 (Figure 3.4C). DNMT1 was 
not a direct target of miR-29b. Due to the increase in miR-29b and decrease in DNMT 
expression by FA, we then determined the effect of FA on the mRNA expression of Sp1. FA 
significantly decreased the expression of Sp1 (p < 0.0001; Figure 3.4D) in HepG2 cells 
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compared to the control. These data suggest that the decrease in the mRNA expression of 
DNMT1, DNMT3A, and DNMT3B may be influenced by miR-29b. 
 
Figure 3.4 The effect of FA on miR-29b and Sp1 in HepG2 cells. (A) DNA isolated from 
control and FA-treated HepG2 cells were assayed for miR-29b promoter methylation using the 
OneStep qMethyl Kit. Fusaric acid induced promoter hypomethylation of miR-29b in HepG2 
cells. (B) RNA isolated from control and FA-treated HepG2 cells were reverse transcribed into 
cDNA and analyzed by qPCR. Fusaric acid significantly increased the expression of miR-29b in 
HepG2 cells. (C) TargetScan analysis of miR-29b to the 3’UTRs of DNMT3A, DNMT3B, and 
Sp1. (D) RNA isolated from control and FA-treated HepG2 cells were reverse transcribed into 
cDNA and analyzed for Sp1 expression by qPCR. Fusaric acid decreased the mRNA expression 
of Sp1 in HepG2 cells. Results are represented as mean fold-change ± SD (n = 3). Statistical 
significance was determined by one-way ANOVA with the Bonferroni multiple comparisons 
test (***p < 0.0001).  
Fusaric acid decreased the ubiquitination of DNMT1, DNMT3A, and DNMT3B by 
decreasing the expression of UHRF1 and USP7 in HepG2 cells 
PTMs such as acetylation and ubiquitination regulate the activity and expression of DNMTs. 
The acetylation of DNMTs triggers the ubiquitination of DNMTs leading to proteasomal 
degradation. We determined if the decrease in the protein expression of DNMT1, DNMT3A, 
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and DNMT3B in the FA treatments were a result of the ubiquitination and proteasomal 
degradation of the DNMTs. FA significantly decreased the ubiquitination of DNMT1 (p = 
0.0753; Figure 3.5A), DNMT3A (p = 0.0008; Figure 3.5A), and DNMT3B (p < 0.0001; Figure 
3.5A) in HepG2 cells compared to the control. However, at 150 µg/ml FA the ubiquitination of 
DNMT1 and DNMT3B were increased. 
The ubiquitination regulators, UHRF1 and USP7, are the major enzymes responsible for 
ubiquitinating and deubiquitinating DNMTs, respectively. The FA-induced decrease in the 
ubiquitination of DNMT1, DNMT3A, and DNMT3B led to the assessment of UHRF1 and 
USP7. FA significantly decreased the mRNA expression of UHRF1 (p < 0.0001; Figure 3.5B) 
and USP7 (p < 0.0001; Figure 3.5B) in HepG2 cells compared to the control. These results 
indicate that the decrease in the protein expression of DNMT1, DNMT3A, and DNMT3B 
observed in the FA-treated cells is not due to the ubiquitination and proteasomal degradation of 
DNMTs.  
 
Figure 3.5 The effect of FA on the ubiquitination of DNMT1, DNMT3A, and DNMT3B in 
HepG2 cells. (A) The ubiquitination of DNMT1, DNMT3A, and DNMT3B were detected by 
immuno-precipitation and western blot. Fusaric acid altered the ubiquitination of DNMT1, 
DNMT3A, and DNMT3B in HepG2 cells. (B) RNA isolated from control and FA-treated 
HepG2 cells were reverse transcribed into cDNA and analyzed by qPCR. Fusaric acid 
significantly decreased the expression of UHRF1 and USP7 in HepG2 cells. Results are 
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represented as mean fold-change ± SD (n = 3). Statistical significance was determined by one-
way ANOVA with the Bonferroni multiple comparisons test (*p < 0.05, **p < 0.005, ***p < 
0.0001).  
Fusaric acid induced MBD2 promoter hypomethylation and increased the expression 
of MBD2 in HepG2 cells  
Methyl CpG binding domain protein 2 (MBD2), a major MBD, promotes global DNA 
hypomethylation by binding specifically to methylated DNA and functioning as a methylation-
dependent transcriptional repressor and DNA demethylase. We determined if the FA-induced 
decrease in global DNA methylation occurred as a result of MBD2. FA significantly decreased 
MBD2 promoter methylation (p < 0.0001; Figure 3.6A) and increased the protein expression of 
MBD2 (p < 0.0001; Figure 3.6B) in HepG2 cells compared to the control. The mRNA 
expression of MBD2 (p < 0.0001), and other MBDs such as MBD1 (p < 0.0001), MBD3 (p < 
0.0001), MBD4 (p < 0.0001), MBD5 (p < 0.0001), and MBD6 (p < 0.0001) were significantly 
decreased in the FA-treated cells compared to the control (Supplementary Table S3.1).  
 
Figure 3.6 The effect of FA on MBD2 promoter methylation and MBD2 expression in 
HepG2 cells. (A) DNA isolated from control and FA-treated HepG2 cells were assayed for 
MBD2 promoter methylation using the OneStep qMethyl Kit. Fusaric acid significantly induced 
promoter hypomethylation of MBD2 in HepG2 cells. (B) Protein expression of MBD2 was 
determined by western blot. Fusaric acid significantly increased the protein expression of 
MBD2 in HepG2 cells. Results are represented as mean fold-change ± SD (n = 3). Statistical 
significance was determined by one-way ANOVA with the Bonferroni multiple comparisons 
test (***p < 0.0001). 
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Discussion  
FA, a neglected mycotoxin found in agricultural foods, alters biological pathways causing 
toxicity in various plant and animal models. To date several mechanisms of FA toxicity have 
been described [10, 12, 14, 15, 20, 21, 23]; however, the effect of FA on epigenetic 
modifications is unknown. DNA methylation is an important epigenetic modification that 
regulates chromatin structure and alters gene expression and thus may play a crucial role in FA 
toxicity. In this study, we provide evidence that FA alters global DNA methylation in HepG2 
cells by modulating the expression of DNMTs and demethylases in a mechanism that involves 
alterations in promoter methylation and miR-29b expression, but not the ubiquitination of 
DNMTs.  
FA induced global DNA hypomethylation in HepG2 cells as evidenced by the significant 
decrease in 5-methylcytosine content (Figure 3.1); this global DNA hypomethylation is due to a 
concomitant decrease in the expression of the de novo methyltransferases, DNMT3A and 
DNMT3B, and the maintenance methyltransferase, DNMT1 (Figure 3.2A and Figure 3.2B) as 
well as an increase in the demethylase, MBD2 (Figure 3.6B). Furthermore, FA altered the 
mRNA expression of DNMT1 and DNMT3B by inducing promoter hypermethylation (Figure 
3.3). This is in agreement with previous studies in which promoter hypermethylation of DNMT1 
and DNMT3B decreased the mRNA expression of DNMT1 and DNMT3B, respectively [41, 42]. 
Although promoter hypomethylation of DNMT3A is associated with an increase in the 
transcription of DNMT3A, the decrease in DNMT3A mRNA transcript levels observed in the 
FA-treated HepG2 cells suggests possible regulation at the post-transcriptional level. 
MicroRNAs regulate gene expression at the post-transcriptional level. This occurs in a sequence 
specific manner and leads to either the degradation of the target mRNA or inhibition of 
translation. MiR-29b, regulated by DNA methylation, was previously shown to repress DNA 
methylation by directly targeting DNMT3A and DNMT3B, and indirectly targeting DNMT1 by 
inhibiting the transcriptional activator, Sp1 [35, 36]. This was further confirmed using 
TargetScan version 7.1 (Figure 3.4C). FA significantly upregulated the expression of miR-29b 
in HepG2 cells (Figure 3.4B) and the expression of miR-29b was inversely correlated with the 
DNA methylation status in the FA-treated HepG2 cells, as evidenced by the significant decrease 
in miR-29b promoter methylation (Figure 3.4A). The upregulation of miR-29b also corresponds 
with the decrease in the mRNA expression of Sp1, DNMT1, DNMT3A, and DNMT3B in the FA-
treated cells. This is in agreement with previous studies where overexpression of miR-29b was 
found to downregulate the expression of DNMT3A and DNMT3B, and induce global DNA 
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hypomethylation in acute myeloid leukemia (AML) and lung cancer cells [35, 36]. 
Overexpression of miR-29b in AML was also shown to downregulate the expression of Sp1 
causing a subsequent decrease in DNMT1 expression and global DNA hypomethylation [35, 
40]. Therefore, these results indicate that the FA-induced increase in miR-29b expression may 
be an alternative mechanism for the reduced DNMT3A mRNA expression and an additional 
mechanism for the reduced DNMT1 and DNMT3B mRNA expressions. 
The protein expression of DNMT1, DNMT3A, and DNMT3B were also significantly decreased 
in the FA-treated HepG2 cells (Figure 3.2B).  PTMs such as acetylation and ubiquitination play 
a major role in influencing the catalytic activity, stability, and protein-protein interactions of 
DNMTs. The acetylation of DNMTs is mediated by Tip60 and primes DNMTs for UHRF1-
mediated ubiquitination and proteasomal degradation [29, 37, 38]. The DNMTs are deacetylated 
by HDAC1 and HDAC2, and deubiquitinated by USP7. 
The role of acetylation and ubiquitination on the regulation of DNMT1 is well understood. The 
acetylation of DNMT1 on lysine (K) residues, K1349 and K1415, in the catalytic domain 
decreases DNMT1 activity whereas the acetylation of K1111, K1113, K1115, and K1117 in the 
lysine-glycine rich (KG)-repeat increases the transcriptional repressor activity of DNMT1 [43]. 
The acetylation of lysine residues in the KG-repeat also increases the DNMT1-UHRF1 
interaction and impairs the DNMT1-USP7 interaction, thereby, promoting the ubiquitination 
and degradation of DNMT1 [44, 45]. The overexpression of UHRF1 was also shown to increase 
the ubiquitination of DNMT1 and decrease DNMT1 expression [44]. Previous studies also 
indicate that UHRF1 physically interacts with DNMT3A and DNMT3B, thereby, inhibiting the 
activity of both DNMT3A and DNMT3B and promoting proteasomal degradation [46]. 
The decrease in the protein expression of DNMT1, DNMT3A, and DNMT3B in the FA-treated 
HepG2 cells suggested that FA may also decrease the protein expression of DNMTs by 
ubiquitination and proteasomal degradation. In fact, FA actually decreased the ubiquitination of 
DNMT1, DNMT3A, and DNMT3B in HepG2 cells (Figure 3.5A). The expression of UHRF1 
and USP7 was also significantly decreased in the FA-treated cells (Figure 3.5B), suggesting that 
the decrease in the ubiquitination of DNMT1, DNMT3A, and DNMT3B was a result of UHRF1 
and USP7. Thus, the FA-induced decrease in the protein expression of DNMT1, DNMT3A, and 
DNMT3B was due to the increased DNMT promoter methylation and/or miR-29b expression 
and a subsequent inhibition of translation, and not the ubiquitination and proteasomal 
degradation of the DNMT protein. 
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UHRF1 also contains a methyl DNA-binding domain, SRA (SET and RING associated) 
domain, that binds preferentially to hemi-methylated DNA and functions to recruit DNMT1 to 
hemi-methylated CpG islands to facilitate maintenance of DNA methylation [47]. The observed 
decrease in global DNA methylation in the FA-treated HepG2 cells may also occur as a result of 
the decrease in UHRF1 and DNMT1 leading to a loss in the maintenance of DNA methylation. 
In addition to alterations in the expression of DNMTs and UHRF1, FA may also induce global 
DNA hypomethylation by targeting the transcriptional repressor and demethylase, MBD2.  
MBD2 plays an essential role in hypomethylation and was previously shown to activate gene 
expression by promoting demethylation of several target genes. Our results indicate that FA 
induced MBD2 promoter hypomethylation (Figure 3.6A) and increased the protein expression 
of MBD2 (Figure 3.6B) in HepG2 cells. This occurred despite the significant decrease in the 
mRNA expression of MBD2 (Supplementary Table S3.1), and suggests that the FA-induced 
expression of MBD2 may contribute to global DNA hypomethylation. Previous studies indicate 
MBD2 promoter hypomethylation to be associated with active gene transcription and an 
increase in MBD2 expression. Although MBD2 is associated with gene activation, 
overexpression of MBD2 and global DNA hypomethylation leads to genomic instability in 
several human cancers [48, 49].  
Global DNA hypomethylation is considered a hallmark of cancer as it leads to genomic 
instability and increases the frequency of mutations [50]. Global DNA hypomethylation also 
inhibits cellular differentiation [51] and induces apoptosis [51, 52, 53, 54]. Previously, FB1, a 
Fusarium derived mycotoxin often co-produced with FA, was shown to induce global DNA 
hypomethylation (by modulating the expression of DNMTs and MBD2) and histone 
demethylation, possibly leading to chromatin instability and liver tumourigenesis [55]. FB1 also 
alters promoter methylation of tumor suppressor genes (c-myc, p15, p16, and e-cadherin) [56, 
57], inhibits miR-27b and increases cytochrome P450 1B1 [58] leading to hepatic neoplastic 
transformation. Zearalenone also induces global DNA hypomethylation and reduces the 
viability of human bronchial epithelial cells via DNA damage, cell cycle arrest, and apoptosis 
[59]. In contrary, other Fusarium produced mycotoxins such as deoxynivalenol and T2 toxin 
induce global DNA hypermethylation and histone demethylation [60, 61]. The toxicity of FA 
has been mainly attributed to oxidative stress, DNA damage, and apoptosis [10, 12, 13, 14, 15, 
62], and the FA-induced global DNA hypomethylation may provide an alternative mechanism 
by which FA induces its genotoxic and cytotoxic effects. 
In conclusion, this study provides an alternative mechanism of FA-induced genotoxicity and 
cytotoxicity at the epigenetic level. The results indicate that FA induces global DNA 
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hypomethylation in HepG2 cells by decreasing the expression of DNMT1, DNMT3A, and 
DNMT3B and increasing the expression of MBD2 (Figure 3.7). The results further indicate that 
FA decreases the expression of DNMT1, DNMT3A, DNMT3B, and MBD2 proteins by 
increasing promoter methylation and/or by upregulating miR-29b. It has also been shown that 
miR-29b itself can be regulated by DNA methylation, and that reduced methylation as seen 
globally following treatment with FA may lead to increased expression of miR-29b. These 
findings suggest that FA-induced changes in DNA methylation may potentially be used as a 
biomarker for FA exposure and toxicity. Finally, targeting the DNA methylation pathway via 
epigenetic modulation of DNMTs and miR-29b may provide a therapeutic intervention against 
FA toxicity; this is particularly important in poverty stricken areas where maize forms a staple 
diet and the risk of FA contamination is high. 
 
Figure 3.7 Proposed mechanism of FA-induced global DNA hypomethylation in HepG2 
cells. FA induces global DNA hypomethylation by decreasing the mRNA and protein 
expression of DNMT1, DNMT3A, and DNMT3B. The decrease in DNMTs is caused by 
promoter hypermethylation of DNMT1 and DNMT3B, and promoter hypomethylation and 
upregulation of miR-29b. MiR-29b negatively regulates the mRNA expression of DNMT1, 
DNMT3A, and DNMT3B. In addition, FA may also induce global DNA hypomethylation by 
causing promoter hypomethylation and upregulation of MBD2. 
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Materials and Methods 
Materials 
FA (Gibberella fujikuroi, F6513) and the DNA methylation inhibitor, 5-aza-2-deoxycytidine (5-
aza-2-DC; A3653) were purchased from Sigma-Aldrich. The HepG2 cell line was purchased 
from Highveld Biologicals. Cell culture consumables were obtained from Lonza Biotechnology. 
Western Blot reagents were purchased from Bio-Rad. All other reagents were purchased from 
Merck. 
Cell culture and treatment 
HepG2 cells (1.5 X 10
6
) were cultured (37°C, 5% CO2) in complete culture media (CCM; 
Eagle’s Minimum Essentials Medium (EMEM) containing 10% fetal calf serum, 1% penicillin-
streptomycin fungizone, and 1% L-glutamine), until 90% confluent. Stocks of FA (1 mg/ml) 
were prepared in 0.1 M PBS and the cells were incubated (37°C, 5% CO2, 24 h) with various 
concentrations of FA (25, 50, 104, and 150 µg/ml). These FA concentrations were obtained 
from literature [10] and represented 90%, 75%, 50%, and 40% cell viabilities, respectively. The 
5-aza-2-DC (50 mM) stock was prepared in 100% DMSO. The concentration of 5-aza-2-DC (10 
µM, 24 h) inducing DNA hypomethylation in HepG2 cells was obtained from literature [63] and 
used as a negative control. An untreated control (CCM only) was also prepared. Cell viability 
was determined using the trypan blue cell exclusion method. All results were verified by 
performing two independent experiments in triplicate. 
DNA isolation and quantification of DNA methylation 
Genomic DNA was isolated from control and FA-treated HepG2 cells. Briefly, HepG2 cells 
were incubated in cell lysis buffer (600 µl, 15 min, RT; 0.5 M EDTA (pH 8.0), 1 M Tris-Cl (pH 
7.6), 0.1% SDS) and potassium acetate buffer (600 µl, 8 min, RT; 5 M potassium acetate, 
glacial acetic acid) before centrifugation (13,000xg, 5 min, 24°C). The supernatant containing 
genomic DNA was transferred into fresh 1.5 ml micro-centrifuge tubes and 100% isopropanol 
(600 µl) was added to precipitate the DNA which was recovered by centrifugation (13,000xg, 5 
min, 24°C). The DNA was washed in 100% ethanol (300 µl) and centrifuged (13,000xg, 5 min, 
24°C). The DNA pellets were air dried (30 min, RT), re-suspended in DNA hydration buffer (40 
µl; 10 mM EDTA (pH 8.0), 100 mM Tris-Cl (pH 7.4)), and heated (65°C, 15 min). DNA 
concentration was determined using the Nanodrop2000 spectrophotometer (Thermo-Fischer 
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Scientific) and standardized to 100 ng/µl. DNA purity was assessed using the A260/A280 
absorbance ratios.  
The DNA was used to quantify global DNA methylation using the Colorimetric Methylated 
DNA Quantification Kit (Abcam, ab117128), as per manufacturer’s instructions. The 
percentage 5-methylcytosine (5-mC) content was calculated using the supplied formula 
(Supplementary Information) and represented as fold-change relative to the control. 
Promoter methylation of miR-29b, DNMTs, and MBD2 
Genomic DNA was isolated from control and FA-treated HepG2 cells using the Quick-g-DNA 
MiniPrep Kit (Zymo Research, D3007), as per manufacturer’s instructions. The isolated DNA 
was then eluted in nuclease-free water and purified using the DNA Clean and Concentrator™-5 
Kit (Zymo Research, D4003), as per manufacturer’s instructions. The DNA was quantified 
using the Nanodrop2000 spectrophotometer and standardized to 4 ng/µl. The promoter 
methylation of DNMT1, DNMT3A, DNMT3B, MBD2, and miR-29b was assessed using the 
OneStep qMethyl Kit (Zymo Research, 5310), as per manufacturer’s instructions. Briefly, 20 ng 
DNA was subject to a test and reference reaction containing specific primers (Supplementary 
Table S3.2). Cycling conditions were as follows: digestion by methyl sensitive  restriction 
enzymes (AccII, HpaII, and HpyCH4IV) (37°C, 2 h), initial denaturation (95°C, 10 min), 
followed by 45 cycles of denaturation (95°C, 30 s), annealing (Supplementary Table S3.2, 60 s), 
extension (72°C, 60 s), final extension (72°C, 60 s), and a hold at 4°C. The percentage 
methylation was calculated using the supplied formula (Supplementary Information) and 
represented as fold-change relative to the control. 
RNA isolation and quantitative polymerase chain reaction (qPCR)  
Total RNA was extracted from control and FA-treated HepG2 cells using Qiazol Reagent 
(Qiagen, 79306). Briefly, HepG2 cells were rinsed in 0.1 M PBS and incubated (5 min, RT) in 
500 µl Qiazol and 500 µl 0.1 M PBS before extraction with a cell scraper. Cellular lysates were 
incubated overnight (-80°C). Thereafter, chloroform (100 µl) was added and centrifuged 
(12,000xg, 4°C, 15 min). The aqueous phase containing RNA was transferred to fresh 1.5 ml 
micro-centrifuge tubes and 100% cold isopropanol (250 µl) was added to each sample before 
overnight incubation (-80°C). Samples were centrifuged (12,000xg, 4°C, 20 min) and the RNA 
pellets were washed in 75% cold ethanol (500 µl). Finally, samples were centrifuged (7,400xg, 
4°C, 15 min), RNA pellets were air dried (30 min, RT), re-suspended in nuclease-free water (15 
µl), and incubated (3 min, RT). The RNA was quantified using the Nanodrop2000 
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spectrophotometer and standardized to 1,000 ng/µl. The A260/A280 absorbance ratio was used 
to assess RNA purity.  
The RNA was used to prepare cDNA using the miScript II RT Kit (Qiagen, 218161), as per 
manufacturer’s instructions. The expression of miR-29b was analyzed using the miScript SYBR 
Green PCR Kit (Qiagen, 218073) and specific 10X miScript primer assay [Hs_miR-29b_1, 
Qiagen, MS00006566], as per manufacturer’s instructions. Human RNU6 (Qiagen, 
MS000033740) was used as the housekeeping gene to normalize microRNA expression.     
For mRNA expression, cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad, 
1708891), as per manufacturer’s instructions. The expression of DNMT1, DNMT3A, DNMT3B, 
MBD1-MBD6, Sp1, UHRF1, and USP7 were determined using the Sso Advanced™ Universal 
SYBR Green Supermix (Bio-Rad, 1725270), as per manufacturer’s instructions. GAPDH was 
used as the housekeeping gene to normalise mRNA expression. Primer sequences and annealing 
temperatures are listed in Supplementary Table S3.2. All qPCR experiments were conducted 
using the CFX96 Real Time PCR System (Bio-Rad) and analyzed using the Bio-Rad CFX 
Manager™ Software version 3.1. The comparative threshold cycle (Ct) method was used to 
determine relative changes in expression [64]. 
Protein isolation and Western blot  
The protein expression of DNMT1, DNMT3A, DNMT3B, and MBD2 was determined using 
Western blot. Briefly, crude protein extracts were isolated from control and FA-treated HepG2 
cells using cytobuster reagent (200 µl; Novagen, 71009) supplemented with protease and 
phosphatase inhibitors (Roche; 05892791001 and 04906837001, respectively). The protein was 
quantified using the bicinchoninic acid (BCA) assay, standardized to 1 mg/ml and boiled 
(100°C, 5 min) in a 1:1 dilution with 1X Laemmli buffer [dH2O, 0.5 M Tris-HCl (pH 6.8), 
glycerol, 10% SDS, 5% β-mercaptoethanol, 1% bromophenol blue]. Thereafter, the proteins 
were separated using sodium dodecyl sulphate polyacrylamide gel electrophoresis (10% 
resolving gel, 4% stacking gel; 1 h, 150V) and transferred onto nitrocellulose membranes using 
the Bio-Rad Trans-Blot® Turbo Transfer System (20V, 30 min). Following transfer, the 
membranes were blocked in 5% BSA in Tris buffered saline with 0.05% Tween 20 [TTBS; 150 
mM NaCl, 3 mM KCl, 25 mM Tris, 0.05% Tween 20, dH2O, pH 7.5; 1 h, RT] and probed 
overnight (4°C) with primary antibody [DNMT1 (Cell Signaling Technology, #5032S; 1:250), 
DNMT3A (Cell Signaling Technology, #3598S; 1:500), DNMT3B (Santa Cruz, sc-130740; 
1:250), and MBD2 (Santa Cruz, sc-271562; 1:500)]. The membranes were rinsed five times 
with TTBS (10 min, RT) and probed with a horse-radish peroxidase (HRP)-conjugated 
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secondary antibody [goat anti-rabbit (Cell Signaling Technology, #7074S; 1:10,000) and goat 
anti-mouse (Cell Signaling Technology, #7076P2; 1:5,000); 1 h, RT]. The membranes were 
rinsed five times in TTBS (10 min, RT). The Clarity™ Western ECL Substrate Kit (Bio-Rad, 
#170-5060) was used to detect specific protein bands and the images were captured using the 
ChemiDoc™ XRS+ Molecular Imaging System (Bio-Rad). The membranes were then 
quenched in hydrogen peroxide (5%, 37°C, 30 min), rinsed once in TTBS (10 min, RT) and 
probed with the housekeeping protein, anti-β-actin (Sigma-Aldrich, A3854; 1:5,000; 30 min, 
RT) to normalise protein expression. Densitometric analysis was performed using the Bio-Rad 
Image Lab Software version 5.1 and the results were represented as a fold-change in band 
density (RBD) relative to the control.  
Immuno-precipitation  
Immuno-precipitation was used to determine ubiquitinated DNMT1, DNMT3A, and DNMT3B 
levels. Briefly, crude protein extracts were isolated from control and FA-treated HepG2 cells 
using 1X cell lysis buffer [500 µl; 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 10% 
glycerol, 1% Triton X-100]. The protein was quantified using the BCA assay and standardized 
to 1.5 mg/ml. Thereafter, the protein lysates (200 µl) were incubated with primary antibody 
[DNMT1 (Cell Signaling Technology, #5032S); DNMT3A (Cell Signaling Technology, 
#3598S); and DNMT3B (Santa Cruz, sc-130740); 1:100] overnight (4°C) and the antigen-
antibody complex was precipitated using protein A beads (20 µl 50% bead slurry; Cell 
Signaling Technology, #9863) for 1-3 h at 4°C. The immuno-precipitates were recovered by 
centrifugation (14,000xg, 4°C, 30 s), washed five times in 1X cell lysis buffer (500 µl), re-
suspended in 3X Laemmli buffer (20 µl), and boiled (100°C, 5 min). The samples were then 
analyzed by Western blotting using the following antibodies: primary antibody [ubiquitin (BD 
BioSciences, BD550944; 1:1,000), DNMT1 (Cell Signaling Technology, #5032S; 1:1,000), 
DNMT3A (Cell Signaling Technology, #3598S; 1:1,000), and DNMT3B (Santa Cruz, sc-
130740; 1:500)] and secondary antibody [goat anti-rabbit (Cell Signaling Technology, #7074S) 
and goat anti-mouse (Cell Signaling Technology, #7076P2); 1:5,000]. The protein expression of 
ubiquitin was divided by the total protein expressed to determine the ratio of ubiquitinated 
protein. 
Statistical analysis 
GraphPad Prism version 5.0 (GraphPad Prism Software Inc.) was used to perform all statistical 
analyses. The one way analysis of variance (ANOVA) with the Bonferroni multiple 
comparisons test was used to analyze the data. The results were expressed as the mean fold-
77 
 
change ± standard deviation (SD) (n = 3), unless otherwise indicated. Statistical significance 
was considered at p < 0.05. 
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Supplementary Information 
Quantification of DNA methylation formula: 
5-Methylcytosine (ng) =           –                                   
5-Methylcytosine (%) =                                                 
 
Quantification of promoter methylation formula: 
Methylation (%) = 100 X 2
-ΔCt
, where ΔCt = Ct (test) – Ct (reference) 
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Supplementary Table S3.1: The effect of FA on the mRNA expression of MBD1, MBD2, 
MBD3, MBD4, MBD5, and MBD6 in HepG2 cells 
Gene Concentration of Fusaric Acid (µg/ml) p value 
0 25 50 104 150 
MBD1 1.02±0.01 0.38±0.03*** 0.42±0.08*** 0.18±0.03*** 0.48±0.03*** <0.0001 
MBD2 1.02±0.01 0.17±0.01*** 0.64±0.08*** 0.14±0.01*** 0.09±0.01*** <0.0001 
MBD3 1.02±0.01 0.40±0.05*** 0.31±0.02*** 0.34±0.08*** 0.34±0.03*** <0.0001 
MBD4 1.02±0.01 0.14±0.01*** 0.67±0.09*** 0.20±0.04*** 0.22±0.04*** <0.0001 
MBD5 1.02±0.01 0.16±0.11*** 0.31±0.13*** 0.28±0.04*** 0.13±0.07*** <0.0001 
MBD6 1.02±0.01 0.18±0.01*** 0.15±0.02*** 0.18±0.03*** 0.72±0.06*** <0.0001 
RNA isolated from control and FA-treated HepG2 cells were reverse transcribed into cDNA and 
analyzed for MBD1-MBD6 expression by qPCR. Results are represented as mean relative fold-
change ± SD (n = 3). Key: ***p < 0.0001, denotes statistical significance, one-way ANOVA 
with the Bonferroni multiple comparisons test.  
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Supplementary Table S3.2: qPCR primer sequences and annealing temperatures 
Gene GenBank 
Accession 
no. 
Sense Primer (5’→3’) Anti-Sense Primer (5’→3’) Annealing 
Temperature 
(°C) 
Promoter Methylation 
DNMT1 NM_00113
0823 
ACCGCTTCTACTTCCTCG
AGGCCTA 
GTTGCAGTCCTCTGTGA
ACACTGTGG 
60 
DNMT3A NM_17562
9 
GGGGACGTCCGCAGCGT
CACAC 
CAGGGTTGGACTCGAG
AAATCGC 
58 
DNMT3B NM_00689
2 
CCTGCTGAATTACTCAC
GCCCC 
GTCTGTGTAGTGCACAG
GAAAGCC 
58 
MBD2 NM_00392
7 
AGGTAGCAATGATGAGA
CCCTTTTA 
TAAGCCAAACAGCAGG
GTTCTT 
60 
miR-29b 
 
-  TCCGTATGCTGGTTACT
CAC 
ATTCTGATAAAACCACC
AACT 
54 
Gene Expression 
DNMT1 NM_00113
0823 
ACCGCTTCTACTTCCTCG
AGGCCTA 
GTTGCAGTCCTCTGTGA
ACACTGTGG 
60 
DNMT3A NM_17562
9 
GGGGACGTCCGCAGCGT
CACAC 
CAGGGTTGGACTCGAG
AAATCGC 
58 
DNMT3B NM_00689
2 
CCTGCTGAATTACTCAC
GCCCC 
GTCTGTGTAGTGCACAG
GAAAGCC 
58 
Sp1 NM_13847
3 
CTTGGTATCATCACAAG
CCAGTT 
TCCCTGATGATCCACTG
GTAGTA 
56 
UHRF1 NM_00104
8201 
GCCATACCCTCTTCGAC
TACG 
GCCCCAATTCCGTCTCA
TCC 
58 
USP7 NM_00347
0 
GGAAGCGGGAGATACA
GATGA 
AAGGACCGACTCACTC
AGTCT 
58 
MBD1 NM_01584
6 
AAGTCTTTCGCAAGTCA
GGGG 
TCAGCTCAACTTTGCTT
CGGA 
58 
MBD2 NM_00392
7 
AGGTAGCAATGATGAGA
CCCTTTTA 
TAAGCCAAACAGCAGG
GTTCTT 
60 
MBD3 NM_00128
1453 
CAGCCGGTGACCAAGAT
TACC 
CTCCTCAGCAATGTCGA
AGG 
58 
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MBD4 NM_00392
5 
TCTAGTGAGCGCCTAGT
CCCAG 
TTCCAATTCCATAGCAA
CATCTTCT 
60 
MBD5 NM_01832
8 
GGTCTTCCAGCTATACA
AGTTCC 
ACCTGCTCCAAGCAAG
ATAAC 
56 
MBD6 NM_05289
7 
GGAGTGTCCACTTAATG
TCCCC 
GTTGCACAGCTTGGTCA
TGTC 
58 
 
 
Supplementary Figure S3.1 CpG islands within the DNMT1, DNMT3A, DNMT3B, and 
MBD2 promoter regions obtained using the MethPrimer software version 2.0. [65]. 
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Abstract  
Background: Fusaric acid (FA), a food-borne mycotoxin, may cause toxicity via epigenetic 
mechanisms such as microRNAs (miRs) and histone methylation. Sirt1, a target of miR-200a, 
maintains H3K9me3 by interacting with SUV39H1. Aim: To determine the effect of FA on 
miR-200a, SUV39H1-mediated H3K9me3, genome integrity, and apoptosis in HepG2 cells and 
C57BL/6 mice livers. Methods: HepG2 cells (0, 25, 50, 104, and 150 µg/ml; 24 h) and 
C57BL/6 mice (0 and 50 mg/kg; 24 h) were treated with FA, and DNA, RNA, and protein was 
isolated. The expression of miR-200a, Sirt1, SUV39H1, MDM2, H3K9me1/3, KDM4B, and p-
S139-H2Ax was quantified using qPCR and/or western blot. Immuno-precipitation was used to 
determine SUV39H1 ubiquitination. Genome integrity was assessed using DNA 
electrophoresis. Cell viability and apoptosis was determined using the crystal violet and 
luminometry assays, respectively. Results: FA upregulated miR-200a and decreased Sirt1 
expression in HepG2 cells and mice livers; decreased expression of SUV39H1 and KDM4B, 
thus decreasing H3K9me3 and increasing H3K9me1; increased cell mortality via apoptosis. 
Conclusion: FA induced apoptosis by upregulating miR-200a and decreasing SUV39H1-
mediated H3K9me3 in HepG2 cells and mice livers. This indicates that FA is toxic via 
epigenetic mechanisms which may serve as potential biomarkers for determining FA exposure 
and toxicity. This is important in poverty stricken areas where mycotoxin-contaminated 
commodities form an integral part of the staple diet. 
Keywords: Fusaric Acid, MiR-200a, Sirt1, SUV39H1, H3K9me3, Apoptosis 
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Introduction 
The contamination of foods and feeds with pathogenic fungi and mycotoxins is a serious 
problem that occurs globally; and exposure to mycotoxin-contaminated commodities has been 
associated with harmful effects in humans and animals [1]. Epigenetic modifications play a key 
role in mycotoxin-induced health effects and understanding the molecular and epigenetic 
mechanisms of mycotoxins will help decrease mycotoxin exposure and lower the risk of 
mycotoxin-related adverse health effects. 
Fusaric acid (FA; 5-butylpicolinic acid) is a mycotoxin produced by fungi of the genus 
Fusarium that contaminates agricultural foods and feeds. Previously other studies have 
indicated feed samples to be contaminated with approximately 643 µg/kg FA [2] whereas 
commercial foods and feeds were contaminated with 2.5-18 µg/kg FA [3]. These foods are an 
essential part of both human and animal diets and the regular consumption of FA-contaminated 
commodities may lead to adverse health effects. 
To date, little is known on the toxic effects of FA on human and animal health. Recently, we 
showed that FA induces DNA hypomethylation as an epigenetic mechanism of FA-induced 
genotoxicity and cytotoxicity in HepG2 cells [4], and this may possibly lead to liver cancer in 
humans and animals.  
FA is a non-specific mycotoxin known to affect multiple biochemical pathways, and acts 
synergistically with other co-produced Fusarium mycotoxins [5-7]. FA is phytotoxic to several 
plants and has been implicated in the pathogenesis of wilt diseases by damaging plant 
photosynthetic machinery and inhibiting root and leaf cell function [8]. FA is also toxic to 
human liver cells by inducing oxidative stress [9], mitochondrial dysfunction [9], DNA damage 
[10], and apoptosis [9, 10]. It is immuno-toxic to peripheral blood mononuclear cells (PBMCs) 
and human monocytic (THP-1) cells by altering the MAPK signaling pathway [11]. FA also 
prevents cardiac hypertrophy and fibrosis by inactivating the TGF-β1/SMADs and PI3K/AKT 
signaling pathways [12].  
FA is a chelator of divalent cations; its chelation of calcium affects bone ossification [13] and 
platelet aggregation [14] whereas copper chelation inhibits the enzymes dopamine β-
hydroxylase and lysyl oxidase that leads to hypotension [15-17] and notochord malformation 
[18].  
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Epigenetic modifications such as DNA methylation, histone modifications and microRNAs are 
important in regulating many cellular processes, and may constitute a mechanism of FA-
induced toxicity.  
MicroRNAs (miRs) are small non-coding RNA molecules that regulate gene expression at the 
post-transcriptional level by negatively regulating the processing, stability, and translation of the 
target messenger RNA (mRNA) [19]. The miR-200 family plays a major role in maintaining 
cellular motility and is implicated in tumourigenesis and metastasis [20]. This family comprises 
of two clusters: cluster 1, located on chromosome 1, consists of miR-200b, miR-200a, and miR-
429; and cluster 2, located on chromosome 12, consists of miR-200c and miR-141. MiR-200a is 
highly expressed in epithelial cells and has high sequence homology with miR-141 [20, 21]. 
Several effects of miR-200a have been described such as modulating the oxidative stress 
response by targeting p38α [21] and the NRF-2 regulator, Kelch-like ECH-associated protein 1 
(Keap1) [22]. It prevents renal fibrogenesis by repressing transforming growth factor beta 2 
(TGF-β2) [23], and targets phospholipase C-gamma 1 (PLCϒ1) to regulate cell proliferation and 
epithelial growth factor (EGF)-mediated invasion in breast cancer [24]. MiR-200a also regulates 
epithelial to mesenchymal transition by targeting the zinc finger E-box binding proteins, ZEB1 
and ZEB2 [25-27], β-catenin [28-30], and Sirtuin 1 (Sirt1) [20].  
Sirt1, a class III histone deacetylase, regulates chromatin structure and gene expression through 
modification of chromatin-associated histones [31]. Sirt1 promotes heterochromatin formation 
by deacetylating histones, H4K16Ac, H3K9Ac, and H1K26Ac [32]; recruits DNA 
methyltransferases to gene promoter regions and facilitates transcriptional repression of tumor 
suppressor genes by modulating the histone methyltransferase, suppressor of variegation 3-9 
homolog 1 (SUV39H1) [20, 33].   
SUV39H1 is a key enzyme responsible for the trimethylation of histone 3 on lysine (K) 9 
(H3K9me3) [32-35]. SUV39H1-mediated H3K9me3 is essential for maintaining genome 
integrity [36], heterochromatin organization [37], chromosome condensation [38] and mitosis 
[39]; and the inhibition of SUV39H1 was previously associated with a reduction in cell viability 
[40], genome instability [33, 36], inhibition of cell growth [41] and apoptosis [35].   
The interaction between Sirt1 and SUV39H1 helps maintain the H3K9me3 repressive mark [32, 
33]. SUV39H1 is subject to post-translational modifications (PTMs) such as acetylation and 
ubiquitination that regulate its activity and expression [33]. The acetylation of SUV39H1 on 
K266 in the catalytic domain decreases SUV39H1 activity [33], and enables the E3 ubiquitin 
ligase, murine double minute 2 (MDM2) to polyubiquitinate SUV39H1 on K87 mediating its 
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proteasomal degradation [33]. Sirt1 directly interacts with, recruits and deacetylates SUV39H1 
on K266 thereby increasing its catalytic activity and inhibiting its MDM2-mediated 
polyubiquitination and proteasomal degradation [32, 33]. Sirt1 also maintains H3K9me3 by 
directly deacetylating H3K9Ac to enable trimethylation by SUV39H1 [33]. 
Although several effects of FA have recently been described, there are currently no studies 
evaluating the effect of FA on epigenetic modifications such as microRNAs and histone 
methylation. This study aimed to determine an epigenetic mechanism of FA-induced toxicity by 
specifically investigating the effect of FA on miR-200a, SUV39H1-mediated H3K9me3, 
genome integrity, and apoptosis in human liver (HepG2) cells and C57BL/6 mice livers.  
Materials and methods 
Materials 
FA (Gibberella fujikuroi, F6513) was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
The miR-200a mimic (Syn-hsa-miR-200a-3p; MSY0000682) and miR-200a inhibitor (Anti-hsa-
miR-200a-3p; MIN0000682) were purchased from Qiagen (Hilden, Germany). The HepG2 cell 
line (HB-8065) was purchased from the American Type Culture Collection (ATCC; 
Johannesburg, SA). Cell culture consumables were purchased from Lonza Biotechnology 
(Basel, Switzerland). Western Blot reagents were purchased from Bio-Rad (Hercules, CA, 
USA). All other reagents were purchased from Merck (Darmstadt, Germany).  
Cell culture and treatment  
HepG2 cells (1.5 X 10
6
, passage 3) were seeded and maintained (37°C, 5% CO2, humidified 
incubator) in 25 cm
3
 sterile cell culture flasks containing complete culture media (CCM; Eagle’s 
Minimum Essentials Medium (EMEM) supplemented with 10% fetal calf serum, 1% penicillin-
streptomycin-fungizone, and 1% L-glutamine), until 90% confluent. A stock solution of 1 
mg/ml FA was prepared in 0.1 M phosphate buffered saline (PBS) and the cells were incubated 
(37°C, 5% CO2, 24 h) with various concentrations of FA (25, 50, 104, and 150 µg/ml) [4]. An 
untreated control (CCM only) was also prepared. All experiments were repeated two 
independent times and in triplicate for reproducibility of results. 
Transfection of HepG2 cells with the miR-200a mimic and miR-200a inhibitor  
To assess the effect of miR-200a on Sirt1 mRNA and protein levels, HepG2 cells were 
transfected with the miR-200a mimic (Syn-hsa-miR-200a-3p; MSY0000682) and miR-200a 
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inhibitor (Anti-hsa-miR-200a-3p; MIN0000682) [42]. Briefly, HepG2 cells were grown (37°C, 
5% CO2) to 90% confluency in 25 cm
3
 cell culture flasks. The lyophilized microRNA mimic 
and inhibitor (1 nmol) were reconstituted in nuclease-free water to a concentration of 20 µM. 
The transfection complex consisting of 15 µl microRNA mimic or inhibitor, 72 µl serum-free 
media and 3 µl attractene was prepared and incubated (15 min, RT). Thereafter, the CCM was 
removed from the cells and 2,910 µl fresh CCM was added to yield a final concentration of 100 
nM mimic and inhibitor. The transfection complex was added in a dropwise manner with gentle 
swirling to allow even distribution. The cells were incubated (37°C, 5% CO2, 24 h) before 
isolating protein and RNA. 
Animal treatment 
Six-to-eight-week-old C57BL/6 male mice were obtained from the Africa Health Research 
Institute (AHRI) at the University of KwaZulu-Natal, Durban, South Africa. The mice were 
maintained according to the ARRIVE guidelines and the rules and regulations of the University 
of KwaZulu-Natal Animal Research Ethics Committee (Ethics approval number: 
AREC/079/016). Mice with a mean body weight of 20 ± 2.99 g were randomly divided into two 
groups, control and FA, with each group consisting of four mice. The mice were housed under 
standard laboratory conditions (temperature = 25°C, humidity = 40-60%, 12 hr light/dark cycle) 
and fed a commercially available mice pellet diet and normal drinking water ad libitum for the 
duration of the experiment. The mice were orally administered either with 0.1 M PBS (control 
group) or 50 mg/kg FA (FA group) [13] at a rate of 0.25 ml/23 g once for a period of 24 h. 
Following treatment, the mice were euthanized using Isofor (halothane anesthesia) and the 
livers were harvested. The livers were rinsed three times in 0.1 M PBS and stored in cytobuster 
reagent (500 µl; Novagen, 71009) and Qiazol reagent (500 µl; Qiagen, 79306) for protein and 
RNA isolation, respectively.  
RNA isolation and quantitative polymerase chain reaction (qPCR)  
Total RNA was isolated from control, FA-treated HepG2 cells, and mice livers using Qiazol 
Reagent (Qiagen, 79306), as previously described [4]. The RNA was quantified using the 
Nanodrop2000 spectrophotometer (Thermo-Fisher Scientific) and standardized to 1,000 ng/µl. 
The purity of the RNA was assessed using the A260/A280 absorbance ratio.  
The RNA was reverse transcribed into complementary DNA (cDNA) using the miScript II RT 
Kit (Qiagen, 218161), as per manufacturer’s instructions. The expression of miR-200a and miR-
141 was analyzed using the miScript SYBR Green PCR Kit (Qiagen, 218073) and 10X miScript 
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primer assays (Hs-miR-200a_1, Qiagen, MS00003738; Mm-miR-200a_1, Qiagen, 
MS00001813; Hs-miR-141_1, Qiagen, MS00003507; Mm-miR-141_1, Qiagen, MS00001610), 
as per manufacturer’s instructions. RNU6 (Qiagen, MS00033740) was used as the internal 
control to normalise microRNA expression.  
For mRNA expression, cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad, 
1708891), as per manufacturer’s instructions. The expression of Sirt1, SUV39H1, and KDM4B 
was determined using the Sso Advanced™ Universal SYBR Green Supermix (Bio-Rad, 
1725270), as per manufacturer’s instructions. GAPDH was used as the housekeeping gene to 
normalise mRNA expression. Primer sequences and annealing temperatures are listed in 
Supplementary Table S4.1. All qPCR experiments were performed using the CFX96 Real Time 
PCR System and analyzed using the Bio-Rad CFX Manager™ Software version 3.1. Data was 
analyzed using the comparative threshold cycle (Ct) method and represented as a mean fold-
change relative to the control [43]. 
Protein isolation and western blot  
Western blots were used to determine the protein expression of Sirt1, MDM2, SUV39H1, 
H3K9me3, H3K9me1, p-S139-H2Ax, cleaved-Asp175-caspase-3, caspase-3, cleaved-Asp330-
caspase-9, and caspase-9 [44]. Briefly, protein was isolated from control, FA-treated HepG2 
cells, and mice livers using cytobuster reagent (Novagen, 71009) supplemented with protease 
and phosphatase inhibitors (Roche; 05892791001 and 04906837001, respectively). The protein 
samples were quantified using the bicinchoninic acid (BCA) assay and standardized to 1 mg/ml 
(HepG2 cells) and 5 mg/ml (mice livers). The samples were then boiled (100°C, 5 min) in a 1:1 
dilution with Laemmli buffer [dH2O, 0.5 M Tris-HCl (pH 6.8), glycerol, 10% SDS, 5% β-
mercaptoethanol and 1% bromophenol blue] and electrophoresed (1 hr, 150 V) in sodium 
dodecyl sulphate polyacrylamide gels (10% resolving gel, 4% stacking gel) using the Bio-Rad 
compact power supply. The separated proteins were transferred onto nitrocellulose membranes 
using the Bio-Rad Trans-Blot® Turbo Transfer System (20 V, 30 min). Non-specific binding 
was blocked by incubating the membranes in 5% BSA in Tris buffered saline with 0.05% 
Tween 20 [TTBS; 150 mM NaCl, 3 mM KCl, 25 mM Tris, 0.05% Tween 20, dH2O, pH 7.5] for 
1 hr at RT. Thereafter, the membranes were probed with primary antibody (Sirt1 [Cell Signaling 
Technology, #2496], MDM2 [Sigma-Aldrich, M4308], SUV39H1 [Abcam, ab155164], 
H3K9me3 [Abcam, ab8898], H3K9me1 [Cell Signaling Technology, #7538S], p-S139-H2Ax 
[Abcam, ab131385], cleaved-Asp175-caspase-3 [Cell Signaling Technology, #9664P], caspase-
3 [Cell Signaling Technology, #9662P], cleaved-Asp330-caspase-9 [Cell Signaling Technology, 
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#7273P], caspase-9 [Cell Signaling Technology, #9504]; 1:1,000) for 1 hr at RT and then 
overnight at 4°C. The membranes were washed five times with TTBS (10 min, RT) and probed 
with a horse-radish peroxidase (HRP)-conjugated secondary antibody (goat anti-rabbit [Cell 
Signaling Technology, #7074S] and goat anti-mouse [Cell Signaling Technology, #7076P2]; 
1:5,000) for 1 hr at RT. The membranes were washed five times in TTBS (10 min, RT). Protein 
bands were visualized using the Clarity™ Western ECL Substrate Kit (Bio-Rad, #170-5060) 
and the images were captured using the ChemiDoc™ XRS+ Molecular Imaging System (Bio-
Rad). Following detection, the membranes were incubated in hydrogen peroxide (5%, 37°C, 30 
min), washed once in TTBS (10 min, RT), blocked in 5% BSA (1 hr, RT) and probed with the 
housekeeping protein, anti-β-actin (Sigma-Aldrich, A3854; 1:5,000; 30 min, RT). The Image 
Lab Software version 5.1 (Bio-Rad) was used to analyze protein expression and the results were 
represented as a mean fold-change in band density (RBD) relative to the control. Protein 
expression was normalized against the housekeeping protein, β-actin.  
Immuno-precipitation  
Immuno-precipitation was used to determine ubiquitinated SUV39H1 levels [4]. Briefly, crude 
protein was harvested from control and FA-treated HepG2 cells using 1X cell lysis buffer [20 
mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 10% glycerol,  and 1% Triton X-100]. The 
protein was quantified using the BCA assay and standardized to 1.5 mg/ml. Thereafter, the 
protein lysates (200 µl) were incubated with primary antibody [SUV39H1 (Abcam, ab155164); 
1:100] overnight (4°C) and then with Protein A beads (20 µl 50% bead slurry; Cell Signaling 
Technology, #9863) for 1-3 h at 4°C. The samples were centrifuged (14,000 x g, 4°C, 30 s); the 
immuno-precipitates were washed five times in 1X cell lysis buffer (500 µl) and re-suspended 
in 3X Laemmli buffer (20 µl) before boiling (100°C) for 5 min. The samples were then 
analyzed by western blotting using the following antibodies: primary antibody [SUV39H1 
(Abcam, ab155164; 1:1,000) and ubiquitin (BD BioSciences, BD550944; 1:1,000)] and 
secondary antibody [goat anti-rabbit (Cell Signaling Technology, #7074S; 1:5,000) and goat 
anti-mouse (Cell Signaling Technology, #7076P2; 1:5,000)]. The protein expression of 
ubiquitin was divided by the protein expression of total SUV39H1 to determine the ratio of 
ubiquitinated SUV39H1.   
Extraction of nuclear and cytoplasmic protein fractions  
The nuclear and cytoplasmic protein fractions were isolated from control and FA-treated HepG2 
cells using the ReadyPrep™ Protein Extraction Kit (Cytoplasmic/Nuclear) (Bio-Rad, #163-
2089), as per manufacturer’s instructions [45]. Briefly, control and FA-treated HepG2 cells 
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were incubated (30 min, 4°C) in cytoplasmic protein extraction buffer (500 µl) supplemented 
with protease (Roche, 05892791001) and phosphatase (Roche, 04906837001) inhibitors before 
passing through a needle (21 gauge/ 20 strokes). Cell lysates were centrifuged (1,000 x g, 4°C, 
10 min) and the supernatant containing the cytoplasmic protein fraction was transferred to fresh 
1.5 ml micro-centrifuge tubes. The remaining nuclear pellet was re-suspended in protein 
solubilization buffer (500 µl) and vortexed (4-5 times, 60 s). The samples were centrifuged 
(16,000 x g, 4°C, 20 min) and the supernatant containing the nuclear protein fraction was 
transferred to 1.5 ml micro-centrifuge tubes. The nuclear and cytoplasmic protein fractions were 
quantified using the Nanodrop2000 spectrophotometer and standardized to a concentration of 
0.3 mg/ml. Thereafter, Laemmli buffer [dH2O, 0.5 M Tris-HCl (pH 6.8), glycerol, 10% SDS, 
5% β-mercaptoethanol and 1% bromophenol blue] was added and the samples were boiled 
(100°C) for 5 min. The protein expression of SUV39H1 was determined in both the nuclear and 
cytoplasmic fractions using western blotting as mentioned above. Antibodies used were as 
follows: primary antibody [SUV39H1 (Abcam, ab155164); 1:1,000] and secondary antibody 
[goat anti-rabbit (Cell Signaling Technology, #7074S); 1:5,000]. The cytoplasmic protein 
expression was normalized against β-actin (Sigma-Aldrich, A3854; 1:5,000) whereas the 
nuclear protein expression was normalized against laminin B1 (Sigma-Aldrich, SAB2101352; 
1:500). Results are represented as a mean fold-change in band density relative to the control. 
DNA isolation and DNA electrophoresis 
DNA electrophoresis was used to determine the effect of FA on genome stability in HepG2 cells 
[46]. Briefly, control and FA-treated HepG2 cells were incubated (15 min, RT) in cell lysis 
buffer (600 µl; 0.5 M EDTA (pH 8.0), 1 M Tris-Cl (pH 7.6), and 0.1% SDS). Thereafter, 
potassium acetate buffer (600 µl; 5 M potassium acetate and glacial acetic acid) was added to 
the samples (8 min, RT) and centrifuged (13,000 x g, 5 min, 24°C). The supernatant containing 
genomic DNA was transferred into fresh 1.5 ml micro-centrifuge tubes and 100% isopropanol 
(600 µl) was added to the samples to precipitate the DNA. The DNA was recovered by 
centrifugation (13,000 x g, 5 min, 24°C), washed once in 100% ethanol (300 µl), and 
centrifuged (13,000 x g, 5 min, 24°C). The DNA pellets were air dried (30 min, RT), re-
suspended in DNA hydration buffer (40 µl; 10 mM EDTA (pH 8.0) and 100 mM Tris-Cl (pH 
7.4)), and heated (65°C, 15 min). The DNA was quantified using the Nanodrop2000 
spectrophotometer, standardized to 100 ng/µl and prepared in a 1:1 ratio with loading dye [3.7 
mM bromophenol blue, 1.2 M sucrose]. The DNA was then electrophoresed (120 V, 25 min) in 
a 1.8% agarose gel containing 2 µl GelRed and visualized using the ChemiDoc™ XRS+ 
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Molecular Imaging System (Bio-Rad). A 500 bp DNA ladder and 5 µM Camptothecin was used 
as a positive control to determine DNA damage/fragmentation. 
Crystal violet cell viability assay  
The crystal violet assay was used to determine the effect of FA on HepG2 cell viability [47]. 
Briefly, HepG2 cells (20,000 cells/well) were seeded in a 96-well microtiter plate and allowed 
to adhere overnight (37°C, 5% CO2), before incubation with FA (37°C, 5% CO2, 24 h). 
Following treatment, the cells were rinsed twice in dH2O and incubated with 0.5% crystal violet 
staining solution (50 µl/well; 20 min, RT). The cells were washed four times in dH2O and 
allowed to air dry overnight. Methanol (200 µl) was added to each well and the cells were 
incubated (20 min, RT). The absorbance was then measured at 570 nm using the Biotek uQuant 
spectrophotometer and the percentage cell viability in each FA treatment was determined 
relative to the control.  
Luminometry 
The activities of caspases -8, -9, and -3/7 were assessed using the Caspase-Glo® luminometry 
assays (Promega) [9]. Briefly, control and FA-treated HepG2 cells (20,000 cells/well in 50 µl 
PBS) were seeded into an opaque 96-well microtiter plate in triplicate. Thereafter, 20 µl of 
Caspase-Glo® Reagent was added to each well and the plate was incubated (30 min, RT) in the 
dark. Luminescence was measured using the Modulus
TM
 microplate luminometer (Turner 
Biosystems) and the results were expressed as relative light units (RLU). 
Statistical analysis   
All statistical analyses were performed using GraphPad Prism version 5.0 (GraphPad Prism 
Software Inc.). Normality was determined using the D’Agostino and Pearson tests. Data from 
the HepG2 cells were analyzed using the one-way Analysis of Variance (ANOVA) with the 
Bonferroni multiple comparisons test and the results were represented as the mean fold-change 
± standard deviation (SD) (n = 3). Data from the mice livers were analyzed using the unpaired t-
test with Welch’s correction and the results were represented as the mean fold-change ± 
standard error of the mean (SEM) (n = 3 (qPCR assays) / n = 4 (western blot assays)). Statistical 
significance was considered at p < 0.05. 
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Results 
Fusaric acid upregulates miR-200a in HepG2 cells and mice livers    
The expression of miR-200a was assessed in control, FA-treated HepG2 cells, and mice livers 
using qPCR. The HepG2 cells were also treated with a miR-200a mimic (positive control) and 
miR-200a inhibitor (negative control). The expression of miR-200a was increased by FA in 
HepG2 cells (p < 0.0001; Figure 4.1A) and mice livers (p = 0.0055; Figure 4.1B) compared to 
the controls. The expression of miR-200a in HepG2 cells by the mimic and inhibitor were 
increased and decreased (p < 0.0001; Figure 4.1A), respectively. Since, miR-200a and miR-141 
have high sequence homology [20, 21], the effect of FA on miR-141 expression was assessed; 
miR-141 expression was significantly increased by FA in HepG2 cells (p < 0.0001; 
Supplementary Figure S4.1A) but decreased in the mice livers (p < 0.0001; Supplementary 
Figure S4.1B) compared to the controls. 
 
Figure 4.1 FA upregulates miR-200a in HepG2 cells and mice livers. qPCR analysis of miR-
200a expression in HepG2 cells and mice livers. (A) FA increased the expression of miR-200a 
in HepG2 cells. The expression of miR-200a in the mimic and inhibitor was significantly 
increased and decreased, respectively. Results are represented as mean fold-change ± SD, n = 3 
(***p < 0.0001; one way ANOVA with the Bonferroni multiple comparisons test). (B) FA 
increased the expression of miR-200a in mice livers. Results are represented as mean fold-
change ± SEM, n = 3 (*p < 0.05; unpaired t-test with Welch’s correction). FA: Fusaric acid.  
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Fusaric acid decreases Sirt1 expression in HepG2 cells and mice livers  
MiR-200a and miR-141 were previously shown to directly target Sirt1 [20]. This was further 
confirmed using the bioinformatics prediction algorithm software, TargetScan (version 7.1), 
where miR-200a and miR-141 were found to have complementary base pairs with Sirt1 at 
positions 1728 - 1734 in humans (Figure 4.2A and Supplementary Figure S4.2A) and positions 
1562 - 1568 in mice (Figure 4.2B and Supplementary Figure S4.2B). Due to the increased 
expression of miR-200a by FA, we next determined the effect of FA on Sirt1 mRNA and 
protein expression levels in HepG2 cells and mice livers. FA decreased Sirt1 mRNA (HepG2 
cells: p < 0.0001, Figure 4.2C; mice livers: p = 0.0006, Figure 4.2D) and protein (HepG2 cells: 
p < 0.0001, Figure 4.2E; mice livers: p = 0.0231, Figure 4.2F) expression levels compared to the 
controls. Treatment of HepG2 cells with the miR-200a mimic and inhibitor resulted in a 
decrease and increase, respectively in Sirt1 mRNA (Figure 4.2C) and protein levels (Figure 
4.2E). This further validates that Sirt1 is a target of miR-200a in the liver. 
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Figure 4.2 FA decreases Sirt1 mRNA and protein expression in HepG2 cells and mice 
livers. qPCR and western blot analysis of Sirt1 in HepG2 cells and mice livers. (A) TargetScan 
analysis of miR-200a to the 3’UTR of Sirt1 in humans. (B) TargetScan analysis of miR-200a to 
the 3’UTR of Sirt1 in mice. (C) FA decreased Sirt1 expression in HepG2 cells. The expression 
of Sirt1 in the miR-200a mimic and inhibitor was decreased and increased, respectively. Results 
are represented as mean fold-change ± SD, n = 3 (*p < 0.05, ***p < 0.0001; one-way ANOVA 
with the Bonferroni multiple comparisons test). (D) FA decreased Sirt1 expression in mice 
livers. Results are represented as mean fold-change ± SEM, n = 3 (**p < 0.005; unpaired t-test 
with Welch’s correction). (E) FA decreased Sirt1 protein expression in HepG2 cells. The 
expression of Sirt1 in the miR-200a mimic and inhibitor was decreased and increased, 
respectively. Results are represented as mean fold-change ± SD, n = 3 (**p < 0.005, ***p < 
0.0001; one-way ANOVA with the Bonferroni multiple comparisons test). (F) FA decreased 
Sirt1 protein expression in mice livers. Results are represented as mean fold-change ± SEM, n = 
4 (*p < 0.05; unpaired t-test with Welch’s correction). FA: Fusaric acid; Sirt1: Sirtuin 1. 
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Fusaric acid alters SUV39H1 ubiquitination in HepG2 Cells   
SUV39H1 is subject to PTMs that regulate its expression and activity. Acetylation of K266 was 
associated with an inhibition in catalytic activity [37] and ubiquitination of K87 was shown to 
promote proteosomal degradation [33]. Sirt1 regulates SUV39H1 ubiquitination by directly 
interacting with and deacetylating SUV39H1 thereby, preventing its ubiquitination and 
degradation. Due to the FA-induced decrease in Sirt1 expression, we evaluated the effect of FA 
on the ubiquitination of SUV39H1 in HepG2 cells using immuno-precipitation. The expression 
of ubiquitinated SUV39H1 was significantly decreased in the 25, 50, and 150 µg/ml FA 
treatments; however, at 104 µg/ml FA the ubiquitination of SUV39H1 was significantly 
increased compared to the control (p < 0.0001; Figure 4.3A).   
The E3 ubiquitin ligase, MDM2, is the main regulator of SUV39H1 ubiquitination [33, 48]. 
Therefore, we determined the effect of FA on the protein expression of MDM2. FA increased 
the expression of MDM2 in HepG2 cells compared to the control (p < 0.0001; Figure 4.3B).  
 
Figure 4.3 FA alters SUV39H1 ubiquitination and increases MDM2 expression in HepG2 
cells. (A) The ubiquitination of SUV39H1 in HepG2 cells was determined by immuno-
precipitation and western blot. FA altered SUV39H1 ubiquitination in HepG2 cells. Results are 
represented as mean fold-change ± SD, n = 3 (***p < 0.0001; one-way ANOVA with the 
Bonferroni multiple comparisons test). (B) Western blot analysis of MDM2 in HepG2 cells. FA 
increased the protein expression of MDM2 in HepG2 cells. Results are represented as mean 
fold-change ± SD, n = 3 (***p < 0.0001; one-way ANOVA with the Bonferroni multiple 
comparisons test). FA: Fusaric acid; SUV39H1: suppressor of variegation 3-9 homolog 1; 
MDM2: murine double minute 2. 
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Fusaric acid alters SUV39H1 nuclear and cytoplasmic levels in HepG2 cells  
PTMs of SUV39H1 are associated with changes in cellular localization. Mobile or free 
SUV39H1 is usually ubiquitinated and found in the cytoplasm where it is targeted for 
proteasomal degradation, however, chromatin-associated SUV39H1 is found in the nucleus 
where it functions to trimethylate H3K9. Due to the changes in SUV39H1 ubiquitination, we 
determined the effect of FA on the protein expression of nuclear and cytoplasmic SUV39H1. 
FA significantly altered the expression of SUV39H1 nuclear levels (p < 0.0001; Figure 4.4) and 
increased its cytoplasmic levels (p < 0.0001; Figure 4.4) in HepG2 cells relative to the control. 
 
Figure 4.4 FA alters expression levels of nuclear and cytoplasmic SUV39H1 in HepG2 
cells. Western blot analyses of SUV39H1 in the nuclear and cytoplasmic protein fractions. FA 
altered SUV39H1 nuclear levels and increased SUV39H1 cytoplasmic levels in HepG2 cells. 
Results are represented as mean fold-change ± SD, n = 3 (***p < 0.0001; one-way ANOVA 
with the Bonferroni multiple comparisons test). FA: Fusaric acid; SUV39H1: suppressor of 
variegation 3-9 homolog 1. 
Fusaric acid decreases the expression of SUV39H1 in HepG2 cells and mice livers   
SUV39H1 ubiquitination as well as changes in cellular localization is known to affect 
SUV39H1 stability and expression [33, 37, 48]; hence, we determined the effect of FA on the 
expression of SUV39H1 mRNA and protein levels. FA significantly decreased SUV39H1 
mRNA (p < 0.0001; Figure 4.5A) and protein (p < 0.0001; Figure 4.5B) levels in HepG2 cells 
compared to the control. The expression of SUV39H1 mRNA (p = 0.0110; Figure 4.5C) and 
protein (p < 0.0001; Figure 4.5D) levels were significantly increased and decreased in the FA-
treated mice livers, respectively. 
104 
 
 
Figure 4.5 FA alters SUV39H1 mRNA and protein expression in HepG2 cells and mice 
livers. qPCR and western blot analysis of SUV39H1 in HepG2 cells and mice livers. (A) FA 
significantly decreased SUV39H1 mRNA expression in HepG2 cells. Results are represented as 
mean fold-change ± SD, n = 3 (***p < 0.0001; one-way ANOVA with the Bonferroni multiple 
comparisons test). (B) FA significantly decreased SUV39H1 protein expression in HepG2 cells. 
Results are represented as mean fold-change ± SD, n = 3 (***p < 0.0001; one-way ANOVA 
with the Bonferroni multiple comparisons test). (C) FA significantly increased SUV39H1 
mRNA expression in mice livers. Results are represented as mean fold-change ± SEM, n = 3 
(*p < 0.05; unpaired t-test with Welch’s correction). (D) FA significantly decreased SUV39H1 
protein expression in mice livers. Results are represented as mean fold-change ± SEM, n = 4 
(***p < 0.0001; unpaired t-test with Welch’s correction). FA: Fusaric acid; SUV39H1: 
suppressor of variegation 3-9 homolog 1. 
Fusaric acid decreases H3K9me3 and increases H3K9me1 in HepG2 cells and mice 
livers 
SUV39H1 is the key regulator of H3K9me3, and an inhibition or depletion in SUV39H1 may 
result in alterations in H3K9me3. Since FA decreased the expression of SUV39H1, we 
determined if FA effects H3K9me3 in HepG2 cells and mice livers. The expression of 
H3K9me3 was significantly decreased in the FA-treated HepG2 cells (p < 0.0001; Figure 4.6A) 
and mice livers (p = 0.0194; Figure 4.6B) compared to the controls.   
The lysine demethylase, KDM4B is responsible for specifically demethylating H3K9me3 by 
converting H3K9me3 to its mono-methylated state (H3K9me1) which then forms a substrate for 
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SUV39H1-mediated trimethylation. Due to FA decreasing H3K9me3, we next evaluated the 
effect of FA on H3K9me1 and the mRNA expression of the lysine demethylase, KDM4B. FA 
increased the expression of H3K9me1 in HepG2 cells (p < 0.0001; Figure 4.6A) and mice livers 
(p = 0.1292; Figure 4.6B) compared to the controls. FA decreased the expression of KDM4B in 
HepG2 cells (p < 0.0001; Figure 4.6C) and mice livers (p = 0.5076; Figure 4.6D) compared to 
their respective controls.   
 
Figure 4.6 FA decreases H3K9me3 and increases H3K9me1 in HepG2 cells and mice 
livers. Western blot analyses of H3K9me3 and H3K9me1 expression, and qPCR analysis of 
KDM4B expression in HepG2 cells and mice livers. (A) FA significantly decreased H3K9me3 
and increased H3K9me1 in HepG2 cells. Results are represented as mean fold-change ± SD, n = 
3 (**p < 0.005, ***p < 0.0001; one-way ANOVA with the Bonferroni multiple comparisons 
test). (B) FA decreased H3K9me3 and increased H3K9me1 in mice livers. Results are 
represented as mean fold-change ± SEM, n = 4 (*p < 0.05; unpaired t-test with Welch’s 
correction). (C) FA significantly decreased KDM4B mRNA expression in HepG2 cells. Results 
are represented as mean fold-change ± SD, n = 3 (***p < 0.0001; one-way ANOVA with the 
Bonferroni multiple comparisons test). (D) FA decreased KDM4B mRNA expression in mice 
livers. Results are represented as mean fold-change ± SEM, n = 3 (non-significant; unpaired t-
test with Welch’s correction). FA: Fusaric acid; H3K9me3: histone 3 lysine 9 trimethylation; 
H3K9me1: histone 3 lysine 9 mono-methylation. 
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Fusaric acid induces genome instability and alters p-S139-H2Ax in HepG2 cells 
and mice livers  
PTMs of histones influence chromatin structure and thus have a crucial role in regulating gene 
transcription and genome integrity [33, 36]. H3K9me3 plays a major role in maintaining 
heterochromatin; and a decrease in H3K9me3 was previously shown to lead to a loss in 
heterochromatin formation and genome instability [33]. We determined if the loss in H3K9me3 
observed in the FA treatments led to genome instability by using DNA electrophoresis. The 
effect of FA on phosphorylated serine 139 Histone H2Ax (p-S139-H2Ax), a marker of DNA 
double-strand breaks and indicator of DNA damage, was also determined. Analysis of DNA 
isolated from the FA-treated HepG2 cells revealed a significant amount of DNA smearing as 
compared to the controls (Figure 4.7A). The expression of p-S139-H2Ax by FA was 
significantly decreased at 25, 50, and 104 µg/ml, however, at 150 µg/ml FA its expression was 
significantly increased (p < 0.0001; Figure 4.7B). The expression of p-S139-H2Ax in the FA-
treated mice livers was also decreased compared to the control (p = 0.2207; Figure 4.7C).   
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Figure 4.7 FA induces genome instability and alters p-S139-H2Ax in HepG2 cells and mice 
livers. (A) Electrophoresis of DNA isolated from control and FA-treated HepG2 cells. FA 
induced DNA fragmentation in HepG2 cells (Lane 1: DNA ladder, lane 2: control, lane 3: 25 
µg/ml FA, lane 4: 50 µg/ml FA, lane 5: 104 µg/ml FA, lane 6: 150 µg/ml FA, lane 7: 5 µM 
Camptothecin). (B) Western blot analysis of p-S139-H2Ax in HepG2 cells. FA altered the 
expression of p-S139-H2Ax in HepG2 cells. Results are represented as mean fold-change ± SD, 
n = 3 (*p < 0.05, ***p < 0.0001; one-way ANOVA with the Bonferroni multiple comparisons 
test). (C) Western blot analysis of p-S139-H2Ax in mice livers. FA decreased p-S139-H2Ax in 
mice livers. Results are represented as mean fold-change ± SEM, n = 4 (non-significant; 
unpaired t-test with Welch’s correction). FA: Fusaric acid; p-S139-H2Ax: phosphorylated 
serine 139 of histone H2Ax. 
Fusaric acid induces apoptosis in HepG2 cells and mice livers  
Since a loss in H3K9me3 is known to affect cell proliferation by regulating apoptotic cell death, 
we determined if FA induced apoptosis by assessing the activity of the caspases -8, -9, and -3/7. 
The crystal violet cell viability assay and the Caspase-Glo luminometry assays were used to 
determine the effect of FA on cell viability and apoptosis in HepG2 cells, respectively. 
Apoptosis in the mice livers was determined by assessing the expression of total and cleaved 
caspases -3 and -9 via western blot. In HepG2 cells, FA significantly decreased cell viability (p 
< 0.0001; Figure 4.8A), increased the activity of caspase-3/7 (p<0.0001; Figure 4.8B), and 
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significantly decreased the activity of caspase-8 as compared to the controls (p < 0.0001; 
Supplementary Figure S4.3A). FA also decreased caspase-9 activity at 25, 50, and 104 µg/ml 
treatments, but increased caspase-9 activity at 150 µg/ml treatment in HepG2 cells (p < 0.0001; 
Supplementary Figure S4.3B). The expression of cleaved-Asp175-caspase-3 (active caspase-3) 
was significantly increased in the FA-treated mice livers (19 kDa: p = 0.0372 and 17 kDa: p = 
0.0004; Figure 4.8C), however, the expression of total caspase-3 was decreased (p = 0.1601; 
Figure 4.8C). The expression of total and cleaved-Asp330-caspase-9 was significantly 
decreased in the FA-treated mice livers (p = 0.0032 and p = 0.0013, respectively; 
Supplementary Figure S4.3C). This suggests that FA decreases cell viability and induces 
apoptosis in HepG2 cells and mice livers.  
 
Figure 4.8 FA decreases cell viability and increases caspase-3/7 activity in HepG2 cells and 
mice livers. (A) Cell viability was determined using the Crystal Violet Assay. FA significantly 
decreased HepG2 cell viability in a dose-dependent manner. Results are represented as a mean 
percentage in cell viability ± SD, n = 3 (***p < 0.0001; one-way ANOVA with the Bonferroni 
multiple comparisons test). (B) Luminometric analysis of caspase-3/7 activity in HepG2 cells. 
FA increased the activity of caspase-3/7 in HepG2 cells.  Results are represented as mean ± SD, 
n = 3 (***p < 0.0001; one-way ANOVA with the Bonferroni multiple comparisons test). (C) 
Western blot analysis of total caspase-3 and cleaved-Asp175-caspase-3 expressions in mice 
livers. FA decreased the expression of total caspase-3 and increased the expression of cleaved-
Asp175-caspase-3 in mice livers. Results are represented as mean fold-change ± SEM, n = 4 (*p 
< 0.05, **p < 0.005; unpaired t-test with Welch’s correction). FA: Fusaric acid. 
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Discussion  
The food-borne mycotoxin, FA causes toxicity by altering cell signaling pathways in both plants 
and animals [10-12, 15, 18]. Currently, only a few studies have elucidated the effects of FA in 
human cells, with sparse information on its mechanisms of toxicity. Recently, epigenetic studies 
on mycotoxins have provided insights into their mechanisms of toxicity. Fumonisin B1 (FB1), a 
Fusarium-produced mycotoxin often co-produced with FA, was shown to cause chromatin 
instability and liver tumorigenesis by inducing global DNA hypomethylation and histone 
demethylation [44]. FB1 inhibits miR-27b, increases cytochrome P450 1B1, and alters promoter 
methylation of tumor suppressor genes (c-myc, p15, p16, and e-cadherin) possibly leading to 
hepatic neoplastic transformation [49, 50]. FB1 also alters the expression of H3K9me2/3, 
H3K9Ac, and H4K20me3 [51]. Similarly, zearalenone induced global DNA hypomethylation 
[52], and decreased H3K9me3, H3K4me2, and H4K20me1/2/3 [53].  
FA was recently shown to exert its genotoxic and cytotoxic effects by inducing global DNA 
hypomethylation in HepG2 cells [4]; however, there are currently no studies evaluating the 
effects of FA on histone modifications both in vitro and in vivo. In this study, we provide 
evidence for an epigenetic mechanism of FA-induced apoptosis by altering miR-200a and 
SUV39H1-mediated H3K9me3 in an in vitro (HepG2 cells) and in vivo (mouse liver) model.  
MicroRNA expression and histone methylation are epigenetic modifications that regulate cell 
signaling pathways by altering chromatin structure and gene transcription. These processes can 
be modified by exogenous agents and alterations in the epigenetic machinery of the cell may 
provide an important mechanism of FA-induced toxicity.  
Our results indicate that FA significantly upregulated miR-200a in HepG2 cells and mice livers 
(Figure 4.1); however, the expression of miR-141 was significantly upregulated in the FA-
treated HepG2 cells (Supplementary Figure S4.1A) but downregulated in the mice livers 
(Supplementary Figure S4.1B). The expression of miR-200a and miR-141 is regulated by DNA 
methylation [20], oxidative stress [21, 54], and p53 expression [54]. DNA hypermethylation 
downregulates miR-200a and miR-141, whereas DNA hypomethylation upregulates them both 
[20]. We recently reported that FA induced DNA hypomethylation in HepG2 cells by 
decreasing the expression of the DNA methyltransferases, DNMT1, DNMT3A, and DNMT3B, 
whilst increasing the expression of the DNA demethylase, MBD2 [4]. Therefore, the increase in 
miR-200a and miR-141 observed in the HepG2 cells and mice livers may be due to the FA-
induced DNA hypomethylation. Further, the expression of miR-200a and miR-141 is stimulated 
by an increase in oxidative stress [21, 54]. Previously, FA was shown to induce oxidative stress 
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in various human cell lines [9, 11, 55], and this may then lead to the increased expressions of 
miR-200a and miR-141 observed in the HepG2 cells and mice livers. MiR-200a and miR-141 
also contain p53-binding sites that enable p53 to bind to miR-200a/miR-141 promoters and 
activate their transcription [54]. Previously, we showed that FA decreased p53 expression in 
HepG2 cells [10] and this may have resulted in the decreased expression of miR-141 observed 
in the FA-treated mice livers.  
MiR-200a and miR-141 were previously shown to directly target Sirt1 [20] and this was further 
confirmed using TargetScan version 7.1 (Figure 4.2A-B and Supplementary Figure S4.2). FA 
significantly decreased the mRNA and protein expressions of Sirt1 in HepG2 cells (Figure 4.2C 
and Figure 4.2E) and mice livers (Figure 4.2D and Figure 4.2F). These results are in agreement 
with previous studies where upregulation of miR-200a and miR-141 was found to downregulate 
Sirt1 expression at both the protein and transcript levels [20, 56].  
Sirt1 is an NAD
+
-dependent lysine deacetylase that regulates gene transcription via its 
interaction with chromatin-associated proteins such as histones [31-33]. Sirt1 also maintains 
genome stability and is involved in regulating heterochromatin formation [32] by direct 
deacetylation of histones, recruitment of histone H1, and alterations in the chromatin modifying 
enzymes, histone methyltransferases and histone acetyltransferases [57].  
SUV39H1 is a SET-domain containing histone methyltransferase responsible for catalyzing 
H3K9me3 [33-35, 37, 39]. SUV39H1 is involved in heterochromatin organization and genome 
stability via its association with heterochromatin protein 1 (HP1), and a loss in SUV39H1 and 
H3K9me3 causes delocalization of HP1 and a reduction in heterochromatin levels [33, 37, 57].  
PTMs such as acetylation and ubiquitination regulate SUV39H1 activity and expression [33, 37, 
48, 58]. The acetylation of SUV39H1 on K266 in the catalytic SET-domain reduces its 
enzymatic activity [33] and enables MDM2 to polyubiquitinate SUV39H1 on K87 thereby, 
targeting it for proteosomal degradation [37]. Sirt1 regulates SUV39H1 activity and expression. 
Previously, Sirt1 was shown to interact with the N-terminal chromo-domain of SUV39H1 
causing deacetylation of K266 and an increase in its histone methyltransferase activity [33, 37]. 
Sirt1 also regulates SUV39H1 protein levels by inhibiting MDM2-mediated polyubiquitination 
of K87 in the SUV39H1 chromo-domain thereby, preventing its proteasomal degradation and 
increasing its half-life by nearly four times [33]. This was further confirmed in cervical cancer 
(HELA) cells, where an increase in Sirt1 expression correlated with an increase in SUV39H1 
protein levels [33]. The decrease in the expression of Sirt1 by FA in HepG2 cells and mice 
livers suggests that FA may decrease SUV39H1 expression by ubiquitination. FA significantly 
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altered SUV39H1 ubiquitination (Figure 4.3A) and increased the expression of MDM2 in 
HepG2 cells (Figure 4.3B). The ubiquitin specific peptidase 7 (USP7) is a deubiquitinating 
enzyme that regulates SUV39H1 stability by protecting it from MDM2-mediated 
polyubiquitination and degradation [48]. Mechanistically, USP7 interacts with MDM2 and 
forms a trimeric protein complex with SUV39H1 [48]. This protein complex is independent of 
DNA and occurs only in the presence of MDM2, indicating that the interaction between USP7, 
MDM2 and SUV39H1 is essential for USP7 to deubiquitinate SUV39H1 as well as for MDM2 
to ubiquitinate SUV39H1 [48]. Previously, FA was shown to decrease USP7 expression in 
HepG2 cells [4] and this decrease in USP7 may inhibit the USP7-MDM2-SUV39H1 complex 
leading to the alterations in ubiquitinated SUV39H1 observed in the FA-treated HepG2 cells.    
PTMs of SUV39H1 are often associated with changes in sub-cellular localization. The 
ubiquitination of SUV39H1 causes SUV39H1 to translocate from the nucleus to the cytoplasm 
where it is degraded by the proteasome. The expression of nuclear SUV39H1 was decreased in 
the lower (25 µg/ml) FA concentration and increased in the higher (50, 104, and 150 µg/ml) FA 
concentrations (Figure 4.4). FA significantly increased cytoplasmic SUV39H1 levels in HepG2 
cells (Figure 4.4); however, the expression of SUV39H1 mRNA (Figure 4.5A) and protein 
(Figure 4.5B) was significantly decreased in the FA-treated HepG2 cells. The expression of 
SUV39H1 mRNA (Figure 4.5C) and protein (Figure 4.5D) was increased and decreased, 
respectively, in the FA-treated mice livers. The activation of p53 reduces SUV39H1 at the 
transcriptional level by inducing p21 and repressing E2F activity [59]. FA was previously 
shown to activate p53 in HepG2 cells [10]; hence the decrease in SUV39H1 transcript levels 
may occur due to the FA-induced p53 activation in HepG2 cells. Further, the decrease in 
SUV39H1 protein expression observed by FA in the HepG2 cells may result from a combined 
decrease in SUV39H1 transcription and translation. The decrease in SUV39H1 ubiquitination 
suggests that the FA-induced decrease in SUV39H1 protein expression may not necessarily 
occur due to proteasomal degradation, albeit an increase in SUV39H1 cytoplasmic levels. The 
increase in SUV39H1 mRNA expression and decrease in SUV39H1 protein expression observed 
in the FA-treated mice livers may have occurred due to possible MDM2-mediated 
ubiquitination of SUV39H1 and proteasomal degradation.  
Sirt1 deficiency is known to inhibit SUV39H1 deacetylation and enzymatic activity [33, 37]. 
Therefore, although FA upregulated SUV39H1 nuclear levels, it may not necessarily be active 
as a decrease in H3K9me3 was observed (Figure 6A-B).  
The methylation of lysine residues on the amino-terminal tails of histone proteins is a dynamic 
epigenetic modification that regulates chromatin structure and gene expression. H3K9me3 
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maintains heterochromatin formation and plays a crucial role in preserving genome stability and 
gene silencing [36, 37]. H3K9me3 is regulated by SUV39H1 and KDM4B. KDM4B decreases 
chromosomal H3K9me3 by catalyzing the removal of H3K9 di- and tri- methyl marks resulting 
in H3K9me1, which then forms a substrate for trimethylation by SUV39H1 [59]. FA 
significantly increased the expression of H3K9me1 (Figure 4.6A-B) and decreased the mRNA 
expression of KDM4B in HepG2 cells and mice livers (Figure 4.6C-D). The decrease in 
SUV39H1 expression and KDM4B mRNA expression as well as the increase in H3K9me1 
observed in the FA-treated HepG2 cells and mice livers, suggests that the decrease in H3K9me3 
was due to the decrease in SUV39H1 and not KDM4B.  
Since Sirt1 also regulates H3K9me3 by directly interacting with and deacetylating H3K9Ac to 
enable trimethylation by SUV39H1, the loss in Sirt1 expression may also be responsible for the 
decrease in H3K9me3 observed in the FA-treated HepG2 cells and mice livers.   
DNA damage can also indirectly regulate H3K9me3 by promoting SET7/9-mediated 
methylation of SUV39H1 [58]. SET7/9 interacts with and methylates SUV39H1 at K105 and 
K123 resulting in a decrease in SUV39H1 activity and a loss in H3K9me3 [58].  
The loss in H3K9me3 was previously associated with genome instability [36], inhibition of cell 
proliferation [40, 41] and apoptosis [35]. Analysis of DNA integrity using DNA electrophoresis 
revealed that FA induced a loss in genome stability/DNA integrity in HepG2 cells (Figure 
4.7A). This is in agreement with previous studies in which FA induced DNA damage in several 
human cell lines [10, 60-63].  
P-S139-H2Ax is an early response to the induction of DNA double-strand breaks and important 
molecular indicator of DNA damage. During DNA damage, H2Ax is rapidly phosphorylated on 
serine 139 by the phosphatidyl-inositol 3-kinase (PIKK) family of proteins, ataxia telangiectasia 
mutated (ATM), DNA-dependent protein kinase, and ATM and RAD3-related protein (ATR), 
causing a conformational change in the DNA-H2Ax complex. This enables DNA repair proteins 
such as poly (ADP-ribose) polymerase 1 (PARP1) to be recruited to sites of DNA double-strand 
breaks initiating the repair of the damaged DNA. FA decreased the expression of p-S139-H2Ax 
in HepG2 cells and mice livers (Figure 4.7B-C). H3K9me3 maintains genome stability by 
controlling ATM signaling and promoting the repair of DNA double-stand breaks. The ATM 
protein kinase is activated in response to DNA damage and functions to promote the 
phosphorylation of proteins involved in checkpoint activation and DNA repair [64]. The 
acetyltransferase, Tip60 acetylates and activates ATM by interacting with H3K9me3 [64]. 
Depletion of intracellular H3K9me3 prevents ATM activation and impairs the repair of DNA 
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double-strand breaks resulting in genome instability. The decrease in p-S139-H2Ax observed in 
the FA-treated HepG2 cells and mice livers may have resulted from a decrease in H3K9me3 and 
inactivation of ATM. 
Sirt1 also functions in DNA damage response by relocating to sites of genomic instability and 
enabling the efficient repair of DNA double-strand breaks [57]. Therefore, FA induced genome 
instability by decreasing Sirt1 expression and H3K9me3 in HepG2 cells and mice livers.  
The loss in H3K9me3 and subsequent increase in genomic instability induced by FA in HepG2 
cells and mice livers suggests it may decrease cell viability by apoptotic signaling.  Caspases 
form a major part of the apoptotic machinery and are responsible for both the initiation and 
execution of apoptosis [65]. Initiator caspases such as caspase -8 and -9 are the apical caspases 
in apoptosis and their activation is required for the cleavage and activation of the downstream 
executioner caspases -3 and -7. FA decreased HepG2 cell viability (Figure 4.8A) and induced 
apoptotic cell death as shown by the increase in the activity of caspase-3/7 (Figure 4.8B). The 
expression of cleaved-Asp175-caspase-3 was significantly increased in the FA-treated mice 
livers (Figure 4.8C). This is in keeping with previous studies where FA was shown to cause 
apoptosis by activating p53 [10] and caspase-3/7 [9] in HepG2 cells. FA also induced apoptosis 
in human promyelocytic leukemia (HL-60) cells [60] and human esophageal cancer (SNO) cells 
[66].   
Conclusion 
This study provides a novel insight into an epigenetic mechanism of FA-induced apoptosis in 
the liver via modulation of the Sirt1/SUV39H1/H3K9me3 pathway. The results indicate that FA 
upregulates miR-200a and decreases H3K9me3 by downregulating Sirt1 expression and 
decreasing SUV39H1 ultimately leading to a loss in genome stability and apoptosis of HepG2 
cells and mice livers. The results further suggest that FA-induced changes in miR-200a and 
SUV39H1-mediated H3K9me3 may serve as a potential biomarker for determining FA 
exposure and toxicity; this is particularly important in developing countries and poverty stricken 
areas where maize is a staple diet and the risk of exposure to FA is high. 
Future perspective 
MicroRNAs and histone methylation are epigenetic mechanisms that regulate gene expression 
and play a crucial role in cell signaling pathways; however, the effect of mycotoxins on 
epigenetic mechanisms is limited. This study provided evidence for the role of miR-200a and 
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H3K9me3 in regulating genome integrity and apoptotic cell death following exposure to the 
food-borne mycotoxin, Fusaric acid (FA); and paves the way for future research on histone 
modifications and microRNAs in mycotoxicology. It also suggests that FA may have an effect 
on other essential histone modifications and microRNAs that contribute to its toxicity and 
studies targeting these modifications may provide insight into possible therapeutic interventions 
against FA toxicity. Furthermore, this study indicates a possible role for histone-modifying 
compounds such as histone deacetylase inhibitors in reversing FA-induced toxicity.  
Executive summary 
 Fusaric acid (FA) is a Fusarium produced mycotoxin that commonly contaminates 
agricultural foods intended for human and animal consumption. 
 FA displays various toxicological effects in plants and animals; however, its epigenetic 
effects are unclear.  
 This study investigated the ability of FA to regulate genome integrity and apoptotic cell 
death via epigenetic mechanisms such as miR-200a and H3K9me3 in vitro and in vivo. 
 FA upregulates miR-200a and downregulates Sirt1 expression.  
 FA increases MDM2 expression and alters the ubiquitination of SUV39H1.  
 FA alters nuclear and cytoplasmic SUV39H1 levels.  
 FA decreases SUV39H1-mediated H3K9me3.  
 FA induces genome instability/damage. 
 FA induces apoptotic cell death.  
 Results from this study provide evidence for alternative mechanisms of FA-induced 
genotoxicity and cytotoxicity at the epigenetic level. 
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Supplementary Information 
Supplementary Table S4.1: qPCR primer sequences and annealing temperatures 
Gene GenBank 
Accession 
no.  
Sense Primer 
5’→3’ 
Anti-sense Primer 
5’→3’ 
Annealing 
Temperature 
(°C) 
Sirt1 
(human) 
NM_0122
38 
AGGACATCGAGGAAC
TACCTG 
GATCTTCCAGATCCT
CAAGCG 
57 
SUV39H
1 
(human) 
NM_0012
82166 
ATATCCAGACTCAGA
GAGCACC 
CAGCTCCCTTTCTAA
GTCCTTG 
57 
KDM4B 
(human) 
NM_0150
15 
GTCATCACCAAGAAC
CGCAACG 
CAGTCCCTACTCGT
GATGCTC 
60 
GAPDH 
(human) 
NM_0020
46 
TCCACCACCCTGTTG
CTGTA 
ACCACAGTCCATGC
CATCAC 
Same as gene 
of interest 
Sirt1 
(mouse) 
NM_0198
12 
CAGCCGTCTCTGTGT
CACAAA 
GCACCGAGGAACTA
CCTGAT 
58 
SUV39H
1 
(mouse) 
NM_0115
14 
GAGAGCTTGTCCGAC
GACAC 
CTTCTGCACCAGGT
AATTGGC 
60 
KDM4B 
(mouse) 
NM_1721
32 
TCCAAGCCGAGAGGA
AGTTCA 
AGAAGAGGGTACAG
ATGGCAC 
60 
GAPDH 
(mouse) 
NM_0012
90631 
AATGGATTTGGACGC
ATTGGT 
TTTGCACTGGTACGT
GTTGAT 
Same as gene 
of interest 
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Supplementary Figure S4.1 FA alters miR-141 expression in HepG2 cells and mice livers. 
qPCR analysis of miR-141 in HepG2 cells and mice livers. (A) FA increased the expression of 
miR-141 in HepG2 cells. Results are represented as mean fold-change ± SD, n = 3 (*p < 0.05, 
***p < 0.0001; one-way ANOVA with the Bonferroni multiple comparisons test). (B) FA 
decreased the expression of miR-141 in mice livers. Results are represented as mean fold-
change ± SEM, n = 3 (***p < 0.0001; unpaired t-test with Welch’s correction). FA: Fusaric 
acid.     
 
Supplementary Figure S4.2 TargetScan analyses of miR-141 to the 3’ UTR of Sirt1 in 
humans and mice. (A) MiR-141 has complementary base pairs with the 3’ UTR of Sirt1 at 
positions 1728-1734 in humans. (B) MiR-141 has complementary base pairs with the 3’ UTR of 
Sirt1 at positions 1562-1568 in mice.  
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Supplementary Figure S4.3 FA decreased caspase -8 and -9 activities in HepG2 cells and 
mice livers. (A)  Luminometric analysis of caspase-8 activity in HepG2 cells. FA significantly 
decreased the activity of caspase-8 in HepG2 cells. Results are represented as mean ± SD, n = 3 
(***p < 0.0001; one-way ANOVA with the Bonferroni multiple comparisons test). (B) 
Luminometric analysis of caspase-9 activity in HepG2 cells. FA significantly altered the activity 
of caspase-9 in HepG2 cells. Results are represented as mean ± SD, n = 3 (***p < 0.0001; one-
way ANOVA with the Bonferroni multiple comparisons test). (C) Western blot analysis of total 
caspase-9 and cleaved-Asp330-caspase-9 expressions in mice livers. FA decreased the 
expression of total caspase-9 and cleaved-Asp330-caspase-9 in mice livers.  Results are 
represented as mean fold-change ± SEM, n = 4 (**p < 0.005; unpaired t-test with Welch’s 
correction). FA: Fusaric acid. 
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Abstract 
Fusaric acid (FA), a food-borne mycotoxin, mediates toxicity with sparse information on its 
epigenetic mechanisms. The tumor suppressor protein, p53 is activated in response to cellular 
stress and regulates cell cycle arrest and apoptotic cell death. The expression of p53 is regulated 
at the transcriptional and post-transcriptional level by promoter methylation and N-6-
methyladenosine (m6A) RNA methylation, respectively; and alterations in p53 may provide an 
alternative mechanism of FA-induced toxicity. We investigated the effect of FA on p53 
expression and its epigenetic regulation via promoter methylation and m6A RNA methylation in 
vitro and in vivo. In vitro, FA induced p53 promoter hypermethylation and decreased p53 
expression. FA decreased m6A-p53 levels by decreasing METTL3 and METTL14; and 
suppressed expression of YTHDF1, YTHDF3, and YTHDC2 that ultimately reduced p53 
translation. In vivo, FA induced p53 promoter hypomethylation and increased p53 expression. 
FA increased m6A-p53 levels by increasing the expression of METTL3 and METTL14; and 
upregulated expressions of YTHDF1, YTHDF3, and YTHDC2, thus increasing p53 translation. 
FA differentially induces epigenetic regulation of p53 expression via promoter methylation and 
m6A RNA methylation in HepG2 cells and C57BL/6 mice livers. These results provide 
evidence for an alternative mechanism of FA toxicity at the epigenetic level. 
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Introduction 
Fusaric acid (FA; 5-butylpicolinic acid) is a mycotoxin produced by the Fusarium species that 
parasitize agricultural foods and feeds and impacts on human and animal health. To date, little is 
known on the toxic and epigenetic effects of FA in humans and animals and understanding the 
molecular and epigenetic mechanisms of toxicity is important in decreasing FA contamination 
and lowering the risk of FA-related adverse health effects. Thus far, the only epigenetic study 
on FA showed induction of DNA hypomethylation that led to genotoxicity and cytotoxicity in 
an in vitro model 
1
.  
FA has diverse toxicological effects in plants 
2-5
 and animals 
6-9
; it exhibits phytotoxicity by 
causing necrosis and wilt disease symptoms in various plants 
5
. FA is also toxic to human and 
animal cells by inducing oxidative stress 
10
, mitochondrial dysfunction 
11
, DNA damage 
12,13
, 
and apoptotic cell death 
10-12,14,15
. It has neurochemical effects in mice 
16
, rats 
17
 and pigs 
18,19
; 
and reduced aggressive behavior and motor activity 
16
. Additionally, the toxicity of FA was 
associated with alterations in platelet function 
20
, delayed bone ossification 
21
, hypotension 
7,22
, 
and notochord malformation 
8
. Synergism between FA and other Fusarium-produced 
mycotoxins such as deoxynivalenol (DON) 
23
, Fumonisin B1 (FB1) 
24
, and 4,15-
diacetoxyscirpenol (DAS) 
25
 have also been demonstrated.  
The tumor suppressor protein, p53 is a transcription factor that is activated in response to 
cellular stress 
26
. The most common p53 activating stressors include oxidative stress, DNA 
damage, excessive oncogene activation, and hypoxia 
26,27
. Once activated, p53 recruits core 
transcriptional machinery to its target promoters, enabling the transcription of genes, with 
cellular outcomes such as cell cycle arrest and apoptosis 
28,29
. Dysregulation in p53 expression 
has been associated with several human diseases including neurodegenerative diseases 
30,31
 and 
cancer 
32
. 
Although previous studies have indicated that p53 is regulated at the post-translational level by 
ubiquitination, phosphorylation, and acetylation 
33-35
, the expression of p53 is also regulated 
epigenetically at the transcriptional and post-transcriptional levels by promoter methylation and 
N-6-methyladenosine (m6A) RNA methylation. 
Promoter methylation, methylation of CpG islands within the promoter regions of specific 
genes, is crucial in regulating gene transcription. The p53 promoter region was sequenced and 
basal promoter activity was localized to an 85bp region (nucleotides 760-844) that is 
indispensable for its full promoter activity 
36
, and the p53 promoter has putative binding sites for 
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transcription factors. Alterations in p53 promoter methylation have been linked with an array of 
p53 mutations, loss in tumor suppressor function, and cancer progression 
32
. Previously, it was 
shown that promoter hypermethylation of p53 prevents binding of transcription factors and is 
associated with a reduction in p53 expression whereas promoter hypomethylation increases p53 
expression 
37,38
.  
Post-transcriptional regulation of messenger RNA (mRNA) expression involves RNA-protein 
and RNA-RNA interactions 
39
. M6A RNA methylation occurs in approximately 0.2-0.5% of 
adenines and is the most abundant post-transcriptional modification of mammalian mRNA 
40,41
. 
M6A is commonly found in the coding region and 3’ untranslated region (UTR) of mRNA and 
is involved in regulating cellular processes including mRNA translation 
42,43
, degradation 
44
, 
splicing 
45
, and cellular localization 
46
. Dysregulation in the m6A methylation pattern has been 
associated with developmental abnormalities 
46-48
, obesity 
49,50
, type 2 diabetes 
51
, cancer 
52-54
, 
and other human diseases 
55
.  
M6A is catalyzed by the methyltransferase complex which consists of methyltransferase-like 3 
(METTL3), methyltransferase-like 14 (METTL14), and Wilm’s tumor 1-associated protein 
(WTAP) 
56,57
. METTL3 is catalytically active and regulates m6A levels by binding to s-
adenosyl methionine and catalyzing the transfer of a methyl group to the N-6 position of 
specific adenines on the target mRNA, METTL14 functions to maintain structure and substrate 
recognition by interacting with and stabilizing METTL3, whereas WTAP is catalytically 
inactive and facilitates RNA binding and m6A deposition by coordinating the localization of the 
METTL3-METTL14 complex 
57
. The m6A demethylases, fat mass and obesity-associated 
protein (FTO) and ALKB homolog 5 (ALKBH5) are Fe
2+
 and alpha-ketoglutarate-dependent 
and function by oxidizing N-methyl groups of m6A to a hydroxymethyl group 
39,58
.  
Chemical modifications of RNA transcripts alter the charge, base-pairing, secondary structure, 
and RNA-protein interactions, thereby, regulating gene expression by modulating RNA 
processing, localization, translation, and decay 
42,44-46
. Similarly, m6A also affects RNA 
processing by recruiting specific reader proteins. The m6A readers such as the YT521-B 
homology domain containing proteins 1 and 2 (YTHDC1 and YTHDC2) and the YT521-B 
homology domain family proteins 1, 2, and 3 (YTHDF1, YTHDF2, and YTHDF3) specifically 
recognize m6A modified RNAs and regulate the expression and function of specific mRNAs 
and proteins. YTHDF1, YTHDF3, and YTHDC2 regulate mRNA translation 
42,43
, YTHDF2 
regulates mRNA degradation 
44
, and YTHDC1 regulates mRNA splicing and cellular 
localization 
45,46
.  
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Previously, we evaluated the effect of FA on cell proliferation, DNA damage, and apoptosis in 
HepG2 cells 
12
; however, the mechanism underlying these effects is not well understood. p53 
plays a crucial role in regulating these pathways and may provide an important mechanism of 
FA-induced toxicity.  
Thus far, little is known on the effect of FA on p53 expression and its epigenetic regulation in 
vitro and in vivo. This study aimed to determine the effect of FA on p53 expression and its 
epigenetic regulation at the transcriptional and post-transcriptional level by promoter 
methylation and m6A RNA methylation in human liver (HepG2) cells and C57BL/6 mice livers 
as an alternative mechanism of FA-induced toxicity. Here we show that FA regulates the 
mRNA and protein expression of p53 via changes in promoter methylation and m6A RNA 
methylation in vitro and in vivo; however, contrasting results were observed between the in vitro 
and in vivo models. In vivo models, due to their complexity, multicellularity, and absence of 
disease, are more reliable models for epigenetic and toxicity testing compared to an in vitro 
model which consists of a single cell type in either a cancerous or transformed cell line that has 
a substantially abnormal function. 
Results 
Fusaric acid alters p53 expression in HepG2 cells and mice livers 
The tumor suppressor protein, p53 is activated during cellular stress and functions in cell cycle 
control and apoptosis 
27
. Previously, we showed that FA activates p53 via phosphorylation and 
acetylation in HepG2 cells 
12
; however, its effect on p53 mRNA and protein expression is not 
well understood. This study determined the effect of FA on p53 mRNA and protein expression 
in HepG2 cells and mice livers using qPCR and western blot, respectively. FA significantly 
decreased p53 mRNA (p < 0.0001; Fig. 5.1a) and protein (p < 0.0001; Fig. 5.1b) expression in 
HepG2 cells compared to the control; however, the expression of p53 mRNA (p = 0.0262; Fig. 
5.1c) and protein (p = 0.0003; Fig. 5.1d) was significantly increased in the FA-treated mice 
livers compared to the control. 
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Figure 5.1 FA alters p53 expression in HepG2 cells and mice livers. p53 mRNA and protein 
expression was detected in HepG2 cells and mice livers using qPCR and western blot, 
respectively. (a) FA significantly decreased p53 mRNA expression in HepG2 cells. (b) FA 
significantly decreased p53 protein expression in HepG2 cells. Blot images were derived from 
the same gel; a single membrane was first probed for p53 and then re-probed for β-actin. Full 
length blots are presented in Supplementary Fig. S5.1. (c) FA significantly increased p53 
mRNA expression in mice livers. (d) FA significantly increased p53 protein expression in mice 
livers. Blot images were derived from the same gel; a single membrane was first probed for p53 
and then re-probed for β-actin. Full length blots are presented in Supplementary Fig. S5.2. 
Densitometric analysis was performed using Image Lab Software (Bio-Rad). Results are 
represented as mean fold-change ± SD, n = 3. Statistical significance was determined using the 
one-way ANOVA with the Bonferroni multiple comparisons test (HepG2 cells) and the 
unpaired t-test with Welch’s correction (mice livers) (*p < 0.05, **p < 0.005, ***p < 0.0001).  
Fusaric acid alters p53 promoter methylation in HepG2 cells and mice livers 
The promoter methylation of genes is essential in regulating transcriptional activity and gene 
expression. Previously, p53 promoter hypomethylation was shown to increase p53 expression 
59,60
 whereas p53 promoter hypermethylation was shown to decrease p53 expression 
37,38
. We 
determined if the decrease and increase in p53 mRNA expression observed in the FA-treated 
HepG2 cells and mice livers, respectively, were a result of alterations in p53 promoter 
methylation. FA significantly increased p53 promoter methylation in the 25, 104, and 150 µg/ml 
FA treatments; however, the promoter methylation of p53 was significantly decreased by the 50 
µg/ml FA in HepG2 cells (p < 0.0001; Fig. 5.2a). The promoter methylation of p53 in the FA-
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treated mice livers was significantly decreased compared to the control (p = 0.0026; Fig. 5.2b). 
This suggests that FA may alter p53 transcript levels via promoter methylation in vitro and in 
vivo. 
 
Figure 5.2 FA alters p53 promoter methylation in HepG2 cells and mice livers. DNA 
isolated from controls, FA-treated HepG2 cells, and mice livers were assayed for p53 promoter 
methylation using the OneStep qMethyl Kit. (a) FA significantly altered p53 promoter 
methylation in HepG2 cells. (b) FA significantly decreased p53 promoter methylation in mice 
livers. Results are represented as mean fold-change ± SD, n = 3. Statistical significance was 
determined using the one-way ANOVA with the Bonferroni multiple comparisons test (HepG2 
cells) and the unpaired t-test with Welch’s correction (mice livers) (**p < 0.005, ***p < 
0.0001).  
Fusaric acid alters m6A-p53 levels in HepG2 cells and mice livers 
M6A, an abundant and dynamic post-transcriptional modification of mRNA, regulates mRNA 
degradation and translation 
42-44
. Due to the FA-induced changes in p53 expression at both the 
transcript and protein levels, we determined the effect of FA on m6A-p53 levels in HepG2 cells 
and mice livers using RNA immuno-precipitation. FA significantly decreased m6A-p53 
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expression in HepG2 cells (p < 0.0001; Fig. 5.3a) compared to the control. In the mice livers, 
FA significantly increased m6A-p53 expression levels compared to the control mice (p = 
0.0382; Fig. 5.3b).   
 
Figure 5.3 FA alters m6A-p53 levels in HepG2 cells and mice livers. RNA immuno-
precipitation using m6A antibody and quantification of p53 mRNA levels in HepG2 cells and 
mice livers. (a) FA decreased m6A-p53 levels in HepG2 cells. (b) FA increased m6A-p53 
levels in mice livers. Results are represented as mean fold-change ± SD, n = 3. Statistical 
significance was determined using the one-way ANOVA with the Bonferroni multiple 
comparisons test (HepG2 cells) and the unpaired t-test with Welch’s correction (mice livers) (*p 
< 0.05, ***p < 0.0001).  
Fusaric acid alters the expression of m6A methyltransferases and demethylases in 
HepG2 cells and mice livers 
The m6A levels of RNA transcripts are regulated by the methyltransferases, METTL3 and 
METTL14, and the demethylases, FTO and ALKBH5. Due to the FA-induced changes in m6A-
p53 levels observed in the FA-treated HepG2 cells and mice livers; we determined the effect of 
FA on the mRNA expression of METTL3, METTL14, FTO, and ALKBH5. FA significantly 
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decreased the expression of METTL3 (p < 0.0001; Fig. 5.4a), METTL14 (p < 0.0001; Fig. 5.4a), 
FTO (p < 0.0001; Fig. 5.4b), and ALKBH5 (p < 0.0001; Fig. 5.4b) in HepG2 cells compared to 
the control. The expression of METTL3 (p = 0.0007; Fig. 5.4c), METTL14 (p = 0.0041; Fig. 
5.4c), FTO (p = 0.0017; Fig. 5.4d), and ALKBH5 (p = 0.0018; Fig. 5.4d) in the FA-treated mice 
livers was increased compared to the control. This suggests that FA may alter m6A-p53 levels 
by modulating the expression of the m6A methyltransferases in HepG2 cells and mice livers. 
 
Figure 5.4 FA alters the expression of m6A methyltransferases and demethylases in 
HepG2 cells and mice livers. qPCR analysis of m6A methyltransferases and demethylases in 
HepG2 cells and mice livers. (a) FA significantly decreased the expression of METTL3 and 
METTL14 in HepG2 cells. (b) FA significantly decreased the expression of FTO and ALKBH5 
in HepG2 cells. (c) FA significantly increased the expression of METTL3 and METTL14 in mice 
livers. (d) FA significantly increased the expression of FTO and ALKBH5 in mice livers. 
Results are represented as mean fold-change ± SD, n = 3. Statistical significance was 
determined using the one-way ANOVA with the Bonferroni multiple comparisons test (HepG2 
cells) and the unpaired t-test with Welch’s correction (mice livers) (**p < 0.005, ***p < 
0.0001).  
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Fusaric acid alters the expression of m6A readers in HepG2 cells and mice livers 
M6A plays a major role in RNA processing by recruiting specific readers which recognize m6A 
modified RNAs and regulate the expression of the target mRNA and protein 
55
. The m6A 
readers, YTHDF1, YTHDF3, and YTHDC2 have been shown to regulate mRNA 
translation/protein expression 
42
 whereas YTHDF2 was shown to regulate mRNA expression 
44
. 
Due to the FA-induced decrease and increase in p53 mRNA and protein expression observed in 
the FA-treated HepG2 cells and mice livers, respectively as well as the FA-induced changes in 
m6A-p53 levels, we determined the effect of FA on the mRNA expression of YTHDF1, 
YTHDF2, YTHDF3, and YTHDC2. FA significantly decreased the expression of YTHDF1 (p < 
0.0001; Fig. 5.5a), YTHDF2 (p < 0.0001; Fig. 5.5a), YTHDF3 (p < 0.0001; Fig. 5.5a), and 
YTHDC2 (p < 0.0001; Fig. 5.5a) in HepG2 cells compared to the control; however, the 
expression of YTHDF1 (p = 0.0136; Fig. 5.5b), YTHDF2 (p = 0.0062; Fig. 5.5b), YTHDF3 (p = 
0.0060; Fig. 5.5b), and YTHDC2 (p = 0.0039; Fig. 5.5b) was significantly upregulated in the 
FA-treated mice livers compared to the control mice.  
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Figure 5.5 FA alters the expression of m6A readers in HepG2 cells and mice livers. qPCR 
analysis of m6A readers in HepG2 cells and mice livers. (a) FA significantly decreased the 
expression of YTHDF1, YTHDF2, YTHDF3, and YTHDC2 in HepG2 cells. (b) FA significantly 
increased the expression of YTHDF1, YTHDF2, YTHDF3, and YTHDC2 in mice livers. Results 
are represented as mean fold-change ± SD, n = 3. Statistical significance was determined using 
the one-way ANOVA with the Bonferroni multiple comparisons test (HepG2 cells) and the 
unpaired t-test with Welch’s correction (mice livers) (*p < 0.05, **p < 0.005, ***p < 0.0001). 
Discussion 
Exposure to mycotoxins causes harmful/adverse effects in humans and animals. FA is a 
common food-borne mycotoxin and chelator of divalent cations that alters cellular pathways 
causing toxicity in plants and animals 
3,5,7,8,61
; however, its epigenetic mechanisms of toxicity 
are unclear. Recently, FA was shown to induce global DNA hypomethylation as an epigenetic 
mechanism of genotoxicity and cytotoxicity in liver cells 
1
. Similarly, Fumonisin B1 (a common 
mycotoxin found in corn) caused chromatin instability and liver tumorigenesis by inducing 
global DNA hypomethylation and histone demethylation 
62
. Zearalenone (a myco-estrogen) also 
reduced cell viability and caused apoptotic cell death by inducing global DNA hypomethylation 
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63
 and decreasing histone methylation 
64
. Despite several studies indicating the genotoxic and 
cytotoxic effects of mycotoxins, no studies have been conducted on mycotoxins and its effect on 
the epigenetic regulation of p53 expression at the transcriptional and post-transcriptional level 
in vitro and in vivo.  
Previously, FA was shown to inhibit cell proliferation and induce apoptosis in HepG2 cells by 
post-translational modifications of p53 
12
; however, the effect of FA on p53 expression and its 
epigenetic regulation is not well understood. In addition to post-translational regulation of p53 
protein stability and activity, the expression of p53 is also regulated at the transcriptional and 
post-transcriptional level by promoter methylation and m6A RNA methylation. In this study, we 
provide evidence for an epigenetic mechanism of FA-induced changes in p53 expression at both 
the transcript and protein levels by altering p53 promoter methylation and m6A RNA 
methylation in human liver (HepG2) cells and C57BL/6 mice livers. 
Our results indicate that FA significantly decreased p53 mRNA (Fig. 5.1a) and protein (Fig. 
5.1b) expression by inducing p53 promoter hypermethylation (Fig. 5.2a) and decreasing m6A-
p53 expression levels (Fig. 5.3a) in HepG2 cells; however, in the mice livers, FA significantly 
increased p53 mRNA (Fig. 5.1c) and protein (Fig. 5.1d) expression by inducing p53 promoter 
hypomethylation (Fig. 5.2b) and increasing m6A-p53 levels (Fig. 5.3b). This is in agreement 
with previous studies in which p53 promoter hypermethylation was associated with a decrease 
in p53 transcript levels 
37,38
 and p53 promoter hypomethylation was associated with an increase 
in p53 expression levels both in vitro and in vivo 
59,60
.  
Chemical modifications of RNA transcripts regulate gene and protein expression by modulating 
RNA processing, translation, and degradation 
65
. As an epi-transcriptomic marker, m6A is the 
most abundant post-transcriptional modification of internal mRNA that occurs predominantly at 
the 3’ UTRs of mRNA 
43,66,67
. M6A, regulated by the methyltransferases, METTL3, METTL14 
and WTAP, and the demethylases, FTO and ALKBH5 
39,57,58
, promotes translation efficiency 
and mRNA degradation by recruiting specific readers capable of recognizing m6A modified 
mRNAs.  
Previous studies have shown that the aberrant regulation of m6A RNA transcripts affect many 
biological processes, including circadian rhythm and lipid metabolism 
68
, adipogenesis 
49
, cell 
differentiation 
41
, and embryonic stem cell renewal 
47
. Additionally, modulation of m6A RNAs 
were associated with various cancers such as acute myeloid leukemia 
69,70
, breast cancer 
71
, liver 
cancer 
72
, and lung cancer 
67
.  
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Previous studies have shown dietary factors to affect RNA m6A levels 
73,74
, and studies on p53 
and m6A have indicated that m6A at the point mutated codon 273 of p53 pre-mRNA promotes 
the expression of p53 R273H mutant protein and drug resistance of cancer cells 
75
.  
In our study, we found that FA decreased m6A-p53 levels in HepG2 cells (Fig. 5.3a). This 
occurred despite the significant decrease in both m6A methyltransferases (METTL3 and 
METTL14; Fig. 5.4a) and demethylases (FTO and ALKBH5; Fig. 5.4b) in the FA-treated HepG2 
cells. The FA-induced decrease in FTO and ALKBH5 suggests that it may not necessarily be 
responsible for the decrease in m6A-p53 levels in the HepG2 cells, and that the decrease in 
m6A-p53 levels is rather a consequence of the FA-induced decrease in METTL3 and METTL14. 
In contrast, FA significantly increased m6A-p53 levels (Fig. 5.3b) in mice livers despite 
significantly increasing the expression of both methyltransferases (METTL3 and METTL14; Fig. 
5.4c) and demethylases (FTO and ALKBH5; Fig. 5.4d). This suggests that the increased m6A-
p53 levels in the mice livers may result from the increase in METTL3 and METTL14. This is in 
agreement with previous studies in which knockdown of METTL3 or METTL14 was associated 
with a substantial decrease in m6A mRNA levels 
57
 whereas overexpression of METTL3 or 
METTL14 was associated with an increase in m6A mRNA levels 
68
. Interestingly, although 
ALKBH5 and FTO have been recognized as m6A demethylases, it was shown that FTO is 
highly co-expressed with the m6A methyltransferases in vitro and in vivo 
76
, and this may 
account for the positive correlation between FTO and METTL3 and METTL14 expression in the 
FA-treated HepG2 cells and mice livers.  
On a global level, m6A is highly conserved between humans and mice 
66
; however, 
transcriptome wide analysis of the m6A methylome of different tissue types in humans and 
mice indicated that the overlap between m6A containing genes is grouped by species rather than 
tissue types 
76
 and this may account for the differences in m6A-p53 expression levels observed 
between the FA-treated HepG2 cells and mice livers. Furthermore, the differences in m6A-p53 
expression levels in vitro and in vivo may occur due to the fact that in vivo FA acts in the entire 
animal and the liver consists of various cell types (hepatocytes, stellate cells, kupffer cells, and 
endothelial cells) with each cell type having its own m6A methylation pattern as opposed to the 
in vitro model which consists of a single cell type and thus a single m6A methylation pattern. 
This can affect the overall average m6A methylation pattern in liver tissue versus an in vitro 
model. A previous study indicated a similar trend in the DNA methylation pattern of human 
liver tissue where each individual cell type (stellate cells and kupffer cells) displayed a different 
DNA methylation pattern and thus affected the overall average DNA methylation pattern of the 
liver tissue 
77
.  Additionally, functional heterogeneity among the individual cell types including 
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hepatocytes, stellate cells, kupffer cells, and endothelial cells in liver tissue may contribute to 
cell-cell variations in methylation 
77
. 
YTHDF1, YTHDF2, YTHDF3, and YTHDC2 specifically recognize m6A modified mRNAs 
and regulate mRNA degradation 
44
 and translation 
42,43
. In HepG2 cells, the FA-induced 
decrease in m6A-p53 levels led to a decrease in the expression of YTHDF1, YTHDF2, YTHDF3, 
and YTHDC2 (Fig. 5.5a). YTHDF2 plays a major role in mRNA degradation; the carboxy-
terminal domain of YTHDF2 selectively binds to m6A-containing mRNA, whereas the amino-
terminal domain is responsible for the localization of the YTHDF2-mRNA complex to RNA 
decay sites such as processing bodies 
44
. The decrease in YTHDF2 expression, decrease in p53 
mRNA expression, and increase in p53 promoter methylation observed in the FA-treated 
HepG2 cells suggests that FA may decrease p53 mRNA expression via promoter 
hypermethylation and inhibition in p53 transcription, and not YTHDF2-mediated degradation of 
p53 mRNA. YTHDF1, YTHDF3, and YTHDC2 function by interacting with translational 
machinery and actively promote protein synthesis to ensure effective protein production from 
dynamic transcripts that are marked by m6A 
43
. Therefore, the FA-induced decrease in 
YTHDF1, YTHDF3, and YTHDC2 may be responsible for the decrease in p53 protein 
expression observed in the HepG2 cells. Contrastingly in the mice livers, the FA-induced 
increase in m6A-p53 levels led to an increase in the expression of YTHDF1, YTHDF2, 
YTHDF3, and YTHDC2 (Fig. 5.5b). The increase in YTHDF2, increase in p53 mRNA 
expression, and decrease in p53 promoter methylation in the FA-treated mice livers indicates 
that FA increased p53 mRNA expression via promoter hypomethylation and induction of p53 
transcription. Although YTHDF2 may play a role in degrading p53 mRNA, the increase in p53 
mRNA expression suggests that the transcription of p53 may be greater than that of its 
degradation. The FA-induced increase in YTHDF1, YTHDF3, and YTHDC2 in the mice livers 
led to an increase in p53 translation and increase in p53 protein expression. These results are in 
agreement with the study by Wang et al (2015) in which ribosome profiling on METTL3 
knockdown cells showed that YTHDF1 promotes translation efficiency in an m6A-dependent 
manner, and knockdown of YTHDF1 reduced ribosome occupancy and translation efficiency of 
m6A targeted transcripts 
43
. Similarly, YTHDF3 and YTHDC2 promote protein synthesis in 
synergy with YTHDF1 by interacting with ribosomal proteins and unwinding the 5’UTR of 
mRNA 
78-80
.  
In conclusion, this study provides evidence for a possible mechanism of FA-induced p53 
expression at the epigenetic level. The results indicate that FA epigenetically regulates p53 
expression at both the transcript and protein levels by altering p53 promoter methylation and 
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m6A RNA methylation in HepG2 cells and C57BL/6 mice livers. The results further indicate 
that the alterations in m6A-p53 expression levels was mediated by alterations in the expression 
of the m6A methyltransferases, METTL3 and METTL14, and occurred independently of the 
demethylases, FTO and ALKBH5. Although FA regulates p53 transcript and protein expression 
at the epigenetic level, differences were observed between the epigenetic regulation of p53 
expression in the FA-treated HepG2 cells and mice livers. The in vivo model is a more reliable 
and representative model for determining FA-induced toxicity and epigenetic regulation as its 
level of complexity, multicellularity, and health status is similar to that of the human system. 
Epigenetic modifications also vary based on the health status of the cells and changes in 
epigenetic patterns are often associated with various disease states, therefore, the difference 
between our results in vitro and in vivo may also occur due to the health status of the cells: our 
in vivo model comprised of healthy mice whereas our in vitro model was a cancerous cell line; 
this is important as majority of the population exposed to mycotoxins are healthy individuals. 
These findings suggest that the increase in p53 expression, as shown in the mice livers, may 
provide an alternative mechanism of FA-induced genotoxicity and cytotoxicity in the liver.  
Materials and methods 
Materials 
FA (Gibberella fujikuroi, F6513) was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
The HepG2 cell line (HB-8065) was purchased from the American Type Culture Collection 
(ATCC; Johannesburg, SA). Cell culture reagents were purchased from Lonza Biotechnology 
(Basel, Switzerland). Western blot reagents were purchased from Bio-Rad (Hercules, CA, 
USA). All other reagents were purchased from Merck (Darmstadt, Germany).  
Cell culture and treatment  
HepG2 cells (1.5 X 10
6
, passage 3) were cultured (37°C, 5% CO2, humidified incubator) to 90% 
confluency in 25 cm
3
 cell culture flasks containing complete culture media (CCM; Eagle’s 
Minimum Essentials Medium (EMEM) supplemented with 10% fetal calf serum, 1% penicillin-
streptomycin fungizone, and 1% L-glutamine). A stock solution of 1 mg/ml FA in 0.1 M 
phosphate buffered saline (PBS) was prepared and the cells were incubated (37°C, 5% CO2, 24 
h) with a range of FA concentrations (25, 50, 104, and 150 µg/ml) 
1
. An untreated control (CCM 
only) was also prepared. The viability of the cells was assessed using the trypan blue cell 
exclusion method. All results were verified by performing two independent experiments in 
triplicate.  
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Animal treatment 
Six-to-eight-week-old C57BL/6 male mice were obtained from the Africa Health Research 
Institute (AHRI; University of KwaZulu-Natal, Durban, SA) and housed under standard 
laboratory conditions (temperature: 25°C, humidity: 40-60%, 12 h light/dark cycle) with ad 
libitum access to a commercial mice feed and normal drinking water. After one week 
acclimatization, mice with a mean body weight of 20 ± 2.99 g were randomly divided into two 
groups, control and FA, with each group consisting of three mice. For the treatments, mice were 
orally administered with either 0.1 M PBS (control group) or 50 mg/kg FA 
21
 (FA group) at a 
rate of 0.25 ml/23 g once for a period of 24 h. Thereafter, the mice were euthanized using Isofor 
and the livers were harvested. The livers were rinsed three times in 0.1 M PBS, cut into 1 cm x 
1 cm sections, and stored in Cytobuster reagent (500 µl; Novagen, 71009) and Qiazol reagent 
(500 µl; Qiagen, 79306) for protein and RNA isolation, respectively. All mice were maintained 
according to the ARRIVE guidelines and the rules and regulations of the University of 
KwaZulu-Natal Animal Research Ethics Committee (Ethics approval number: AREC/079/016). 
RNA isolation and quantitative polymerase chain reaction (qPCR) 
Total RNA was extracted from controls, FA-treated HepG2 cells, and mice livers using Qiazol 
reagent (Qiagen, 79306), as previously described 
1
. The RNA was quantified using the 
Nanodrop2000 spectrophotometer (Thermo-Fischer Scientific), standardized to 1,000 ng/µl, and 
reverse transcribed into complementary DNA (cDNA) using the Maxima H Minus First Strand 
cDNA Synthesis Kit (Thermo-Fischer Scientific, K1652). Thereafter, the mRNA expression of 
p53, METTL3, METTL14, FTO, ALKBH5, YTHDC2, YTHDF1, YTHDF2, and YTHDF3 was 
determined using the PowerUp™ SYBR™ Green Master Mix (Thermo-Fischer Scientific, 
A25742) and the CFX96 Real Time PCR System (Bio-Rad) with the following cycling 
conditions: initial denaturation (95°C, 8 min), followed by 40 cycles of denaturation (95°C, 15 
s), annealing (Supplementary Table S5.1, 40 s), and extension (72°C, 30 s). Primer sequences 
and annealing temperatures are listed in Supplementary Table S5.1. GAPDH was used as the 
internal control to normalise mRNA expression. The comparative threshold cycle (Ct) method 
was used to determine relative changes in expression 
81
.   
Protein isolation and western blot 
The protein expression of p53 was determined using western blot 
12
. Briefly, crude protein was 
isolated from controls, FA-treated HepG2 cells, and mice livers using cytobuster reagent (200 
µl; Novagen, 71009) supplemented with protease and phosphatase inhibitors (Roche; 
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05892791001 and 04906837001, respectively). The Bicinchoninic Acid (BCA) Assay was used 
to quantify the proteins and the samples were subsequently standardized to 1 mg/ml (HepG2 
cells) and 5 mg/ml (mice livers). The samples were then boiled (100°C, 5 min) in a 1:1 dilution 
with 1X Laemmli buffer [dH2O, 0.5 M Tris-HCl (pH 6.8), glycerol, 10% SDS, 5% β-
mercaptoethanol, 1% bromophenol blue], separated in sodium dodecyl sulphate polyacrylamide 
gels (10% resolving gel, 4% stacking gel; 1 h, 150 V), and transferred onto nitrocellulose 
membranes using the Bio-Rad Trans-Blot® Turbo Transfer System (20 V, 30 min). The 
membranes were then blocked in 5% non-fat dry milk (NFDM) in Tris buffered saline with 
0.05% Tween 20 [TTBS; 150 mM NaCl, 3 mM KCl, 25 mM Tris, 0.05% Tween 20, dH2O, pH 
7.5; 1 h, RT] and probed overnight (4°C) with primary antibody [p53 (1:500; Santa Cruz, sc-
6243)]. Membranes were rinsed five times in TTBS (10 min, RT) and incubated with a horse-
radish peroxidase (HRP)-conjugated secondary antibody [goat anti-rabbit (1:5,000; Cell 
Signaling Technology, #7074S); 1 h, RT]. Membranes were rinsed five times in TTBS (10 min, 
RT). Immunoblots were visualized using the Clarity™ Western ECL Substrate Kit (Bio-Rad, 
#170-5060) and the images were captured using the ChemiDoc™ XRS+ Molecular Imaging 
System (Bio-Rad). Following detection, membranes were quenched in hydrogen peroxide (5%, 
37°C, 30 min) and probed with the housekeeping protein, anti-β-actin (1:5,000, 30 min, RT; 
Sigma-Aldrich, A3854) to normalize protein expression. Protein expression was determined 
using the Image Lab Software version 5.1 (Bio-Rad) and the results were represented as a fold-
change in band density (RBD) relative to the control. 
 Promoter methylation of p53 
Genomic DNA was extracted from controls, FA-treated HepG2 cells, and mice livers using the 
Quick-g-DNA MiniPrep Kit (Zymo Research, D3007) and purified using the DNA Clean and 
Concentrator™-5 Kit (Zymo Research, D4003), as per manufacturer’s instructions 
1
. DNA 
concentration was determined using the Nanodrop2000 spectrophotometer and standardized to 4 
ng/µl. The purity of the DNA was assessed using the A260/A280 absorbance ratio. The 
promoter methylation of p53 was determined using the OneStep qMethyl Kit (Zymo Research, 
5310) in which 20 ng DNA was subject to a test and reference reaction containing specific 
primers 
1
. Primer sequences and annealing temperatures are listed in Supplementary Table S5.1. 
Cycling conditions were as follows: digestion by methyl sensitive restriction enzymes (37°C, 2 
h), initial denaturation (95°C, 10 min), followed by 45 cycles of denaturation (95°C, 30 s), 
annealing (Supplementary Table S5.1, 60 s), extension (72°C, 60 s), final extension (72°C, 60 
s), and a hold at 4°C. The percentage methylation was calculated using the supplied formula 
(Supplementary Information) and represented as a fold-change relative to the control.  
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RNA immuno-precipitation 
Quantification of m6A-p53 levels were conducted using RNA immuno-precipitation [82]. 
Briefly, control, FA-treated HepG2 cells, and mice livers were incubated in nuclear isolation 
buffer [500 µl; 1.28 M sucrose, 40 mM Tris-HCl (pH 7.5), 20 mM magnesium chloride, 4% 
Triton X-100; 4°C, 20 min] and centrifuged (2,500 x g, 4°C, 15 min). Nuclear pellets were re-
suspended in RNA immuno-precipitation buffer [1 ml; 150 mM potassium chloride, 25 mM 
Tris-HCl (pH 7.4), 5 mM EDTA, 0.5 mM DTT, 0.5% IGEPAL, 100 U/ml SUPERase IN™ 
RNase Inhibitor (Thermo-Fisher Scientific, AM2694), protease inhibitors (Roche, 
05892791001), phosphatase inhibitors (Roche, 04906837001)] and the chromatin was 
mechanically sheared using a needle (20 gauge/20 strokes). Thereafter, the nuclear pellet and 
debris were pelleted by centrifugation (13,000 x g, 4°C, 10 min). The supernatant was 
transferred into fresh 1.5 ml micro-centrifuge tubes and incubated with primary antibody [m6A 
(1:100; Abcam, ab208577)] overnight at 4°C. The RNA-antibody complex was precipitated 
using protein A beads [20 µl 50% bead slurry (Cell Signaling Technology, #9863), 4°C, 3 h]. 
Thereafter, the immuno-precipitates were recovered by centrifugation (2,500 x g, 4°C, 60 s), 
washed three times in RNA immuno-precipitation buffer, followed by re-suspension in Qiazol 
reagent (500 µl; Qiagen, 79306). RNA was isolated as previously described 
1
. The RNA was 
quantified using the Nanodrop2000 spectrophotometer, standardized to 400 ng/µl, and reverse 
transcribed into cDNA using the Maxima H Minus First Strand cDNA Synthesis Kit (Thermo-
Fischer Scientific, K1652). The expression of m6A-p53 was then determined using qPCR as 
mentioned above. Primer sequences and annealing temperatures are listed in Supplementary 
Table S5.1. 
Statistical analysis 
GraphPad Prism version 5.0 (GraphPad Prism Software Inc.) was used to perform all statistical 
analyses. The D’Agostino and Pearson tests were used to determine normality. Data from the 
HepG2 cells were analyzed using the one-way Analysis of Variance (ANOVA) followed by the 
Bonferroni multiple comparisons test. Data from the mice livers were analyzed using the 
unpaired t-test with Welch’s correction. All results were represented as a mean fold-change ± 
standard deviation (SD) (n = 3). Statistical significance was considered at p < 0.05. 
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Supplementary Information 
Supplementary Table S5.1: qPCR primer sequences and annealing temperatures 
Gene GenBank 
Accession 
no. 
Sense Primer 
5’→3’ 
Anti-sense Primer 
5’→3’ 
Annealing 
Temperature 
(°C) 
qPCR 
p53 
(human) 
NM_0012
76760 
GCCCAACAACACC
AGCTCCT 
CCTGGGCATCCTTG
AGTTCC 
56 
METTL3 
(human) 
NM_0198
52 
TTGTCTCCAACCTT
CCGTAGT 
CCAGATCAGAGAG
GTGGTGTAG 
56 
METTL14 
(human) 
NM_0209
61 
GAACACAGAGCTT
AAATCCCCA 
TGTCAGCTAAACCT
ACATCCCTG 
56 
FTO 
(human) 
NM_0010
80432 
GCTGCTTATTTCGG
GACCTG 
AGCCTGGATTACC
AATGAGGA 
56 
ALKBH5 
(human) 
NM_0177
58 
ATCCTCAGGAAGA
CAAGATTAG 
TTCTCTTCCTTGTC
CATCTC 
60 
YTHDF1 
(human) 
NM_0177
98 
ATACCTCACCACC
TACGGACA 
GTGCTGATAGATGT
TGTTCCCC 
58 
YTHDF2 
(human) 
NM_0162
58 
CCTTAGGTGGAGC
CATGATTG 
TCTGTGCTACCCAA
CTTCAGT 
56 
YTHDF3 
(human) 
NM_1527
58 
TCAGAGTAACAGC
TATCCACCA 
GGTTGTCAGATATG
GCATAGGCT 
56 
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YTHDC2 
(human) 
NM_0228
28 
CAAAACATGCTGT
TAGGAGCCT 
CCACTTGTCTTGCT
CATTTCCC 
60 
GAPDH 
(human) 
NM_0020
46 
TCCACCACCCTGTT
GCTGTA 
ACCACAGTCCATG
CCATCAC 
Same as gene of 
interest 
p53 
(mouse) 
XM_0065
32900 
GGGCCCGTGTTGG
TTCATCC 
CCGCGAGACTCCT
GGCACAA 
60 
METTL3 
(mouse) 
NM_0197
21 
CTGGGCACTTGGA
TTTAAGGAA 
TGAGAGGTGGTGT
AGCAACTT 
58 
METTL14 
(mouse) 
NM_2016
38 
GACTGGCATCACT
GCGAATGA 
AGGTCCAATCCTTC
CCCAGAA 
60 
FTO 
(mouse) 
NM_0119
36 
CCGTCCTGCGATG
ATGAAGT 
CCCATGCCGAAAT
AGGGCTC 
60 
ALKBH5 
(mouse) 
NM_1729
43 
GCATACGGCCTCA
GGACATTA 
TTCCAATCGCGGTG
CATCTAA 
60 
YTHDF1 
(mouse) 
NM_1737
61 
ACAGTTACCCCTC
GATGAGTG 
GGTAGTGAGATAC
GGGATGGGA 
58 
YTHDF2 
(mouse) 
NM_1453
93 
ACAGGCAAGGCCG
AATAATG 
GGCTGTGTCACCTC
CAGTAG 
58 
YTHDF3 
(mouse) 
NM_1726
77 
TACATGGGGAACA
AGTGGATCT 
TAGGTGGATAGCC
GTAACTGC 
58 
YTHDC2 
(mouse) 
NM_0011
63013 
GAAGATCGCCGTC
AACATCG 
GCTCTTTCCGTACT
GGTCAAA 
60 
GAPDH 
(mouse) 
NM_0012
89726 
ATGTGTCCGTCGT
GGATCTGAC 
AGACAACCTGGTC
CTCAGTGTAG 
Same as gene of 
interest 
Promoter methylation 
147 
 
p53 
(human) 
XM_0244
50825 
GTGGATATTACGG
AAAGT 
AAAATATCCCCGA
AACC 
54 
p53 
(mouse) 
XM_0065
32900 
CAGCTTTGTGCCA
GGAGTCT 
TAACTGTAGTCGCT
ACCTAC 
54 
RNA immuno-precipitation 
p53 
(human) 
NM_0012
76760 
GCCCAACAACACC
AGCTCCT 
CCTGGGCATCCTTG
AGTTCC 
56 
p53 
(mouse) 
XM_0065
32900 
GGGCCCGTGTTGG
TTCATCC 
CCGCGAGACTCCT
GGCACAA 
60 
 
Quantification of promoter methylation formula: 
Methylation (%) = 100 X 2
-ΔCt
, where ΔCt = Ct (test) – Ct (reference) 
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Original western blot images 
Membrane 1 – HepG2 cells 
 
Supplementary Figure S5.1: Full size western blot images for Figure 5.1b. Protein 
expression of p53 was determined by western blot. A single membrane was first probed for p53, 
and then the same membrane was re-probed for β-actin. Blots were developed using enhanced 
chemi-luminescence together with the Bio-Rad ChemiDoc™ XRS+ Molecular Imaging System. 
Key: 1 - Control; 2 – 25 µg/ml FA; 3 – 50 µg/ml FA; 4 – 104 µg/ml FA; 5 – 150 µg/ml FA. 
Membrane 2 – Mouse liver 
 
Supplementary Figure S5.2: Full size western blot images for Figure 5.1d. Protein 
expression of p53 was determined by western blot. A single membrane was first probed for p53, 
and then the same membrane was re-probed for β-actin. Blots were developed using enhanced 
chemi-luminescence together with the Bio-Rad ChemiDoc™ XRS+ Molecular Imaging System. 
Key: 1 – 3 - Control; 4 - 6 – 50 mg/kg FA. 
 
 
 
                                      1 
1      2      3      4      5 
p53 (53kDa) 
1      2      3       4      5 
β-actin (42kDa) 
                                           1 
1       2      3        4      5      6 
p53 (53kDa) 
1       2      3        4      5      6 
β-actin (42kDa) 
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CHAPTER 6 
CONCLUSION 
FA, a neglected food-borne mycotoxin, displays various toxic effects and increases the risk for 
the development of human and animal pathologies (Yin et al., 2015, Reddy et al., 1996, Hidaka 
et al., 1969, Abdul et al., 2016, Abdul et al., 2019, Devnarain et al., 2017, Dhani et al., 2017). 
Thus far, studies on FA have focused mainly on its toxic effects with limited information on its 
molecular and epigenetic mechanisms of action. The lack of knowledge on the molecular 
mechanisms of FA-mediated toxicities is of concern as it obscures the development of 
preventative and therapeutic measures, thereby, increasing human and animal susceptibility to 
FA exposure and adverse health effects. 
Recently, several studies have postulated that FA possesses genotoxic properties and this may 
be crucial for adverse outcomes in mammals (Ghazi et al., 2017, Mamur et al., 2018, Stack Jr et 
al., 2004). Epigenetics, due to its close interaction with DNA and vital role in regulating cellular 
function, is particularly relevant in FA-mediated genotoxicity. Hence, elucidating the epigenetic 
mode of action of FA may form the basis for the development of diagnostic biomarkers and 
therapeutic interventions against FA toxicity. 
This study, for the first time, shows that FA altered the epigenetic landscape in liver cells; and 
these epigenetic modifications may provide insight into alternative mechanisms of FA-induced 
hepatotoxicity.  
FA induced global DNA hypomethylation in human liver (HepG2) cells by decreasing the 
expression of DNA methyltransferases (DNMT1, DNMT3A, and DNMT3B) and increasing the 
expression of the demethylase, MBD2. The decrease in the expression of DNMT1, DNMT3A, 
and DNMT3B occurred due to promoter hypermethylation and/or upregulation of miR-29b. 
Additionally, miR-29b was itself regulated by DNA methylation and the decrease in global 
DNA methylation coupled with a decrease in miR-29b promoter methylation by FA led to an 
increase in the expression of miR-29b. 
The protein expressions of DNMT1, DNMT3A, and DNMT3B were also significantly 
decreased by FA and hence DNMT regulation via post-translational modifications such as 
ubiquitination was assessed. FA decreased the ubiquitination of DNMT1, DNMT3A, and 
DNMT3B by decreasing the expression of the ubiquitination regulators, UHRF1 and USP7, and 
suggested that FA did not decrease DNMT protein expression via ubiquitination and 
proteasomal degradation; instead the decrease in DNMT protein expression observed by FA 
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may be a consequence of the FA-induced decrease in DNMT mRNA expressions and an 
inhibition of translation. FA also induced MBD2 promoter hypomethylation and increased the 
protein expression of MBD2 contributing to the decrease in global DNA methylation observed 
in the HepG2 cells. These findings confirmed that FA induced epigenetic changes via global 
DNA hypomethylation and alterations in promoter DNA methylation, leading to genotoxicity 
and cytotoxicity in human liver cells. 
In addition to DNA hypomethylation, a loss in H3K9me3 also disrupts chromatin structure 
leading to genome instability and/or DNA damage (Putiri and Robertson, 2011, Peters et al., 
2001). Sirt1 expression is inversely regulated by miR-200a and post-translationally modifies 
both SUV39H1 and H3K9Ac to maintain H3K9me3 and genome integrity (Eades et al., 2011, 
Bosch-Presegué et al., 2011, Vaquero et al., 2007). Transfection of HepG2 cells with a miR-
200a mimic and inhibitor proved, in addition to computational prediction software (TargetScan 
version 7.1), that Sirt1 is a target of miR-200a. FA upregulated miR-200a and decreased Sirt1 
expression at both the transcript and protein level in HepG2 cells and C57BL/6 mice livers. The 
decrease in Sirt1 expression by FA led to changes in MDM2-mediated SUV39H1 
ubiquitination, and nuclear and cytoplasmic SUV39H1 expression. This ultimately led to a 
decrease in total SUV39H1 expression in HepG2 cells and mice livers. 
The FA-induced decrease in SUV39H1 and KDM4B decreased H3K9me3 and increased 
H3K9me1 in HepG2 cells and mice livers. The decrease in H3K9me3 by FA decreased genome 
stability/DNA integrity as shown via DNA electrophoresis. The decrease in H3K9me3 also 
decreased p-S139-H2Ax (a marker of DNA damage) by preventing ATM activation and 
inhibiting the repair of damaged DNA. Furthermore, the loss in H3K9me3 and subsequent 
decrease in genome integrity caused cell death via apoptotic signaling, as evidenced by the 
decrease in HepG2 cell viability and increase in the activity of the executioner caspase-3/7. 
These results indicated that FA has genotoxic and cytotoxic effects by upregulating miR-200a 
and decreasing SUV39H1-mediated H3K9me3 in HepG2 cells and mice livers. 
DNA damage is a major activator of p53 which arrests the cell cycle to initiate DNA repair or 
apoptosis (Laptenko and Prives, 2006). In HepG2 cells, the FA-induced p53 promoter 
hypermethylation decreased p53 expression which in turn decreased m6A-p53 levels despite the 
decrease in both m6A methyltransferases (METTL3 and METTL14) and demethylases (FTO and 
ALKBH5). The decreased m6A-p53 levels by FA suppressed the m6A-dependent readers, 
YTHDF1, YTHDF2, YTHDF3, and YTHDC2, consequently decreasing p53 translation 
efficiency and reducing p53 protein expression. Contrastingly in the mice livers, the FA-
induced p53 promoter hypomethylation increased p53 expression which subsequently increased 
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m6A-p53 levels despite an increase in both METTL3 and METTL14, and FTO and ALKBH5. 
The increased m6A-p53 levels upregulated expressions of YTHDF1, YTHDF2, YTHDF3, and 
YTHDC2, consequently increasing p53 translation and protein expression. These results 
indicated that FA differentially regulates p53 expression at the epigenetic level via promoter 
methylation and m6A methylation, and these differences between the HepG2 cells and mice 
livers can be alluded to the fact that in the mice FA acts in the entire animal that has a greater 
degree of complexity, multicellularity, and absence of disease compared to the HepG2 cell line 
that consists of a single cell type that is either cancerous or transformed.  
Taken together, this study indicates that FA induced epigenetic changes via global DNA 
hypomethylation, modulated miRNA expression, decreased H3K9me3, and altered m6A-
mediated regulation of p53 expression in vitro and in vivo; these epigenetic modifications may 
provide evidence for alternative mechanisms of FA-induced genotoxicity and cytotoxicity that 
leads to apoptosis in the liver. It also provides evidence for the possible involvement of FA 
exposure in human diseases especially cancer where epigenetic changes are the underlying 
cause. This is extremely important in underprivileged areas where quantity outweighs quality 
due to an inadequate food supply and improper storage facilities (Bennett and Klich, 2003). 
However, while this study indicated novel mechanisms for FA-induced hepatotoxicity at the 
epigenetic level, it focused on an acute (24 h) FA exposure in both the in vitro and in vivo 
aspects; and chronic (greater than 24 h) exposure to FA may exhibit different patterns of 
epigenetic changes with different cellular outcomes. Hence this study provides insight for future 
epigenetic studies at a longer FA exposure time as well as to determine the effect of FA on other 
epigenetic modifications such as long non-coding RNAs.  
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ADDENDUM A 
The following study titled, “Fusaric acid induces DNA damage and post-translational 
modifications of p53 in human hepatocellular carcinoma (HepG2) cells” set the foundation 
for this study. 
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ADDENDUM B 
Ethical Approval Letter – In Vitro Study 
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ADDENDUM C 
Ethical Approval Letter – In Vivo Study 
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ADDENDUM D 
Quantification of DNA Methylation 
The Methylated DNA Quantification Kit (ab117128) is a colorimetric assay used to measure 5-
methylcytosine on DNA. It is a highly sensitive assay, detecting as little as 0.2ng of methylated 
DNA, and is based on the principle of an ELISA. First, DNA together with a series of 5-
methylcytosine standards (0, 1, 2, 5, and 10 ng/µl) are bound to strip wells that are specifically 
treated to have a high affinity for DNA; and 5-methylcytosine is detected using capture and 
detection antibodies that result in a color change from yellow to blue. The optical density (OD) 
is measured spectrophotometrically at a wavelength of 450 nm. The ODs of the 5-
methylcytosine standards are used to construct a standard curve from which the percentage 5-
methylcytosine in each sample is determined (Figure A1). The amount of methylated DNA is 
proportional to the OD intensity measured. 
 
Figure A1 Standard curve used to determine 5-methylcytosine in DNA  
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ADDENDUM E 
Quantification of M6A RNA Methylation 
The m6A RNA methylation quantification kit (ab185912) is a highly sensitive, detects as little 
as 10 pg of m6A, colorimetric assay that utilizes the principle of antigen-antibody binding to 
measure m6A levels in total RNA. First, total RNA together with various m6A standards (0, 
0.01, 0.02, 0.05, and 0.1 ng/µl) are bound to strip wells using a high affinity RNA binding 
solution. Thereafter, m6A is detected using a specific m6A capture and detection antibody. The 
detected signal is enhanced and the OD is measured at a wavelength of 450 nm using a 
microplate spectrophotometer. The ODs of the standards are used to construct a standard curve 
from which the percentage m6A in each sample is determined (Figure A2). The amount of m6A 
is proportional to the intensity of the OD measured.  
 
Figure A2 Standard curve used to determine m6A levels in total RNA  
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Fusaric Acid Increases Total M6A Levels in HepG2 Cells 
We determined the effect of FA on total m6A levels in HepG2 cells. Briefly, total RNA was 
isolated from control and FA-treated HepG2 cells, as previously described (Ghazi et al., 2019). 
The RNA was then quantified using the Nanodrop2000 spectrophotometer, standardized to 500 
ng/µl, and m6A levels were measured using the colorimetric m6A RNA methylation 
quantification kit (ab185912), as per manufacturer’s instructions. FA significantly increased the 
percentage of m6A in HepG2 cells in a dose-dependent manner compared to the control (p = 
0.0005; Figure A3). 
 
Figure A3 The effect of FA on total m6A levels in HepG2 cells. FA increased the percentage 
m6A RNA methylation in HepG2 cells. Results are represented as the mean ± SD (n = 3). 
Statistical significance was determined using the one-way ANOVA with the Bonferroni 
multiple comparisons test (**p <0.005). 
